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ABSTRACT 
 
Nanoparticle and microsphere technologies have enormous diagnostic and therapeutic 
potential in medicine. We characterised the behaviour of Quantum Dots (QD) in live 
mammalian cells and discovered that QD surface coating deficiencies can lead to the 
formation of aggregates, which are recognised as foreign objects by the innate immune 
defenses of cells and actively transported along microtubules within lysosomes. Applying the 
principles of viral nucleotide delivery systems, we designed a nature-inspired, smart ‘universal’ 
nanoparticle for intracellular oligonucleotide delivery using a combination of natural and 
synthetic stimuli-responsive polymers. We then developed and tested a nature-inspired 
polymer alginate-poly-L-lysine-alginate (APA) microcapsule to encapsulate allogeneic cells 
for Factor VIII delivery in a mouse model of haemophilia A. We also developed a novel flow 
cytometry-based assay to evaluate the behaviour of encapsulated cells and discovered that 
both implanted and non-implanted APA microcapsules reduced the viability of cells, induced 
changes in the cytoplasmic composition and morphology of the cells, and altered the 
proliferation rate, suggest that the local microenvironment can significantly alter the behaviour 
of encapsulated cells. We then developed and tested a novel single-colour flow cytometry-
based in vitro cytotoxicity assay to measure both necrotic and apoptotic cell death. We then 
developed and tested a novel method to potentially delay or prevent organ rejection upon 
transplantation using viral nanoparticles to selectively modify allogeneic donor cells ex vivo 
using viral mechanisms of immune evasion. To our knowledge, this was the first study to 
employ viral immune evasion strategies to simultaneously reduce CD8+ T cell-mediated 
cytotoxicity without altering Natural Killer cell-mediated cytotoxicity against allogenic human 
cells. Finally, we present a rare clinical case of hemicorporectomy due to chronic non-healing 
pressure ulcers to highlight the potential role for nanoparticles, microspheres and tissue-
engineered constructs for wound healing applications via suppression of inflammation and 
promotion of tissue regeneration.  
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BACKGROUND 
 
NANOPARTICLES FOR DIAGNOSTICS AND BIOPHARMACEUTICAL 
DELIVERY IN MEDICINE 
 
Over the past two decades, the field of nanotechnology has evolved from a subject of mere 
academic inquiry to a burgeoning arena in the pharmaceutical industry, giving rise to cutting 
edge materials that can be implemented in clinical medicine, especially for diagnosis and drug 
delivery [1,2]. Nanoparticles can be broadly classified into two major types: non-viral and viral. 
Although non-viral nanoparticles vary significantly in their physical size and shape, chemical 
composition, electrical charge and optical properties, their applications in clinical medicine 
have been limited to date due to several challenges, including the innate and adaptive immune 
response to nanomaterials. Given the sheer diversity of non-viral nanoparticles, this review 
will focus on small semiconductor nanoparticles called Quantum Dots (QD) to illustrate the 
salient features and current applications in vitro, in vivo and in clinical settings. This discussion 
will serve to highlight some of the major challenges that limit the application of all nanoparticles 
in clinical medicine.  
 
Quantum dots are small semiconductor nanocrystals (2-15 nm core) with highly customisable 
optical and chemical properties (Figure 1) [3]. Optically, QD have excellent photostability, high 
quantum yields, large two-photon cross sections, broad excitation spectra, large effective 
Stokes shifts and narrow size-dependent emission spectra. Quantum dots also have a long 
fluorescence lifetime (10-100x longer than organic fluorophores) and exhibit a tendency to 
blink [4–6]. Blinking is a photophysical effect where the QD alternate between a light state and 
a dark state at irregular intervals [6]. These qualities provide an unambiguous optical signature 
that allows single QD to be easily distinguished among other fluorophores using epi-
fluorescence microscopy. Chemically, QD have a three-layered core-shell-hydrophilic 
structure (Figure 1). The inorganic (typically CdSe-ZnS) core-shell is then protected with a 
hydrophilic layer, which renders them water-soluble and allows them to be functionalised with 
biomolecules. This feature provides QD with a highly customisable surface chemistry that 
permits their use in various in vitro and in vivo applications. Furthermore, the inorganic 
composition of QD makes them highly resistant to photobleaching and biodegradation, which 
permits their use in long-term imaging applications [7]. With the development of functionalised 
QD, it is possible to circumvent the limitations of organic fluorophores to label biomolecules of 
interest, study subcellular processes and design experiments with greater flexibility [3,4,8,9]. 
 
8 
 
More recently, QD have increasingly been exploited for their imaging and therapeutic potential 
in vivo. Fluorescent QD emitting in the visible range (400-700nm) have shown promising 
results for superficial imaging, while near infrared-emitting (NIR) QD (700-850nm) have been 
successfully applied for whole body imaging of small animals in preclinical studies [10–13]. In 
2008, the first in vivo human clinical trials were performed for sentinel lymph node (SNL) 
imaging in oncology using NIR organic dyes, paving the way for other NIR fluorophores to be 
tested [13–16]. However, the efficacy and potential toxicity of using QD as biological probes 
has not been well-established. This review will explore the potential applications of QD as 
biological probes in vitro and in vivo and assess their suitability for clinical applications, 
especially for diagnosis and treatment. 
 
Quantum dots as biological probes in vitro:  
 
Quantum dot applications in histological and live cell imaging: 
Histological imaging techniques such as immunohistochemistry (IHC) and fluorescence in situ 
hybridisation (FISH) have traditionally been performed using organic fluorophores to evaluate 
the phenotype of cells and detect protein biomarkers within cell and tissue specimens with 
high sensitivity, specificity and spatial resolution. In 1998, Bruchez et al and Chan et al were 
the first to demonstrate the potential application of QD for in vitro histological imaging of cell 
and tissue samples [13–18]. Bruchez et al successfully labeled F-actin filaments in fixed 
mouse 3T3 fibroblasts using biotinylated QD interacting with phalloidin-biotin and streptavidin 
[17]. Alternatively, QD have also been successfully employed in FISH analysis [19]. In 2007, 
Knoll demonstrated that QD conjugates can be used in human metaphase chromosome FISH 
to visualise single copy sequence DNA probes as short as 1500 nucleotides in length, which 
significantly enhances the sensitivity of conventional cytogenetic analysis to detect subtle 
chromosomal rearrangements and to provide diagnostic and prognostic information for 
chromosomal disorders [20]. Quantum dots have also been successfully applied for high-
resolution immunofluorescence imaging of fixed cells and subcellular structures, such as 
membrane proteins [21,22], microtubules [21], actin filaments [17], cytoplasmic organelles and 
nuclear proteins [21,23].  
 
Although QD imaging of fixed cells and tissues can provide useful information about 
biomolecule expression, distribution and cellular and subcellular structure, it provides little 
information about function and the dynamic interactions between subcellular biomolecules. 
Hence, many studies are employing QD in live cell and tissue imaging to label intracellular 
targets such as cytoskeletal components and nuclear antigens, and to investigate complex 
subcellular dynamic processes such as cell-surface receptor or lipid transport [24–26]. In 
2003, pioneering studies by Dahan et al demonstrated the Single Particle Tracking (SPT) of 
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individual glycine receptors in neuronal membranes of live cells over periods ranging from 
milliseconds to at least 20 minutes [27]. This was in stark contrast to their SPT of glycine 
receptors with organic dye Cy3, when tracking was limited to only 5 seconds [27]. In following 
studies, Howarth et al successfully employed streptavidin-conjugated QD and E. coli biotin 
ligase to label and track the motion of cell-surface epidermal growth-factor receptors (tagged 
to an acceptor peptide sequence) in live HeLa cells with high sensitivity using a versatile 
approach that can be applied to virtually any cell-surface protein [28]. In 2016, Verala et al 
advanced this technique to label neocortical neuron dopamine receptors with QD in rats in 
vivo and subsequently used SPT in acute rat brain slices ex vivo [29]. In other live cell imaging 
studies, FRET technology has also been applied successfully to increase signal to noise ratio 
and to unambiguously track the subcellular motion of biomolecules [30–32]. Given the 
proliferation of modern cancer drugs that alter gene expression and target subcellular 
processes and structures, numerous studies are employing QD to study endocytosis, nuclear 
and cytoplasmic transport of biomolecules in order to improve subcellular drug delivery 
[17,21,33–38].  
 
 
Quantum dots as biological probes in vivo:  
The application of QD in vivo presents a special optical challenge. First, the elevated levels of 
autofluorescence from cells and tissues precludes the use of visible light (400-700nm) for in 
vivo imaging. Second, the absorption and scattering of visible light wavelengths severely 
restricts the imaging of tissues beyond a few millimeters in depth. However, near infrared 
(NIR) wavelengths (700-1100nm) are located within a region of the spectrum where the 
absorption coefficients of tissue (λ <600nm) and water (λ >1150nm) are minimal [39]. This 
minimises the tissue autofluorescence and increases the signal to noise ratio for imaging 
purposes. Moreover, these NIR wavelengths have a tissue penetration depth of several 
centimeters and minimise the photodamage to cytosolic and nuclear material induced by 
shorter wavelengths [40–42]. Taken together, this presents an opportunity to use NIR 
wavelengths to take advantage of this ‘optical tissue window’ for in vivo imaging [39]. As 
opposed to using NIR emitting QD, pioneering studies by Larson et al have successfully 
demonstrated that two-photon excitation of green-emitting QD can also be used to image 
dynamic processes in mice within capillaries several hundred micrometres deep [41]. Since 
then, other research groups have further developed multiphoton excitation of QD to image 
various dynamic processes such as the vascular circulation and subsequent extravasation of 
tumor-labelled QD into lung tissue in vivo [43].  
 
Despite all the optical and chemical advantages of employing QD for human clinical 
applications, the vast majority of research in vivo has been done using animal models due to 
the concerns of potential QD accumulation and toxicity within cells and tissues [44,45]. 
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However, it is important to highlight the advances being made in this in vivo frontier in animal 
models. Over the last decade, QD have been used for six major applications in vivo: 1) 
biodistribution studies such as pharmacokinetics, histological analysis, renal and 
reticuloendothelial system (RES) clearance [46], 2) vascular imaging studies such as blood 
and lymphatic vessel imaging [41], and sentinel lymph node mapping [45,47], 3) QD tracking 
studies of stem cells [48], metastatic cancer cells [43,49,50], and embryological and malignant 
cell division, 4) tumor imaging studies such as superficial and deep tissue imaging for image-
guided surgery [51,52], 5) therapeutic studies for cancer such as Photodynamic therapy (PDT) 
[53], and 6) theranostics for cancer, where QD are employed for simultaneous diagnostic 
imaging (fluorescence combined with MRI, PET, CT contrast agents) and therapeutic 
interventions, including active targeting and drug delivery in tumors [54–56].       
 
Potential clinical applications of Quantum Dots 
Tissue diagnostics 
In vitro and ex vivo tissue diagnostics of patient samples are perhaps the most important 
clinical applications of currently available QD technologies. It allows for the simultaneous 
collection of multi-dimensional information from both the tumor microenvironment and from 
cancer cells to foster a personalised medicine approach to patient care. For example, Chen 
et al quantitatively determined the cell-surface receptor distribution of invasive breast cancer 
cells recovered from 700 patients, using QD-based spectral analysis techniques [57,58]. 
When compared with conventional IHC, the QD-conjugate IHC approach was found to be 
much more sensitive, specific and cost-efficient [57,58]. In a follow up study by the same group 
of researchers, Li and colleagues enhanced the prognostic potential of QD IHC by adding a 
new macropathologic indicator, namely tumor size [59]. Through this approach, they were able 
to identify a new subgroup of HER2-expressing breast cancer patients with a drastically 
reduced 5-year disease-free survival, who were not identified by traditional HER2 gene 
amplification methods [59]. The results of such studies will likely be instrumental in early 
detection and formulating a more personalized targeted therapy for breast cancer.  
 
The multiplexing capabilities of QD have enormous potential for clinical biomarker detection 
and imaging using IHC techniques [58,60–63]. In 2011, Liu et al conducted a QD-based 
double color imaging of HER2-overexpressing breast cancer invasion by simultaneously 
labelling cell surface HER2 and type IV collagen in the tumor matrix [64]. Furthermore, the 
authors demonstrate the inverse correlation between cell surface HER2 expression level and 
the amount of type IV collagen in the cancer matrix, suggesting a metastatic progression 
sequence. In another study by Yezhelyev et al, QD multiplexing was used for the simultaneous 
characterization of multiple biomarkers (HER2, ER, PR, EGFR and mTOR) in the MCF-7 
breast cancer cell line, as well as formalin-fixed paraffin-embedded clinical specimens of 
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breast cancer [65]. Importantly, this study demonstrated the ability of QD-conjugates to detect 
low levels of HER2 cell surface expression that correlate closely with HER2 gene 
amplification, quantified using traditional techniques including FISH, Western blot analysis and 
IHC. This study clearly demonstrated the multiplexing potential of QD for the molecular 
profiling of single tissue specimens in anatomic pathology. Such advances suggest that QD 
will have significant implications in anatomic pathology and become a powerful diagnostic and 
prognostic tool in clinical medicine for the quantitative detection of multiple biomarkers 
simultaneously in small biopsy specimens. 
 
Sentinel lymph node mapping 
Ever since the pioneering studies by Kim et al in 2003, where they successfully demonstrated 
the application of NIR type II QD for sentinel lymph node (SLN) mapping in mice and pigs in 
vivo, many other research groups have subsequently explored NIR QD for solid tumor studies 
[66]. Given the steady rise in the incidence of lymph node-negative breast cancer, there has 
been increasing interest in axillary lymphatic system mapping to determine cancer metastasis 
by identifying the SLN, plan for biopsy/surgery and evaluate patient prognosis [67]. The 
multiplexing potential of QD enables the simultaneous mapping of multiple lymphatic drainage 
territories in real time. For example, Huma et al employed the use of two types of NIR QD with 
different emission spectra to simultaneously visualize two separate lymphatic flows draining 
the breast and upper extremity in mice [68]. A subsequent study by the same group of 
researchers expanded the multiplexing potential of QD to simultaneously image five separate 
lymphatic basins using five colours of QD in mice [69]. Moreover, a similar SLN mapping study 
by Robe et al did not reported any detectable levels of QD accumulation in RES organs like 
the liver, spleen and kidney in mice [70]. Such studies suggest that QD can provide a non-
invasive alternative for axillary lymphatic system mapping to determine the lymphatic drainage 
pattern for SLN biopsy and the path of cancer cell migration in vivo for periods over 24h [70].  
 
Micrometastatic detection 
Efforts to elucidate the path of cancer cells as they emigrate outside the primary tumor site 
has become increasing important in determining effective therapy and improving patient 
prognosis [71,72]. This ‘micrometastasis’ of individual and small aggregates of cancer cells is 
believed to be the earliest form of metastasis and happens long before clinically recognized 
macroscopically visible metastasis [71]. However, conventional histological techniques using 
hematoxylin and eosin (H&E) staining are not sensitive enough to reliably detect 
micrometastasis during intraoperative frozen section analysis [73]. In 2013, Ojima et al 
implemented a QD-based double labeling technique with IHC and H&E staining to 
demonstrate that when compared to conventional H&E staining alone, their technique 
significantly reduced the false-negative rate of micrometastasis detection (single cells and 
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small aggregates of cancer cells) in intraoperative frozen section specimens collected from 
the lymph nodes of 100 breast cancer patients [73]. The in vivo imaging potential of QD for 
tracking micrometastasis was established by Gonda et al, where they employed anti-protease-
activated receptor 1 antibody conjugated QD to identify four distinct stages of cancer cell 
micrometastasis: cancer cells within the tumor and away from blood vessels, near blood 
vessels, in the blood stream, and adherent to the inner luminal surface of blood vessels in 
normal tissues near the primary tumor [74]. Such advances in QD-based imaging in vivo, have 
led to the development of high-resolution 3D imaging [75] and multimodal imaging techniques 
[76] for diagnosis and image-guided surgery [52][67]. For example, Ma et al developed 
multilayered, targeted core-shell nanoparticles composed of ferric oxide (core), visible-
fluorescent QD (inner shell), NIR QD (outer shell) and conjugated to anti-HER2 antibodies 
(surface) for multimodal imaging of human breast cancer-bearing mice in vivo [77]. This study 
successfully demonstrated the multimodal imaging potential of QD for fluorescence, MRI and 
NIR imaging in real-time at tissue depths of greater than 1cm. The inclusion of various MRI 
contrast agents (within nanoparticles) can significantly increase the diagnostic potential of 
these hybrid nanoparticles by permitting deep tissue imaging using MRI scanners widely 
available at modern clinical facilities [78]. Therefore, it is expected that this technology will 
make a significant contribution to noninvasive SLN mapping, biopsy techniques and surgical 
excision of tumors in clinical medicine.  
 
Theranostic Quantum Dots for cancer treatment 
Recently, theranostic QD have also been employed in breast cancer treatment. In 2007, Tan 
et al conjugated QD with small-interfering RNA (siRNA) oligonucleotides targeted towards 
HER-2, and successfully downregulated the receptor expression in breast cancer cell lines 
[79]. In 2008, Park et al synthesized a multifunctional nanoparticle composed of NIR QD, iron 
oxide and the anti-cancer drug doxorubicin to perform QD-based fluorescence imaging, MRI 
and drug delivery in breast cancer-bearing mice in vivo [56]. These studies highlight the 
theranostic potential of QD for simultaneous dual-mode diagnosis and therapy for cells in vitro 
and organs in vivo or ex vivo by combining the advantages of optical imaging and MRI. 
Another dynamic area of research that exemplifies the theranostic potential of QD is PDT, 
where light of a specific wavelength is used to irradiate a photosensitiser drug, triggering the 
generation of reactive oxygen species (ROS) from intracellular oxygen [80]. The locally 
produced ROS induce cell death and necrosis in surrounding tissues, making PDT an 
attractive therapeutic option for non-invasively targeting cancer cells. Photosensitizer drugs 
are typically highly hydrophobic and have limited solubility, which has prompted a number of 
attempts to incorporate the photosensitiser into a carrier system, such as polymeric 
nanoparticles, gold nanoparticles, liposomes, carbon nanotubes and graphenes in order to 
enhance solubility [81–86]. Other research groups have conjugated nanocarriers with 
targeting ligands, such as peptides, proteins, monoclonal antibodies, steroids and folic acid in 
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order to enhance cellular targeting and cellular internalization and reduce damage to healthy 
tissues [87–91]. Alternatively, Ge et al recently developed a novel PDT agent using non-
cadmium-based graphene quantum dots (GQD) [92]. The GQD possessed high singlet 
oxygen quantum yields, a broad absorption band spanning the entire visible region as well as 
the UV region, and a strong deep-red emission. Promising in vivo PDT efficacy of the GQD 
was demonstrated against subcutaneous breast cancer xenografts in female BALB/nu mice. 
Tumors treated in the PDT GQD group initially turned dark and festered, increasing in volume 
slightly, then began to decrease in volume around day 9 and were destroyed 17 days post 
treatment. Tumor regrowth was not observed in the PDT CQD group over the course of 50 
days. Tumors in the control groups however, which included mice receiving GQD injections 
but no irradiation and mice receiving irradiation but no GQD treatment, continued to grow 
significantly throughout the study period and exhibited a strong fluorescent signal, indicating 
that nether GQD injection or light irradiation alone were sufficient to kill tumor cells. Thus, Ge 
et al have demonstrated the theranostic potential of QD PDT agents, which may be used for 
imaging and treating breast cancer.   
 
Active and passive targeting of solid tumors with nanoparticles 
One major advantage of using nanoparticles for drug delivery is their ability to employ active 
and passive targeting of solid tumors. As a case in point, approximately 25% of all breast 
tumors overexpress HER2 [93]. In treating this type of breast tumor, an FDA-approved 
humanised monoclonal antibody against HER2, called Herceptin (trastuzumab), is usually 
administered in conjunction with other chemotherapeutic drugs [94]. The availability of 
Herceptin immediately presents an opportunity to create targeted nanoparticle drug delivery 
systems, through which many anti-cancer therapeutics can be delivered to the cancer site. 
This type of antibody-targeted delivery system is referred to as active targeting. 
 
In contrast, passive targeting in breast cancer constitutes the accumulation of 
macromolecules, between 5-200 nm in diameter, at the tumor site. It is believed that this 
accumulation occurs primarily for two reasons: first, the tumors are known to have abnormal 
vasculature, which may be disorganized, unresponsive to vasoactive stimuli and up to 10 
times more permeable than normal capillaries. This allows for nanoparticles 5-200nm in 
diameter to extravasate and accumulate in solid tumors. However, nanoparticles less than 
~5nm extravasate at the same rate as the inverse diffusion process, thus do not accumulate 
in solid tumors. Second, tumors are also known to have poor lymphatic drainage, decreasing 
the rate of macromolecular clearance from the solid tumor. Together, these factors result in 
the selective accumulation of nanoparticles (5-200 nm) at the tumor site. Originally 
documented in 1986 for solid tumors in mice, this enhanced permeability and retention (EPR) 
effect has been reported for many types of solid tumors in humans as well [95][96,97].  
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MICROSPHERES FOR BIOPHARMACEUTICAL DELIVERY IN MEDICINE 
AND TRANSPLANTATION IMMUNOLOGY 
 
Microspheres are small (usually 100-800um) spherical structures that can be used for drug 
and cell delivery. Given the diversity in the size, structure, composition and application of these 
microspheres, this review will focus on hollow alginate-based microspheres, known as 
microcapsules, for drug and cell delivery. Alginate is among the few biomaterials that has 
passed most stages of the scientific and regulatory approval for human applications. Alginate 
is a natural linear polymer derived from algae and is composed of mannuronic (M) and 
glucuronic (G) acid units in homopolymers of M-M, G-G and G-M [98]. Controlling the amount 
of each homopolymer in the mixture determines the alginate biomaterial properties including 
its permeability, which allows it to serve as a selectively-permeable membrane for biological 
applications such as immuno-isolation.       
Immuno-isolation is a relatively simple idea to the tissue rejection problem. It proposes to 
encapsulate the transplanted cells in a selectively-permeable membrane that allows nutrient 
and gas exchange, while preventing the humoral and cellular immune system from contacting 
the foreign cells. The transplanted cells can then provide a means of long-term, continuous 
sensing, synthesising and delivering cell-derived biological molecules of interest in vivo in a 
localised manner [98]. Moreover, this microencapsulation technology can be configured into 
a medical device such that it can be scalable and retrievable [99]. In 1964, T.M.S Chang 
proposed the idea of using ultra-thin polymer membrane microcapsules for immunoprotection 
of transplanted cells [100]. Since then, there have been many allogeneic and xenogeneic 
transplantation trials of various kinds of cells, with varying results. For example, pancreatic 
islet beta-cells are perhaps the most commonly transplanted cell type since they provide a 
solution to insulin-dependent diabetes mellitus (IDDM) that affects a great proportion of the 
diabetes population. Such bioencapsulation has provided a range of therapeutic treatments 
for diabetes, renal failure, haemophilia and cancer. However, a lack of reproducibility and 
consistency of previous studies has been a major problem, which can generally be attributed 
to variability in microcapsule manufacturing protocols and the immune response. First, the 
lack of clinical-grade polymers has hindered the success of the bioencapsulation strategy. 
Although many natural and synthetic polymers are being explored, most of them have 
compatibility issues and illicit a deleterious immune response. Second, current methods of 
encapsulating cells are inconsistent and tend to be non-uniform. Third, the variability in the 
polymer membrane types necessitates their individual characterisation to determine 
compatibility with the immune system [100]. Fourth, encapsulated cells undergo a period of 
ischemia post-implantation, which alters their viability and growth characteristics. Hence, a 
method to reliably evaluate the viability, proliferation and secretory ability of encapsulated cells 
can greatly improve our understanding of the factors that influence their survival. 
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Transplantation immunology 
The mammalian immune system is divided into two parts: innate and adaptive. The innate 
immune system responds immediately to foreign antigen with limited strength. In contrast, the 
adaptive system has a delayed onset; however, it can be tuned to be much more effective 
against the foreign antigen. The adaptive immune system can be activated by two separate 
pathways: direct and indirect (Figure A). The direct pathway depends critically on the migration 
of allogeneic antigen presenting cells (APC) (e.g., dendritic cells) from within the grafted tissue 
to host lymphoid tissue, where they directly present peptide to CD4+ T cells and induce their 
activation [101]. An encapsulating membrane that prevents allogeneic APC migration would 
effectively prevent graft rejection through this mechanism. The direct pathway is considered 
the major mechanism of graft rejection. In contrast, the indirect pathway is a relatively minor 
mechanism of acute graft rejection. In this mechanism, protein fragments normally shed from 
allogeneic cells are internalised by host APCs and presented to CD4+ T cells to induce their 
activation [101]. Encapsulating cells in a membrane does not prevent the indirect pathway of 
activating the immune system since some soluble protein fragments are too small to be 
retained within currently employed microcapsule membranes. The indirect pathway is 
considered to play a greater role in chronic graft rejection, which can occur over weeks to 
months post-transplant. Once the immune system is activated, either through the direct or the 
indirect pathway, the effector cells of the immune system such as CD8+ Cytotoxic T 
Lymphocytes (CTL) bind the foreign major histocompatibility complex (MHC) molecules and 
kill the allogeneic cells. This cytotoxic effect can also be mediated through soluble factors such 
as reactive aldehydes, oxygen free radicals and granzymes, which are all too small to be 
excluded by most encapsulating membranes [101]. Overall, it seems inevitable that immuno-
isolation alone is not sufficient to prevent graft rejection and can only be a temporary solution 
to the many challenges encountered in allogeneic transplantation. Thus, many mechanisms 
of peripheral tolerance induction are currently being investigated, including the inhibition of 
CD8+ T cell activation, antigen presentation without costimulation, inhibition of CD4+ T cell 
cytokine production and induction of Regulatory T cells (Tregs). It is important to note that 
tolerance induction requires time to take effect and immuno-isolation provides a simple 
solution to attenuate aggressive immune responses while the induction of tolerance is being 
processed. Hence, it follows that a combination of immuno-isolation and tolerance induction 
strategies would provide a long-term solution to the graft rejection problem. 
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Figure A: Pathways of allograft recognition. This figure illustrates the direct and indirect 
pathways of allograft recognition. Self-created figure based on theory presented by Game et 
al [102]. 
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GENE THERAPY WITH VIRAL NANOCARRIERS 
 
The American Society of Gene and Cell Therapy defines gene therapy as the “introduction of 
genetic material and/or cells in the body to treat or prevent disease.” Over the years, gene 
therapy has been successfully applied to several conditions including known protein 
deficiencies such as haemophilia, in addition to cancer, neurodegenerative disorders, 
cardiovascular conditions and infectious diseases.  
 
The bioengineered adeno-associated viral (AAV) vector has been exploited for the purposes 
of gene delivery mainly due to its high transduction efficiency, replication-deficient nature, 
reduced chance of integration into the host genome, and convenience to produce in the 
laboratory with high titres. The AAV genome is a 7kb single stranded DNA molecule and 
requires a helper virus such as adenovirus for replication. This makes AAVs ideal to 
bioengineer and use in humans as a ‘single-shot’ gene delivery system, since they do not 
have the ability to replicate themselves in human cells. Despite all these advantages, several 
initial clinical trials were unsuccessful in long-term gene expression at therapeutic levels in 
humans. However, there are several other bioengineered variants of AAV, such as self-
complementary AAV vectors (scAAV) that are able to increase Factor IX expression by 20 
times compared to regular AAV vectors, which are currently being developed to enhance long-
term gene expression in clinical trials [103]. If successful, this AAV-based gene therapy 
strategy may be used to treat many multiple genetic disorders with known protein deficits 
[104].   
 
Adenoviruses are (80-100nm) non-enveloped icosahedral double stranded DNA (dsDNA) 
viruses [105]. They can be used as highly effective gene delivery vectors with transduction 
efficiencies approaching 100%. Furthermore, they can be used to deliver gene fragments up 
to 30kb in length. However, the major drawback with adenoviral vectors is their transient gene 
expression, which can last from a few days to about a month. This is a result of their inability 
to integrate the introduced DNA segment into the chromosomes of the transduced cell.  
 
In contrast, retroviruses are enveloped RNA viruses (80nm-120nm) that can be used to deliver 
genes up to 10kb in length [105]. Retroviruses have three salient features that make them 
ideal for gene delivery: First, the retrovirus can integrate into the host cell genome for long-
term gene delivery. Although integration into the host genome raises the concern for oncogene 
activation, many new site-specific insertion techniques have been developed to minimise the 
chance of insertional mutagenesis. Second, the retroviral genome can be modified to tailor 
gene delivery for various tissue and cell types despite having a smaller gene delivery capacity. 
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Third, high gene product levels can be achieved using cell-specific promoters [105]. These 
three characteristics make retroviral nanoparticles ideal for gene delivery in cell-based tissue 
engineering constructs and for the allogeneic transplantation of cells, tissue and organs. It is 
evident that viral nanoparticles can be employed for efficient, targeted gene delivery for the 
long-term modification of human cells. Strategies to enhance gene transduction efficiency in 
human cells, understanding and modulating the immune response to viral nanoparticles in 
vivo, and the potential of using genome editing techniques for the treatment of diseases are 
all subjects of investigation [103].  
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AIMS AND OBJECTIVES 
The aim of this study is to evaluate the suitability of nanoparticles and microspheres for 
biopharmaceutical delivery in medicine, with an emphasis on biomaterial interactions with the 
innate and adaptive immune system. Specifically, we study the behaviour of QD nanoparticles 
in live mammalian cells, design a smart non-viral nanocarrier for intracellular oligonucleotide 
delivery, develop and test viral nanoparticles for gene delivery in tissue engineering and 
allogeneic transplantation, develop and test microspheres for cell encapsulation and 
biopharmaceutical delivery, and discuss the potential applications of these technologies in the 
clinical context of chronic non-healing pressure ulcers.  
 
 
Objectives: 
 
1. Characterize QD behavior in aqueous solution and within live mammalian cells 
2. Design a smart non-viral nanocarrier for intracellular oligonucleotide delivery 
3. Develop and test microspheres for cell encapsulation and biopharmaceutical delivery 
4. Develop a flow cytometry assay to study the behaviour of encapsulated cells and 
measure cell-mediated cytotoxicity 
5. Develop viral nanoparticles for gene delivery and test the transduced human cells 
against allogeneic immune cells in vitro 
6. Highlight the suitability of nanoparticle and microsphere technologies in a rare case 
of hemicorporectomy due to chronic non-healing pressure ulcers  
 
 
METHODS 
Please refer to the published papers in the appendix for details. 
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SUMMARY OF PUBLISHED WORK 
 
PAPER 1: “CHARACTERIZATION OF QUANTUM DOT BEHAVIOUR IN LIVE 
MAMMALIAN CELLS” (2005) CANADIAN UNDERGRADUATE PHYSICS 
JOURNAL. 3(3), PP.7-12. 
 
Until recently, studies of live cells were limited to the use of organic fluorescent probes to label 
molecules of interest. However, organic probes have many undesirable optical, physical and 
chemical properties that limit their use in live cells. With the development of functionalised QD, 
it has become possible to circumvent the limitations of organic fluorophores and design 
experiments with greater flexibility [3,4,8]. However, the application of QD as fluorescent 
probes in live cells remains a challenge mainly due to manufacturing deficiencies in their outer 
hydrophilic layer and difficulty in their intracellular delivery.  
In this paper, we first characterised the optical behaviour of three types of QD in aqueous 
solution using fluorescence correlation spectroscopy. We found that although all the QD were 
made of the CdSe-ZnS core-shell material (Figure 1), their optical and physical characteristics 
differed significantly in aqueous solution. We observed that the hydrodynamic radius of single 
QD varied up to 30% (radius 13.9- 19.8nm) and their molecular brightness varied up to 4x 
based on their hydrophilic coating. Interestingly, in some types of QD, we observed the 
presence of a larger second component diffusing in solution. We modified our mathematical 
model of diffusion to include a second diffusing component in solution and determined that 
these larger diffusing components were approximately 150nm in radius and were aggregates 
of QD. We then immobilized QD in polyacrylamide gel to further characterise the optical 
behaviour of single QD and aggregates (Figure 2). Aggregates are collections of QD, held 
together mainly through electrostatic interactions due to an imperfect hydrophilic layer [106]. 
We observed that single QD exhibit the unique phenomenon of ‘blinking,’ a on-and-off 
fluorescence behaviour that allows them to be distinguished from other fluorophores in the 
system, including aggregates of QD, which do not blink (Figure 3). 
We then studied the behaviour of three types of QD in live mammalian cells cultured in vitro. 
Most significantly, we discovered that QD aggregates are recognized by innate immune 
defenses of cells as foreign bodies and packaged into lysosomes (Figure 4). We also 
observed the directed and saltatory motion of QD within cells (using colocalization and SPT 
studies) and measured their average velocity to be 0.18-0.26 µm/s, suggesting that QD are 
trafficked via motor proteins along microtubules (Figure 5). In contrast to QD aggregates, we 
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observed that single QD with an uncompromised surface coating are not recognized as foreign 
objects and therefore can be useful as biological probes. 
To our knowledge, this was the first study to show how the QD surface coating significantly 
influences their optical properties (molecular brightness and blinking) and behaviour in 
solution (deficient coatings promote aggregation in aqueous environments). In our live 
mammalian cell studies, we were also the first to suggest that QD were not innocuous and 
that subcellular innate immune defenses are recognizing these QD aggregates as foreign 
objects and packaging them into lysosomes and trafficking them along microtubules. 
Furthermore, we learned that a multicomponent diffusion model is required to analyze the 
diffusive behaviour model of QDs due to the presence of aggregates. In the complex 
intracellular environment of living cells, equations like the Stokes-Einstein relationship and 
equations modeling Brownian motion in solution are harder to apply given the multitude of 
possible interactions with intracellular proteins.  
Our published results highlight the importance of preventing QD aggregation by using a proper 
hydrophilic surface coating. In addition, our research also serves to emphasise the limitations 
of currently available commercial QD nanoparticles and the potential consequences of their 
use in studying biological processes. 
Perhaps the most complete study to date of QD behaviour at the subcellular and systemic 
level involved the QD targeting of HER2-overexpressing breast cancer conducted by Tada et 
al in 2007 [107]. The authors quantitatively tracked single NIR-emitting QD-anti-HER2 
antibody conjugates injected into HER2-overexpressing tumor-bearing mice in real-time, 
using high-speed confocal microscopy. Importantly, the authors were able to identify six 
stages of QD delivery: 1) initial circulation within blood vessels, 2) extravasation from blood 
vessels, 3) diffusion in the extracellular region, 4) binding to cell surface HER2, 5) transport 
from the cell surface to the perinuclear region, and 6) accumulation in the perinuclear region. 
This seminal study provides a unique perspective of all the stages of delivery, as well as the 
challenges that an anti-cancer theranostic QD-conjugate injected in vivo will have to overcome 
for it to successfully reach its target site (cell cytoplasm) and have the intended effect. 
Interestingly, this study also revealed that movement of the QD-conjugate within cells was 
“stop-and-go,” a type of saltatory motion highly suggestive of retrograde active transport along 
microtubules using molecular motors. This study not only confirms our experimental 
observations that QD are actively transported within cells along microtubules (Figure 5), but 
also provides new insight into nanoparticle behavior in complex biological environments such 
as intravascular, extracellular and intracellular compartments.  
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Figure 1: Schematic of a quantum dot. A typical CdSe-ZnS core-shell QD with a hydrophilic 
layer that terminates in carboxylic acid functional groups for covalent coupling to other 
molecules of interest. This figure was reproduced from the publication being presented in this 
section. 
 
 
Figure 2: Immobilised single QD and QD aggregates. Fluorescence microscopy image of 
unfiltered QD embedded in a 5% polyacrylamide gel. The long arrow points to an aggregate 
and the short arrow points to a single QD. Self-acquired image reproduced from the 
publication being presented in this section. 
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Figure 3: Blinking of single QD compared to aggregates. Fluorescence intensity as a 
function of time for a particle identified as a single QD (thick black line) and a particle identified 
as an aggregate (thin grey line). These QD were embedded in 5 % polyacrylamide gel and 
imaged using time-lapse video microscopy with a time resolution of 100 milliseconds. A 
background intensity has been subtracted. This figure was reproduced from the publication 
being presented in this section. 
 
 
Figure 4: Confocal microscopy of CdSe-ZnS QD in Rat fibroblasts. QD (orange) were 
introduced into the cytoplasm of live Rat fibroblasts (yellow) using pinocytic loading and 
confocal imaging shows single QD and aggregates within the cytoplasm and on the cell 
surface. Rat fibroblasts appeared unperturbed by the presence of QD within the cytoplasm 
and the QD were extremely photostable over the imaging period of 8h. Self-acquired image 
captured using a Nikon Eclipse upright confocal microscope.    
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Figure 5. Directed QD trafficking along microtubules in live Rat fibroblasts. 
Chronological image sequence of a region of the cytoplasm in a live Rat fibroblast showing 
the saltatory directed trafficking of commercial CdSe-ZnS QD (images a, b, c, f, g, h) along 
microtubules within lysosomes (images d, e) stained with Lysotracker dye. Self-acquired 
image reproduced from the publication being presented in this section.  
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PAPER 2: “STRATEGIES FOR OCULAR SIRNA DELIVERY: POTENTIAL 
AND LIMITATIONS OF NON-VIRAL NANOCARRIERS” (2012) JOURNAL OF 
BIOLOGICAL ENGINEERING. 6(1) PP. 7. 
Ribonucleic acid interference (RNAi) can provide a novel therapeutic modality to treat many 
human diseases by interfering with disease-causing and disease-promoting genes in a 
sequence-specific manner. Theoretically, RNAi can be used to selectively alter the expression 
of any transcribed gene. This new paradigm in therapeutics allows one to address disease 
states previously considered ‘undruggable.’ However, most nanoparticle drug delivery 
systems have numerous limitations, including a short blood half-life, poor specificity and 
uptake in target tissues, and undesirable off-target effects, which significantly hamper the 
successful application of siRNA therapeutics in medicine. Intracellular siRNA delivery poses 
the additional challenge of siRNA recognition by the innate immune system and their inability 
to passively diffuse across cell membranes (Figure 6). 
In this review paper, we evaluate other types of non-viral nanoparticles for oligonucleotide 
delivery, specifically siRNA delivery for ophthalmic applications. We study the eye as a special 
case since it is a relatively immune privileged and accessible site, which allows the direct 
application of drugs, thereby bypassing the systemic circulation and avoiding many innate and 
adaptive immune defenses. We review common non-viral siRNA delivery systems: polymer, 
liposome, protein and dendrimer. Although various types of oligonucleotide delivery systems 
are currently being developed for specific applications, a general strategy for intracellular 
oligonucleotide delivery has not been proposed to our knowledge. Our major contribution to 
the field in this article was to outline the general design features of a ‘universal’ smart 
nanoparticle for intracellular oligonucleotide delivery, based on our previous work with 
nanoparticles as well as ideas presented in reviewed literature. We note that many human 
viruses sequentially deploy strategies to overcome common barriers at the systemic, organ, 
tissue, cellular and subcellular level to deliver their genetic material within cells. We apply the 
principles of viral nucleotide delivery systems for the design of a nature-inspired, smart 
‘universal’ nanoparticle for intracellular oligonucleotide delivery (Figure 6,7). Initial results from 
prototypes of this type of smart nanoparticle are shown in Figure 29 (Future Work section), 
where we successfully demonstrate that degradable polymer nanoparticles with a core-shell 
structure can be used in mammalian cells. Our proposed four component core-shell system 
incorporates stimuli-responsive biodegradable materials, stealth from the immune system, 
targeting ligands for tissue and cell-specific targeted therapeutic delivery, endosomal escape 
strategies for intracytoplasmic delivery, and controlled release and protection of the 
therapeutic agent from biodegradation. We believe that a nature-inspired design to 
sequentially deploy strategies to overcome each barrier for intracellular oligonucleotide 
delivery would significantly improve the biodistribution and bioavailability, reduce toxicity and 
enhance therapeutic outcome. 
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Figure 6: Nanocarrier uptake and intracellular siRNA delivery. This illustration shows that 
uptake of antibody targeted nanocarriers (10-100 nm) occurs via receptor-mediated 
endocytosis. The key step in cytoplasmic siRNA delivery involves low pH-triggered 
nanocarrier disassembly and endosomal escape. A smart nanocarrier can induce endosomal 
escape by lysing or fusing with endolysosomes upon acidification. The pH change can also 
be used to trigger the dissociation of the nanocarrier, therefore releasing the siRNA cargo into 
the cytosol. Self-created figure reproduced from the publication being presented in this 
section. 
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Figure 7: Schematic of four-component ‘universal’ nanocarrier for siRNA delivery. This 
illustration highlights the salient features of a four-component, targeted core-shell nanocarrier 
for siRNA delivery. Self-created figure reproduced from the publication being presented in this 
section. 
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PAPER 3: “TEMPERATURE-SENSITIVE POLYMERS FOR DRUG 
DELIVERY” (2012) EXPERT REVIEW OF MEDICAL DEVICES. 9(4) PP. 
339-351. 
 
In this paper, we present a targeted review on stimuli-responsive polymers, focusing on 
thermoresponsive polymers for drug and cell delivery. First, we review the main types of 
natural (elastin-like polypeptides, chitosan, cellulose derivatives, xyloglucan) and synthetic 
(polyphosphazenes, poly(N-isopropylacrylamide) and poly(ethylene oxide)-based 
copolymers) polymers. We report that natural biomaterials have the benefit of improved 
biocompatibility, non-toxic biodegradability and have defined cellular and biological 
interactions. However, given the limited number of natural polymers and challenges in their 
chemical modification, they have a restricted range of biomaterial properties. Moreover, 
natural materials have greater batch-to-batch variability, limited mechanical strength and the 
possibility of biological impurities that can have been known to trigger an immune response 
[98]. In addition, sterilisation of natural biomaterials for clinical applications is more challenging 
using conventional sterilisation techniques. In contrast, synthetic biomaterials have the benefit 
of greater compositional diversity and synthetic flexibility that offers more control over 
biomaterial properties such as molecular weight, mechanical strength, elasticity, scaffold 
shape and size, drug release profile, stimulus-response, biodegradation and immune 
activation. Moreover, synthetic biomaterials can be more easily sterilised with conventional 
techniques for clinical applications. These features make synthetic biomaterials more 
customisable, so that they can be engineered to suit the intended application.  
Second, we review polymer architecture (hydrogels, micelles, polymerosomes, 
interpenetrating networks, films and bulk gels) and the common internal (pH, temperature 
changes, ionic charge, antigen-antibody interactions, enzymes) or external stimuli (light, 
electricity, magnetism, ultrasound) that can be used to illicit desired changes in biomaterial 
properties. A case in point, Poly(N-isopropylacrylamide) copolymers have been shown to form 
thermoresponsive hydrogels that can be used as scaffolds for drug and cell delivery as 
minimally invasive therapeutics [108]. Interestingly, this material is in a fluid state and therefore 
injectable below its lower critical solution temperature of 33°C, but undergoes a reversible 
phase transition upon heating above that temperature. Hence, this material provides a means 
to deliver biopharmaceuticals including live cells and drugs in vivo, where the fluid polymer 
would transition to a hydrogel and provide a scaffold for cell growth and controlled release of 
the encapsulated drug. This in situ phase transition is particularly useful in hard-to-access 
applications such as the spinal cord and posterior ocular compartment, which require 
minimally invasive techniques.   
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As a contribution to the field, this paper provided a comprehensive review of the state-of-the-
art on thermoresponsive polymers and provided insight into the biomaterial characteristics for 
the design of novel stimuli-responsive and biocompatible drug delivery devices. Finally, we 
conclude that a combination approach, with natural and synthetic stimuli-responsive polymers 
engineered to respond to internal physiologic feedback from disease-specific stimuli and 
external signals will provide the optimal solution to designing novel drug and cell delivery 
scaffolds for clinical applications. 
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PAPER 4: “CHARACTERIZATION OF VIABILITY AND PROLIFERATION OF 
ALGINATE-POLY-L-LYSINE-ALGINATE ENCAPSULATED MYOBLASTS 
USING FLOW CYTOMETRY” (2010) JOURNAL OF BIOMEDICAL 
MATERIALS RESEARCH: PART B. 94B(2) PP. 296-304. 
 
One solution to the organ rejection problem has been to create protective barriers (natural or 
synthetic) between the transplant recipient’s immune system and the allogeneic cells. These 
immunoprotective barriers are designed to be impermeable to cells and large molecules such 
as antibodies, but permit the exchange of small molecules such as oxygen and nutrients. 
Previous studies with such barriers, however, have had limited reproducibility with varied 
success rates [109]. One of the major challenges with immunoprotective membranes is their 
immunocompatibility, which can play a significant role in determining the success of the 
transplanted cells. Many previous studies suggest that the cell-biomaterial interaction after 
encapsulation likely influences their behaviour. However, no prior studies examine the 
behaviour of transplant cells once they have been encapsulated and implanted in vivo. 
Immuno-isolation of allogeneic and xenogeneic cells within a microcapsule likely triggers an 
immune response via the escape of membrane permeable antigens and damage associated 
molecular patterns (DAMPs) from encapsulated cells, via the composition of the microsphere 
including immunogenic impurities, and also via the surface characteristics of the microsphere 
[98,110].  
In this paper, we develop and test nature-inspired hybrid polymer alginate-poly-L-lysine-
alginate (APA) microspheres to encapsulate live allogeneic cells for the delivery of coagulation 
Factor VIII in a mouse model of haemophilia A (Figure 8). In order to assess the behaviour of 
APA encapsulated cells, we developed a novel flow cytometry assay to evaluate their viability, 
granularity and proliferation. Viability is a very important parameter to determine accurately 
and precisely in cell encapsulation studies, as it correlates with the secretion of the therapeutic 
product of interest. First, we validated our novel flow cytometry assay by comparing the 
viability of encapsulated cells in vitro against the traditional trypan blue exclusion method and 
found them to be comparable, both correlating to FVIII secretion levels (Figure 9). 
Our novel flow cytometry assay also allowed us to evaluate the behaviour of encapsulated 
cells in terms of their morphology and proliferation, which can both potentially alter secretion 
of therapeutic product. To our knowledge, neither of these parameters have been previously 
assessed in any type of encapsulated cell preparation. We found that encapsulated cells 
within APA microspheres were morphologically more granular both in vitro and in vivo, when 
compared to non-encapsulated cells (Figure 10-11). We also found that encapsulation itself 
decreases the viability and increases the granularity of cells over the seven-day period 
observed (Figure 10). Moreover, implanted (for 6 weeks) encapsulated cells were significantly 
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smaller in size, with a lower viability than non-implanted encapsulated cells (Figure 11). 
However, when implanted encapsulated cells (retrieved after 6 weeks) were cultured in vitro 
(encapsulated), their average cell size, viability and granularity increased, which correlated 
with FVIII secretion levels (Figure 11-12). 
In our cell proliferation studies, we found that non-implanted encapsulated cells proliferate 
slower compared to free cells (Figure 13). In order to study in vivo proliferation rates, cells 
were labelled with a fluorescent dye, carboxyfluorescein diacetate succinimidyl ester (CFSE), 
encapsulated and implanted, and then retrieved after 7 days. Interestingly, implanted-
encapsulated cells proliferated faster in vivo (over 7 days) and were more heterogenous than 
non-implanted encapsulated cells, suggesting that encapsulated cell proliferation is influenced 
by the local microenvironment (Figure 14). 
Together, these data provide new insight into the behaviour of encapsulated cells, suggesting 
that encapsulating cells within the APA biomaterial itself reduced the viability of cells, induced 
changes in the cytoplasmic composition and morphology of the cells, and decreased the 
proliferation rate of encapsulated cells. Furthermore, the enhanced proliferation rate and 
heterogeneity of implanted encapsulated cells suggest that the local in vivo microenvironment 
can significantly alter the behaviour of encapsulated cells.   
To our knowledge, this was the first published study to characterise and compare 
encapsulated cells in vitro and in vivo using flow cytometry. We also demonstrate the use of 
de-encapsulation protocols in conjunction with flow cytometry to more consistently and 
comprehensively study the behavior encapsulated cells that have been retrieved from the 
complex multicellular in vivo environment. Our flow cytometry assay has four significant 
advantages: 1) can analyse thousands of cells per minute to allow a fast assessment of a 
representative sample population, 2) multiple parameters of cell health can be analysed, 3) 
discriminate between host immune cells and the encapsulating cells in a mixed population, 4) 
and provide objective and quantifiable data. We expect this knowledge to help in the 
development of cell and gene therapy protocols. 
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Figure 8. Murine myoblasts encapsulated within APA microcapsules (approximately 300-
400 µm in diameter). This image was reproduced from the publication being presented in this 
section. 
 
 
Figure 9. Relationship between FVIII secretion rate of non-implanted encapsulated FVIII 
secreting myoblast cells and viability. Secretion rate (■), trypan blue-based viability (▲) 
and flow-based viability (●) all significantly (p<0.05) decreased from day 0 to day 7. Trypan 
blue-based viability and flow cytometry-based viability were not significantly (p<0.05) different. 
Solid and dashed lines represent the linear regression fit of data presented. (Error bars 
indicate standard deviation; n=3). This figure was reproduced from the publication being 
presented in this section.  
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Figure 10. Representative FS/SS plots of non-implanted encapsulated FVIII secreting 
myoblast cells cultured in vitro. Samples of myoblast cells were de-encapsulated on day 0, 
1 and 7, and their viability assessed by flow cytometry. Viability significantly (p<0.05) 
decreases over the week, as indicated by the increased movement of live cells (green) from 
box A into box B. Granularity also increases (p<0.05) over the week, as indicated by the 
movement of cells into box F. (Data presented from ~30,000 events collected). This figure 
was reproduced from the publication being presented in this section. 
 
 
Figure 11. Representative FS/SS plots of encapsulated FVIII secreting myoblast cells 
retrieved 6 weeks post-implantation in mice. The recovered FVIII secreting myoblast cells 
were subsequently cultured in vitro, and samples de-encapsulated on day 0, 1 and 7 to assess 
their viability using flow cytometry. Viability significantly increases over the week, as indicated 
by the movement of cells into box B. Granularity slightly increases over the week, as indicated 
by the movement of cells into box F. (Data presented from >25,000 events collected). This 
figure was reproduced from the publication being presented in this section. 
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Figure 12. Relationship between FVIII secretion rate and viability of encapsulated 
myoblast cells cultured in vitro after being retrieved from mice. Secretion rate (■) did not 
significantly increase from day 0 to day 7. Flow-based viability (●) significantly (p<0.05) 
increased from day 0 to day 7. Trypan blue-based viability (▲) did not significantly decrease 
from day 0 to day 7. Trypan blue-based viability and flow-based viability were significantly 
(p<0.05) different. Solid and dashed lines represent the linear regression fit of data presented. 
(Error bars indicate standard deviation; n=3). This figure was reproduced from the publication 
being presented in this section.   
 
 
Figure 13. Proliferation of non-implanted encapsulated (black) and free (white) FVIII 
secreting myoblast cells cultured in vitro. Encapsulated fluorescently-labelled FVIII 
secreting myoblast cells proliferated slower (on average) than free cells. This figure was 
reproduced from the publication being presented in this section. 
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Figure 14. Proliferation of implanted-encapsulated (black) and non-implanted 
encapsulated (white) FVIII secreting myoblast cells. Implanted capsules were retrieved 
after 7 days and cultured in vitro until day 11. Implanted-encapsulated fluorescently-labelled 
FVIII secreting myoblast cells proliferate slightly faster (on average) than non-implanted 
encapsulated cells. Representative data presented from one implantation. This figure was 
reproduced from the publication being presented in this section. 
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PAPER 5: “SINGLE-COLOUR FLOW CYTOMETRIC ASSAY TO DETERMINE 
NK CELL-MEDIATED CYTOTOXICITY AND VIABILITY AGAINST NON-
ADHERENT HUMAN TUMOR CELLS” (2012) BIOTECHNOLOGY LETTERS. 
34(3) PP. 447-53. 
 
Cell-mediated cytotoxicity assays are essential tools in immunology to quantify effector cell-
mediated cytotoxicity against target cells. The chromium release assay is considered the 
standard technique for measuring cell-mediated cytotoxicity. However, it requires the use of 
radio-isotopes and lacks speed and sensitivity. In this paper, we developed and tested a novel 
flow cytometric assay to measure percent specific target cell death in a cytotoxicity assay 
(FCC) using a single fluorophore, namely Calcein-AM. In our cytotoxicity assay, Calcein-
labelled target cells that have been killed by the effector cells will either have a compromised 
cell membrane or be completely lysed. Target cells with a compromised cell membrane 
(presumably by apoptotic mechanisms) will leak membrane-impermeable Calcein, which 
diffuses out of the target cell reducing the overall target cell brightness. Flow cytometry can 
simultaneously analyse cell size (forward scatter, FSC), granularity (side scatter, SSC) and 
Calcein staining intensity, thereby providing a measure of the target cells compromised by 
effector cells in our cytotoxicity assay. In order to quantify the number of completely lysed 
target cells (by perforin and granzyme mediated necrosis), we employed fluorescent polymeric 
microspheres to measure the reduction in absolute target cell count. We then created an 
equation that uses flow cytometry data to compare viability in the control sample and the test 
sample (accounting for both types of target cell death- apoptosis and necrosis/lysis), to provide 
a measure of the specific cell death in our cytotoxicity assay. We validated this assay using 
two different human cell lines, K562 and U937 (Figure 15). We also used this method to 
measure the viability of cells, which was comparable to Trypan blue and Calcein/7-AAD 
double labelling methods, although it underestimated it by 5-10% due to the stringent live gate 
used in our analysis (Figure 16).   
To our knowledge, this is the first single-colour flow cytometry assay to determine cell-
mediated cytotoxicity that measures both necrotic and apoptotic cell death. This provides 
several advantages over more expensive dual-labelling techniques and the traditional 
chromium release assay. Moreover, flow cytometry provides a more comprehensive and 
precise analysis of viability and health of cells. This FCC assay can be extended to other 
fluorophores and any effector and target cell type to measure cytotoxicity and viability. We 
expect this technique to be employed in the field of transplantation immunology and tissue 
engineering. 
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Figure 15: Comparison of NK cytotoxicity. Determined using Calcein-loss technique in 
K562 (white bars) and U937 (black bars) cell lines at three different Effector:Target (E:T) 
ratios. Specific cell death values increased with the E:T ratios in both cell lines. Specific cell 
death values were also significantly (p<0.05) different between all E:T ratios in both cell lines. 
Error bars indicate standard deviation; n=3. Flow cytometry data presented from ~30,000 
events collected per sample. This figure was reproduced from the publication being presented 
in this section. 
 
 
 
Figure 16: Comparison of viability. Determined using Calcein/7-AAD, Calcein-loss and 
Trypan blue techniques in K562 (white bars) and U937 (black bars) cell lines. Viability 
determined using Calcein-loss is significantly (p<0.05) different in U937 (*) and K562 (*) cell 
lines. Viabilities determined using Calcein/7-AAD and Trypan Blue are not significantly 
(p>0.05) different in both cell lines. Error bars indicate standard deviation; n=3. Flow cytometry 
data presented from ~30,000 events collected per sample. This figure was reproduced from 
the publication being presented in this section. 
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PAPER 6: “RETROVIRAL EXPRESSION OF MIR2 DECREASES BOTH 
SURFACE MHC CLASS I AND THE ALLOIMMUNE CTL RESPONSE” 
(2011) JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE 
MEDICINE. 5(7) PP. 520-528. 
 
In clinical practice, organ transplantation is a solution of last resort to many incurable diseases 
including chronic renal failure, heart disease and end-stage liver disease. However, 
transplanting organs such as the kidney, heart and liver require the recipients of these organs 
to possess a permanently suppressed immune response against the foreign organs – often 
maintained with an aggressive regime of anti-rejection, immunosuppressant drugs. In 
addition, the limited intrinsic supply, and the extensive list of requirements for matching the 
tissue compatibility of the donor to the recipient further reduces the number of organs available 
for transplantation. Together, these factors present a substantial challenge for organ 
transplantation as a solution for many human diseases. Fortunately, the field of tissue 
engineering offers many potential solutions to these medical challenges. In tissue engineering, 
biomaterials provide the physical structure, and allogeneic stem cells and stem cell-derived 
cells are typically incorporated to provide the biological function. Since the cells will be sourced 
in advance, this provides the opportunity to use genetic engineering to evade or manipulate 
and suppress the immune response of the host using viral nanoparticles for gene delivery. 
In this paper, we propose a novel method to potentially delay or even prevent organ rejection 
upon transplantation using viral nanoparticles as gene delivery vehicles. Viruses were the 
inspiration to our work. It is known that viruses have evolved complex mechanisms to evade 
and suppress detection by the immune responses of the host. Tissue engineering a human 
organ that also utilises these mechanisms might potentially elicit a similar response, where a 
fully functional donor organ would not be recognised by the host immune system as ‘foreign,’ 
thus preventing organ rejection. The immunogenicity of allogeneic cells is primarily due to the 
Major Histocompatibility Complex Class I (MHC class I) molecules expressed on these cells 
and is the key factor in acute cellular rejection mediated via alloreactive T cells of the adaptive 
immune system.  
Here we construct a retroviral nanocarrier to stably express a viral immune modulator protein 
(KSHV MIR2) in model human cells with high transduction efficiency. Figure 17 shows that 
retroviral nanocarrier delivery resulted in stable and long-term MIR2-GFP expression with 
HLA-A/B/C downregulation over 100 days of observation. Figure 18 illustrates a dose-
response effect, with an inverse relationship between MIR2-GFP copy-number and HLA-
A/B/C expression. We then selected (high copy-number) and clonally expanded MIR2-GFP 
transduced cells and used flow cytometry to demonstrate that MIR2-GFP expression 
differentially downregulate multiple immunoactive cell surface molecules including MHC class 
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I, ICAM-1 and CD86 (B7-2) (Figure 19). In a functional test of immune evasion, we performed 
a flow cytometry-based CTL and Natural Killer (NK) assays. The allogeneic CD8+ T cells and 
NK cells were isolated from whole blood with healthy human donors to simulate the in vivo 
setting. The CTL assay showed a statistically significant 52% reduction in MIR2-expressing 
target cell death at a 2:1 Effector:Target (E:T) ratio (Figure 20). The NK assay showed no 
statistically significant difference in cell death between MIR2-transduced target cells and 
mock-transduced (LacZ-transduced) cells at multiple E:T ratios (Figure 21).    
In this paper we employ viral nanoparticles to engineer immune acceptance by selectively 
modifying allogeneic donor cells using viral mechanisms of immune evasion without altering 
the host immune system. To our knowledge, this was the first study to use viral immune 
evasion strategies to simultaneously reduce CTL-mediated cytotoxicity without altering NK-
mediated cytotoxicity against allogenic human cells. Controlling the acute cellular immune 
response represents a significant advance since it can be integrated into a multipronged 
strategy to induce selective donor cell tolerance and therefore extend the life of allogeneic 
tissue-engineered constructs and organs. It could also facilitate the development of ‘universal’ 
cells for allogeneic transplantation. 
 
 
Figure 17: Effect of MIR2-GFP transduction on HLA-ABC expression over 100 days. The 
black bars show the percent of day 0 Mean Fluorescence Intensity (MFI) for MIR2-GFP 
expression in U937-MIR2-GFP cells. The white bars show the percent of HLA-ABC MFI 
measured in U937-MIR2-GFP cells relative to its value measured in U937-LacZ cells on day 
0. These measurements were acquired from a clonal population of U937-MIR2-GFP cells in 
active culture for 100 days. Data presented from 100,000 cells analyzed per sample; n = 3 
replicates. (Student’s paired t-test: * indicates significant difference (p < 0.05); Error bars 
indicate standard deviation). This figure was reproduced from the publication being presented 
in this section. 
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Figure 18: Trend showing MIR2-GFP dose-response effect on HLA-ABC expression. 
Figure depicts a decreasing trend in the cell surface HLA-ABC level with increasing levels of 
MIR2-GFP expression (MFI of GFP) as measured by flow cytometry in each of the seven 
U937-MIR2-GFP clones (♦). Untransduced U937 cells (■) and U937-LacZ cells (●) have high 
levels of HLA-ABC expression. Line of best fit data presented from 100,000 cells analyzed per 
sample. This figure was reproduced from the publication being presented in this section. 
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Figure 19: Cell surface characterization of U937-LacZ and U937-MIR2-GFP cells. HLA-
ABC, CD54 and CD86 were all (shaded curves) downregulated in U937-MIR2-GFP cells. 
Expression of MIR2-GFP was quantified by GFP fluorescence, while antibodies were used to 
quantify all other markers. Mean fluorescence intensity (MFI) values for the shaded curves 
are indicated at the bottom right corner of each graph, while MFI values of unlabelled cells 
(white curves) are indicated as MFIcontrol. Representative data presented from 100,000 cells 
analysed per sample. This figure was reproduced from the publication being presented in this 
section. 
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Figure 20: CTL Assay. Specific lysis of Calcein-labelled target cells (U937-LacZ [white bars] 
or U937-MIR2-GFP [black bars] cells) in control samples (without CTLs) and test samples 
(with CTLs) with varying Effector:Target ratios. (Student’s paired t-test: * indicates p < 0.05 
between cell lines for both Effector:Target ratios; Error bars indicate standard deviation; n = 3 
replicates). This figure was reproduced from the publication being presented in this section. 
 
 
Figure 21: NK Assay. Specific lysis of Calcein-labelled target cells (U937-LacZ [white bars] 
or U937-MIR2-GFP [black bars] cells) in control samples (without NK cells) and test samples 
(with NK cells) with varying Effector:Target ratios. (Student’s paired t-test: No significant 
difference between cell lines (p < 0.05); Error bars indicate standard deviation; n = 3 
replicates). This figure was reproduced from the publication being presented in this section. 
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PAPER 7: “SUPPRESSION OF THE MHC CLASS I-MEDIATED 
ALLOIMMUNE RESPONSE IN HUMAN CELLS USING A SINGLE-STEP 
RETROVIRAL TRANSDUCTION PROTOCOL TO EXPRESS KSHV’S 
STEALTH PROTEIN MIR2” (2011) UNIVERSITY OF TORONTO MEDICAL 
JOURNAL. 89(1) PP. 27-32. 
 
In our previous work, we employ viral nanoparticles to genetically modify allogeneic cells ex 
vivo for immune evasion in allogeneic transplantation. These transduced cells were selected 
in vitro, clonally expanded, characterised and then tested in functional CTL and NK assays. 
In the field of tissue engineering, cells are usually sourced in advance. This approach would 
be useful for developing ‘universal’ cells and allogeneic cell-based tissue-engineered 
constructs for off-the-shelf products. However, in clinical transplantation, many types of 
allogeneic cells, tissues and organs from human donors require transplantation within a limited 
time-frame, restricting the ability to select, clonally expand and characterise virally transduced 
cells. Hence, in this paper, we extended our viral gene delivery approach to simulate such a 
clinical scenario, where allogeneic donor cells are transduced with a viral nanoparticle in a 
single step without any clonal expansion or selection. Using fluorescence microscopy, we 
measured the transduction efficiency after a single step transduction protocol and found that 
it varied from 50%-80% (Figure 22). As a result, this single step transduction protocol creates 
in a heterogeneous population of allogeneic cells with varying copy-numbers (MIR2-GFP) as 
well as non-transduced cells (Figure 22). We characterised this heterogeneous population of 
MIR2-GFP transduced cells with flow cytometry and found that approximately 80% of live cells 
significantly downregulated (>90% decrease in MFI) both HLA-ABC and ICAM-1, while 
approximately 10% of cells expressed GFP without downregulating cell-surface HLA-ABC or 
ICAM-1, and the remaining 5-10% did not express GFP or downregulate cell-surface HLA-
ABC and ICAM-1 (Figure 23). We then functionally tested this heterogeneous population of 
allogeneic cells in flow cytometry-based CTL and NK assays. The CTL assay showed a 
significant (30%) decrease in allogeneic target cell death at the 2:1 E:T ratio (Figure 24), 
without increasing the NK cell-mediated target cell death in vitro (Figure 25).  
This study provides proof of concept that a single step ex vivo retroviral gene delivery strategy 
can potentially be implemented in clinical transplantation to extend the life of transplanted 
allogeneic organs, tissues and cell-based tissue engineering constructs. In addition, this 
method of employing viral nanocarriers to transduce cells for allogeneic transplantation would 
greatly increase the flexibility of producing tissue-engineered constructs. Furthermore, this 
form of tissue engineering would accelerate the development of biomaterials that better 
integrate into the recipient and provide new mechanisms for drug delivery.  
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Figure 22: MIR2-GFP expression in U937 cells after MMLV transduction. U937 cells 
express MIR2-GFP (green) after transduction with retrovirus. Images collected in transmission 
(A) and fluorescence (B) channels. Image C overlays the two channels. Scale bar is 20 µm. 
Self-acquired image reproduced from the publication being presented in this section. 
 
Figure 23: Cell-surface characterization of U937-LacZ and U937-MIR2-GFP cells. This 
plot compares the relative amount of GFP, HLA-ABC and ICMA-1 (CD54) detected in each of 
the cell lines. GFP was quantified by its fluorescence, while fluorescently labelled antibodies 
were used to quantify the other markers. Flow cytometry data presented from 30,000 events 
collected per trial. This figure was reproduced from the publication being presented in this 
section. 
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Figure 24: CTL Assay. Shows percent specific lysis of Calcein-labelled target cells (U937-
LacZ [white bars] or U937-MIR2-GFP [black bars] cells) in control samples and test samples 
with varying E:T ratios. (Student’s paired t-test: p < 0.05 between cell lines for 2:1 E:T ratio; 
Error bars indicate standard deviation; n = 3). This figure was reproduced from the publication 
being presented in this section. 
 
Figure 25: NK Assay. Shows percent specific lysis of Calcein-labelled target cells (U937-
LacZ [white bars] or U937-MIR2-GFP [black bars] cells) in control samples and test samples 
with varying E:T ratios. (Student’s paired t-test: no significant difference (p < 0.05) between 
cell lines; Error bars indicate standard deviation; n = 3). This figure was reproduced from the 
publication being presented in this section. 
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PAPER 8: “RECURRENT HOSPITALIZATIONS IN A RARE CASE OF 
HEMICORPORECTOMY: A CHALLENGING CASE FOR MEDICAL 
MANAGEMENT” (2018) BRITISH MEDICAL JOURNAL CASE REPORTS. 
DOI 10.1136 PP. 1-5. 
 
Nanoparticles, microspheres and tissue-engineered constructs can not only be used for cell 
and drug delivery but can also be engineered to provide a 3D scaffold for wound healing, 
inflammation suppression, and promotion of tissue regeneration [111,112]. In this paper, we 
present a patient with recurrent hospitalisations in a rare case of hemicorporectomy due to 
chronic non-healing pressure ulcers and wound infections (Figure 26). 
 
Hemicorporectomy, or translumbar amputation, is a radical surgery involving the dissection of 
the body at the lumbar region (commonly between L4-L5) and is usually reserved for complex 
medical conditions including locally invasive malignancy and terminal pelvic osteomyelitis. Of 
the 71 reported cases of hemicorporectomy (until Dec 2017), 21 (30%) cases have been 
reported for terminal pelvic osteomyelitis, 43 (60%) cases for malignancy, 4 cases for benign 
disease and 3 cases for trauma. Outcomes are generally more favorable for non-malignant 
vs. malignant indications. For terminal pelvic osteomyelitis, more than 50% of patients 
survived at least nine years, with an average survival of 11 years post-hemicorporectomy. 
 
We present a 22-year follow up of a 53-year-old African American male who underwent a 
hemicorporectomy after a series of surgical procedures for terminal pelvic osteomyelitis, 
chronic advanced pressure ulcers and chronic complicated urinary tract infections, which 
occurred after he suffered a gunshot wound at T6 causing paraplegia at the age of 31. 
Unfortunately, these infections persisted post-hemicorporectomy and the patient continued to 
develop advanced pressure ulcers (grades 1-4) on his back and inferior aspect of his body 
(Figure 27). Despite repeated courses of broad-spectrum intravenous antibiotics and surgical 
debridements of his chronic advanced pressure ulcers, this patient suffered recurrent bouts of 
sepsis. In light of the fact that this patient had been admitted to the hospital on average 10 
times/year in recent years, the patient’s family chose to manage his condition conservatively 
with home hospice, with a focus on palliative care. 
 
This case illustrates the significant challenges in the medical and surgical management of 
hemicorporectomy patients, which can lead to recurrent hospitalisations with a diminished 
quality of life and a poor prognosis for patients. However, a significant number of 
hemicorporectomy patients can prolong their life as well as enjoy a relatively good quality of 
life with a multi-disciplinary approach to care. After hemicorporectomy, all patients should 
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undertake a rehabilitation process that involves the integration of different services such as 
occupational and physical therapy, nutrition, psychological counselling, and specialised 
wound care with novel biomaterial and tissue-engineering technologies to suppress 
inflammation and promote healing. Unfortunately, there are currently no guidelines or 
standards of care for the management of hemicorporectomy patients (inpatient and 
outpatient). We hope that this case may help healthcare providers anticipate and manage 
some of the potential complications in similar patients who have undergone hemicorporectomy 
or other radical surgical procedures. 
 
Figure 26: Hemicorporectomy patient. Image shows A) urostomy with ileal conduit and B) 
Ileostomy. Self-acquired image reproduced from the publication being presented in this 
section. 
 
 
Figure 27: Evolution of pressure ulcers. A) 09/2011: Stage 4 sacral pressure ulcer   7 x 9.5 
x 2.8 cm, B) 01/2013: Stage 3 left thorax pressure ulcer 31.5 x 11 x 0.1 cm, C) 09/2016: Stage 
1-4 posterior thorax pressure ulcer 50 x 50 cm. This image reproduced from the publication 
being presented in this section. 
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DISCUSSION 
Despite the significant advances in the development of nanoparticles and microspheres for 
clinical applications, there is a notable paucity of FDA-approved technologies in medicine. 
This can be attributed to our limitations in understanding how living systems interact with 
nanoparticles and microspheres, including the significance of the immune system. Here, I will 
outline some of the major challenges associated with the development of nanoparticles and 
microspheres for diagnostics and biopharmaceutical delivery in medicine. 
 
Challenges associated with QD nanoparticles for diagnostics and drug delivery 
In general, nanoparticles have four major challenges in their development for diagnostics and 
drug delivery. In this discussion, QD nanoparticles will be used as a case in point to illustrate 
these challenges. First, most nanoparticles manufacturing processes result in deficiencies in 
their surface coatings. Although QD have been successfully employed in vitro, the application 
of QD as fluorescent probes in live cells still remains a challenge mainly due to deficiencies in 
their hydrophilic layer [113]. In 2005, our laboratory used time-lapse imaging experiments in 
live cells in vitro and reported that these coating deficiencies greatly increase QD size (up to 
10x) and promote the formation of QD aggregates (Figure 3,4), which trigger the innate 
immune defenses within cells to recognise and process these foreign objects within lysosomes 
(Figure 5) [38,40,114,115].  
 
Second, most commercially available nanoparticles are excessively large to function 
effectively as biological probes. The vast majority of water-soluble QD commercially available 
have a hydrodynamic diameter of 15-35nm. Given that most intracellular globular proteins are 
between 1-10nm, it is easy to conceive that a 15nm QD conjugated to the target protein, would 
greatly influence not only the diffusion of the target protein, but also alter its normal interactions 
with other intracellular molecules. Previous work has shown that nanoparticles larger than 
15nm in diameter have a greatly diminished diffusion capacity within intracellular 
environments, while nanoparticles larger than 50nm in diameter are effectively immobile in 
intracellular environments [116,117]. Interestingly, another study showed that nanoparticles 
smaller than 3nm in diameter can passively diffuse or be actively transported into the nucleus 
[118]. In 2007, Choi et al showed that rodents can renally excrete neutral QD smaller than 
5.5nm (hydrodynamic diameter), while QD larger than 15nm are prevented from renal 
excretion and accumulate in the RES with unknown long-term consequences [46,119,120]. 
Taken together, these results suggest that with the correct organic QD coating, there may be 
a small window of nanoparticle size, <15nm, which would be ideal for intracytoplasmic studies 
while simultaneously avoiding accumulation within the RES, thus making it safer for human 
use.  
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Third, most commercially available nanoparticles have a limited ability to cross biological 
membranes for intracellular delivery. Although previous studies have used techniques such 
as microinjection and electroporation to successfully deliver QD intracellularly, these 
techniques are invasive and not easily translatable to all cell types [40]. Non-invasive QD 
delivery techniques such as pinocytic loading, receptor-mediated endocytosis, peptide 
translocation domains and cationic lipids have all been attempted with varying degrees of 
success, albeit to specific cell lines and QD delivery conditions [40,121]. A more standardised 
approach to non-invasive intracellular QD delivery, such as our proposed four-component 
smart ‘universal’ nanoparticle (Figure 7), is likely required for its successful application in 
clinical settings. 
 
Fourth, the most concerning aspect of QD application in humans is their potential toxicity. A 
closer look at their composition reveals that QD are made of inorganic semi-conducting 
elements. Frequently, the core is composed of elements from group II and VI (e.g. CdS, CdTe, 
CdSe), groups III and V (eg InP, InAs) or groups IV and VI (eg PbSe), while the shell is 
frequently composed of ZnS [40,122]. The 2-15nm inorganic core-shell QD is then coated with 
an organic hydrophilic layer such as thiols, phospholipid micelles and amphiphilic polymers to 
render them water-soluble. Typically, this organic hydrophilic layer is then functionalised with 
peptides, antibodies and other ligands of interest. Although many studies have successfully 
employed QD in various cells types without any adverse effects on cell viability or function, 
this does not imply that QD do not have any observable effect, as reported in our own live cell 
studies (Figure 4,5) [5,114,123,124].  
 
Duration of exposure and concentration of QD also seem to influence toxicity. In our own 
experiments in the in vivo setting, QD were microinjected into the oocyte, the gonad arm and 
the body cavity of a nematode, C. elegans, and did not appear to have any observable short-
term (up to 48h) toxic effects on the worms (Figure 28). In contrast, other studies have reported 
significant adverse effects to cell viability and function. For example, Dubertret et al showed 
that high concentrations of QD have an adverse effect on developing Xenopus embryos [123]. 
Moreover, other studies have demonstrated that the rate at which adverse effects (cell viability 
and function) appeared seemed to be inversely correlated with the degree of QD core-shell 
protection from the environment [125]. This has been correlated with the leakage of QD core-
shell components such as Cd and Se, into the cellular environment and photon-induced free 
radical formation [116,125,126]. Taken together, these studies suggest that QD toxicity is a 
function of QD concentration, duration of exposure and efficacy of the organic layer in isolating 
the core-shell from the cellular environment.  
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Figure 28. In vivo QD imaging in live C. elegans embryos. A single cell within a four-cell-
stage embryo was microinjected with orange QD in live C. elegans and imaged in transmission 
(A) or epifluorescence (B) microscopy on an inverted Nikon microscope coupled to a CCD 
camera. The worm and embryo appeared unperturbed for up to 48h. Self-acquired image from 
unpublished work. 
 
Challenges associated with microspheres for biopharmaceutical delivery in medicine  
Multiple clinical studies with microencapsulated cells have revealed partial function and limited 
survival time of the transplanted cells [98]. The first major challenge is the immune response 
against the microcapsules themselves, and the cells within. It has been shown that 
commercially available polymers, including alginate, used to create microcapsules contain 
pathogen-associated molecular patterns (PAMPs), which are strong initiators of the immune 
response [127]. In a recent study, Paredes-Juarez et al investigated the immune mechanisms 
of encapsulated cell failure [110]. They suggest that encapsulated cells endure a prolonged 
phase of ischemia immediately after transplantation and during revascularisation of the region. 
During this ischemic phase, encapsulated cells are exposed to low-oxygen and low-nutrition 
levels. The authors showed that encapsulated islet beta-cells in such ischemic conditions 
release danger-associate molecular patterns (DAMPs) that activate the innate immune 
response via TLRs in vitro [110]. They also found that the selectively-permeable encapsulating 
membrane only retains relatively large DAMPs, suggesting that the permeability of the 
microcapsule membrane is a key component in initiating the immune response.  
The source of encapsulated cells is another major factor that determines the strength and type 
of immune response. Xenogeneic cells generate highly immunogenic epitopes such as 
terminal (1-3) galactosyl residues that provoke a stronger, often hyperacute immune response 
compared to allogeneic cells [98]. Naturally occurring anti-Gal antibodies can bind galactosyl 
residues diffusing out of microcapsules and subsequently trigger activation of the classical 
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complement pathway. This process can trigger the chemotaxis of neutrophils and subsequent 
neutrophil degranulation near the microcapsules. In addition, an IgM-mediated delayed-type 
hypersensitivity response against xenogeneic epitopes also occurs [98]. Together, these 
immune reactions generate chemokines and cytokines that recruit more inflammatory cells 
and fibroblasts to completely envelop the microcapsules, inducing ischemic changes in the 
encapsulated cells. This process not only reduces the viability of encapsulated cells, but also 
changes their proliferation and secretory behaviour. 
Finally, inconsistencies in the current methods of encapsulation tends to create variability in 
the properties of the polymer membrane such as mechanical strength, permeability, surface 
charge, roughness and protein adsorption characteristics. In addition, current encapsulation 
methods have been known to create microcapsules with some cells protruding from the 
surface. These protruding cells can potentially initiate a strong immune response leading to 
complete fibrosis of the entire transplanted region, which will certainly lower the viability of the 
cells within. In all the scenarios above, evaluating encapsulated cell viability, proliferation and 
secretory ability is of critical importance. Our novel flow cytometry assay to assess the viability 
and proliferation of encapsulated cells provides greater insight into the factors that determine 
the success and failure of transplanted cells. 
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FUTURE WORK 
 
Prospects for QD nanoparticles in medicine 
Current research into Cadmium-free QD for in vivo applications is driving the development of 
the next generation of non-toxic QD that are safe for clinical applications [119,128–131].  
Among the most promising alternatives to QD composed of toxic elements Cd and Se, are 
QD composed of new semiconducting materials called perovskites [132]. Unlike conventional 
QD, these new semiconductors have a variable ratio of elements, so that their emission 
spectra can be tailored based on composition and size, providing two degrees of freedom 
[133]. As an alternative to the use of non-degradable semiconductors, a new generation of 
‘organic,’ carbon-based QD are being developed that are highly biocompatible, water-soluble 
and easily functionalised, yet derive their fluorescence properties due to quantum confinement 
effects. For example, Yang et al have recently developed highly luminescent, water-soluble 
carbon dots called ‘Cdots’ functionalised with transacting activator of transcription (TAT) 
peptide (a type of cell penetration peptide) to directly monitor TAT interactions within a living 
cell membrane using single particle tracking techniques [134]. However, most Cdots currently 
available have a much lower quantum yield compared to inorganic QD and involved complex 
fabrication techniques in harsh reaction conditions [134–136]. Alternatively, another type of 
QD composed of semiconducting polymer called ‘Pdots’ have been particularly advantageous, 
since they provide a way to circumvent the need to synthesise nanoparticles with a narrow 
size distribution [137]. Although these organic Pdots can be tunable, up to 30x brighter than 
traditional inorganic QD of comparable size, and are more likely to be biocompatible, they 
present new challenges that are yet unresolved. For example, Pdots suffer from a 
phenomenon known as ‘quenching,’ where tightly packed long chains of polymers diminish 
the fluorescence quantum yield and thus constrain the size of the nanoparticle [138]. However, 
other types of organic QD take advantage of this aggregation of polymers within nanoparticles 
to increase fluorescence quantum yield through aggregation-induced emission (AIE) [139]. 
These nanoparticles called ‘AIE-dots’ have also been shown to be tunable and up to 40x 
brighter than traditional QD of comparable size, but have a significant caveat: they have broad 
emission spectra and their in vivo safety and efficacy has not yet been established [140].  
 
Aside from optical characteristics of nanoparticles in vitro, imaging in vivo presents special 
optical challenges as ultraviolet and visible light have an extremely limited penetration depth 
into tissues. However, NIR wavelengths can penetrate up to three centimeters and present an 
opportunity for deep tissue imaging. Hence, many research groups are currently developing 
‘upconversion’ nanoparticles composed of lanthanides to absorb low energy NIR photons and 
combine them into higher energy photons in the visible and ultraviolet spectra [141]. This 
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provides a novel photoactive theranostic delivery platform for deep tissue imaging and drug 
delivery using NIR energy to minimize phototoxicity [142].  
 
Given that the market for QD technologies has been predicted to grow to over $5 billion by 
2020, it is important to address the potential challenges associated with their use in humans 
[143,144]. Among the major limitations of QD in vitro and in vivo, a short blood half-life, 
undesirable uptake and accumulation in the RES, cellular toxicity, lack of biodegradability, 
inability to selectively cross target cell membranes and reach the intracellular site of action 
(cytoplasm or nucleus) significantly hamper the successful application of QD in medicine. 
Taken together, these observations suggest that the development of QD technologies for 
clinical applications likely requires a three-pronged approach: 1) standardisation of QD 
synthesis and functionalisation- surface engineering small QD (<15 nm in diameter) with a 
thin, neutral PEG organic layer to promote renal excretion, minimise RES uptake and improve 
intracellular delivery, 2) non-toxic QD- manufacturing heavy metal-free QD, 3) theranostic 
capabilities- smart multifunctional QD capable of diagnostic and therapeutic capabilities. 
Overcoming these challenges will allow for the rational design of personalised, multifunctional 
stimuli-responsive QD to improve their diagnostic and therapeutic value in clinical medicine.  
 
 
Prospects for microspheres in medicine 
Currently microcapsules provide a means of controlled delivery of cells engineered to secrete 
therapeutic product. However, microcapsule technology is being developed for a multitude of 
applications in regenerative medicine with parallel delivery of encapsulated drugs, growth 
factors for improved neovascularisation, extracapsular modification for better integration into 
the host extracellular matrix and cell-based diagnostics. In addition, encapsulation methods 
are evolving to improve control over microcapsule size, microcapsule membrane structure 
and permeability, surface functionalisation with biomolecules, and encapsulated cell 
placement within microcapsules [98].  
Analogous to our proposed smart stimuli-responsive nanoparticles, smart stimuli-responsive 
microcapsules are also being developed. For example, Luo et al recently developed near-
infrared light responsive microcapsules to control drug release in a pulsatile manner [145]. 
The microcapsules can also be engineered to enable precise in vivo localisation using 
traditional imaging modalities such as CT, MRI and US [146–148]. Other research has focused 
on genetically engineering encapsulated cells with externally inducible suicide genes to 
inactivate the implanted cells if termination of therapy is desired [149]. Interestingly, genetic 
engineering of encapsulated cells for fluorescence and bioluminescence imaging provides 
another novel way to evaluate the viability and proliferation of encapsulated cells in vivo. In 
2013, Santos et al engineered encapsulated myoblasts with a TGL triple-fusion reporter gene 
with HSV1 thymidine kinase, green fluorescent protein and firefly luciferase, which allows for 
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the simultaneous imaging with fluorescence and bioluminescence, as well as a biosafety 
strategy (via a suicide gene) to inactivate the encapsulated cells with ganciclovir [149]. In 
summary, smart stimuli-responsive microcapsules with encapsulated cells provides a means 
of multimodal imaging for diagnostics, as well as the long-term delivery of cell-derived and 
non-cell derived therapeutics that are responsive to internal physiologic feedback from 
disease-specific stimuli and external signals for clinical applications.    
 
 
Figure 29: Prototype of a smart biodegradable polymeric nanoparticle for intracellular 
nucleotide delivery. Mammalian cells were pinocytically loaded with the nanoparticle labelled 
with a fluorescent dye (DiI), fixed in paraformaldehyde, and imaged with a confocal 
microscope using YFP and Cy3 channel settings (overlayed image presented). The green 
circle outlines a cell that was analysed in three dimensions. White arrows point to nanoparticle 
fluorescence localised within this cell (X-Y, X-Z and Y-Z planes) in a endolysosome. Cell nuclei 
are marked ‘N.’ Self-acquired image from unpublished work. 
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CONCLUSION 
 
It is evident that nanoparticle and microsphere technologies have a vast potential in medicine. 
Although the technology has been extensively researched and developed for pharmaceutical 
applications over the last few decades, it is apparent that currently non-viral nanoparticle 
technologies are more suitable for tissue and subcellular imaging, single particle tracking 
studies, in vitro diagnostics for the detection of biomolecules and in vivo applications in animal 
models. Similarly, viral nanoparticles and microspheres have demonstrated their tremendous 
potential in the efficient delivery of genes and the sustained delivery of biopharmaceutical 
products for clinical applications. However, until the major challenges associated with 
biomaterial interactions with the innate and adaptive immune system have been addressed, 
these technologies will likely have limited applications in humans in vivo. Nevertheless, the 
next generation of nanoparticles and microspheres are poised to deliver on their promise of 
multifunctional, targeted and stimuli-responsive modalities for imaging, diagnosis and 
treatment in clinical medicine.      
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Strategies for ocular siRNA delivery: Potential and
limitations of non-viral nanocarriers
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Abstract
Controlling gene expression via small interfering RNA (siRNA) has opened the doors to a plethora of therapeutic
possibilities, with many currently in the pipelines of drug development for various ocular diseases. Despite the
potential of siRNA technologies, barriers to intracellular delivery significantly limit their clinical efficacy. However,
recent progress in the field of drug delivery strongly suggests that targeted manipulation of gene expression via
siRNA delivered through nanocarriers can have an enormous impact on improving therapeutic outcomes for
ophthalmic applications. Particularly, synthetic nanocarriers have demonstrated their suitability as a customizable
multifunctional platform for the targeted intracellular delivery of siRNA and other hydrophilic and hydrophobic
drugs in ocular applications. We predict that synthetic nanocarriers will simultaneously increase drug bioavailability,
while reducing side effects and the need for repeated intraocular injections. This review will discuss the recent
advances in ocular siRNA delivery via non-viral nanocarriers and the potential and limitations of various strategies
for the development of a ‘universal’ siRNA delivery system for clinical applications.
Keywords: Biomaterials, siRNA, Drug delivery, Endosomal escape, Nanocarriers, Ocular siRNA delivery, RNAi
Introduction
Challenges of posterior segment ophthalmic therapeutics
Pharmaceutical treatment of retinal degenerative dis-
eases affecting the posterior segment of the eye is
made challenging by restrictive blood ocular barriers
such as the blood aqueous barrier (BAB) and the
blood retinal barrier (BRB), which separate the eye
from systemic circulation [1]. Additionally, the com-
partmentalized structure of the eye limits the passage
of therapeutics from the anterior chamber to the pos-
terior segment, which houses the light-sensing retina
[2]. Finally, once the drug successfully enters the back of
the eye, effective clearance mechanisms act to rapidly clear
the delivered molecules [2]. In conjunction, these barriers
render posterior segment ophthalmic drug delivery par-
ticularly challenging. Figure 1 provides a schematic repre-
sentation of the various physical delivery barriers as well
as the clearance mechanisms, which effectively expel
drugs that successfully enter the eye.
Local and systemic routes for drug delivery
It is estimated that following instillation, only 5% of
topically applied drugs enter the anterior chamber of the
eye, either through trans-corneal permeation (Figure 1,
arrow 1) or non-corneal permeation into the anterior uvea
through the conjunctiva and sclera (Figure 1, arrow 2) [2].
Increasing the residence time on the eye through viscous
formulation can slightly improve uptake. However, due to
the physical barrier created by the corneal and conjunc-
tival epithelium, and the relatively small tear volume
(~7 μl) available [3], a maximal attainable absorption
into the anterior chamber appears to be approximately
10% of the applied dose [4]. Drugs are eliminated from
the aqueous humor via aqueous turnover through the
Schlemm’s canal and trabecular meshwork (Figure 1,
arrow 4) and by uptake into systemic circulation through
uveoscleral blood flow (Figure 1, arrow 5) [2]. Elimination
via the first route occurs through convective flow at a rate
of approximately 3 μl/min and is independent of drug
type. Clearance through uveal blood flow however, is
influenced by the ability of the drug to penetrate the
endothelial walls of the blood vessels. Thus, lipophilic
drugs clear more rapidly than hydrophilic drugs, often
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in the range of 20 – 30 μl/min [2]. Coupled with the
physical barrier created by the lens, flow of drugs from
the anterior chamber to the posterior segment of the
eye is negligible. Therefore, topical drug administration
is typically limited to anterior complications. The sys-
temic route is also severely limited in its ability to effect-
ively deliver drugs to the back of the eye. Only an
estimated 1 – 2% of compounds delivered via this route
successfully cross the BAB (Figure 1, arrow 3) and the
BRB (Figure 1, arrow 6) and accumulate within the ret-
inal tissues [1]. With many newly developed pharma-
ceuticals being protein-based, oral formulations become
increasingly difficult to administer, as the drugs need to be
protected from degradation within the gastro-intestinal
tract. Furthermore, the large concentrations of drug
required to achieve therapeutically relevant concentra-
tions within the retinal tissues and the increased poten-
tial for off-target interactions makes oral administration
an undesirable route of delivery for posterior segment
therapies.
There are numerous potential sites surrounding the
eye that can house solid drug releasing scaffolds for loca-
lized treatment, as illustrated in Figure 2. [3]. Periocular
instillation that does not require perforation of the eye
wall is desirable as it can minimize invasiveness. How-
ever, approaches that utilize this route require drugs to
pass through several layers, including the episclera,
sclera, choroid Bruch’s membrane and retinal pigment
epithelium (RPE), in order to reach the vitreous chamber
and the retina [5]. Therefore, due to poor penetration
into the posterior segment, this route of delivery lacks
clinical significance to date [4]. Subconjunctival injec-
tions represent an attractive option for delivery of drugs
to the choroid as the sclera is highly permeability to
large molecules; however, this approach is less appealing
for drug delivery to the retina as the compound must
still cross the choroid and the RPE [4].
Intravitreal drug delivery
The most efficient means to deliver drugs into the pos-
terior segment is through direct injection into the vitre-
ous cavity (Figure 1, arrow 7) [5]. Using a high-gauge
needle, therapeutics may be introduced into the vitreous
through simple injection, producing high concentrations
of drug locally surrounding the retinal tissues while lim-
iting off-target exposure. However, the concentration of
drug is rapidly depleted from the posterior segment via
permeation across the BRB (Figure 1, arrow 8) and by
diffusion across the vitreous to the anterior chamber
(Figure 1, arrow 9), which allows drugs to be cleared
through the anterior route [2]. Thus, repeat injections
are required, often every 4 – 6 weeks, to maintain
Figure 1 Schematic representation of the various routes of ocular drug delivery and drug elimination from the eye. 1) trans-corneal
permeation, 2) non-corneal drug permeation, 3) drug delivery to the anterior chamber via the BAB, 4) drug elimination from the anterior
chamber via the trabecular meshwork and Sclemm’s canal, 5) drug elimination from the anterior chamber into the uveoscleral circulation, 6)
drug delivery to the posterior chamber via the BRB, 7) intravitreal drug delivery, 8) drug elimination from the vitreous via the BRB, 9) drug
elimination from the vitreous via the anterior route. Reproduced with permission from Elsevier [2].
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therapeutic concentrations of drug within the posterior
segment [6]. Repeat instillations are associated with
increasing risk of injection-related complications, such as
raised intraocular pressure, vitreous or retinal hemorrhage,
retinal detachment, retinal tears, endophthalmitis, cat-
aracts, floaters and transient blurry vision [5]. Rates of
endophthalmitis and cataract formation per injection
are 0.2% and 0.05% respectively [5]. Repeat injections
are also associated with patient discomfort and adherence
issues [1]. Therefore, while intravitreal injections have the
greatest clinical efficacy, they are also the most risky.
Currently, the most promising solutions to combat
the challenges of posterior segment drug delivery are
approaches that successfully utilize direct intravitreal
delivery and sustain therapeutic concentrations for
extended periods of time, thereby decreasing the frequency
of intervention. The first commercially successful sus-
tained release intravitreal device for treatment of cyto-
megalovirus retinitis was Vitrasert (Bausch and Lomb), a
non-degrading implant that is surgically implanted at the
pars plana [5]. Vitrasert is a US Food and Drug Adminis-
tration (FDA) approved drug delivery system, which con-
sists of a tablet of ganciclovir coated with polyvinyl alcohol
(PVA) and ethylene vinyl acetate (EVA) [5]. The imperme-
able EVA coating limits the surface area through which
ganciclovir can release, forcing drug to diffuse through the
small PVA rate-limiting membrane, slowing the release
and allowing treatment for a period of 5 to 8 months [1].
However, Vitrasert is a relatively large non-degrading
device and therefore requires an incision for introduction
into the vitreous cavity, as well as a secondary surgical
intervention for device removal following exhaustion of
the drug reservoir. The I-vation (Surmodics) drug delivery
system is another example of a non-degrading, sustained
intravitreal release device for the treatment of diabetic
macular edema. The helical construct was designed to fa-
cilitate ease of implantation and removal, maximize sur-
face area available for drug release, and allow sutureless
anchorage within the vitreous [7]. The titanium helix is
coated with a blend of poly(methyl methacrylate) and
EVA, which is loaded with triamcinolone acetonide and
provides sustained release for 18–36 months [5,8]. In con-
trast, the Iluvien (Alimera Sciences) drug delivery system
consists of a very small cylindrical polyimide rod loaded
with fluocinolone acetonide (FAc) capable of being
injected through a 25-gauge needle and releasing low
levels of drug for up to 3 years [5,8]. However, as this scaf-
fold is composed of non-degrading materials and is not
fixed to the eye wall, it is expected to remain within the
patient’s orbit following depletion of the drug and is cur-
rently under review by the FDA [9]. Ozurdex (Allergan),
an FDA approved dexamethasone loaded intravitreal insert
for the treatment of macular edema and noninfectious
uveitis, is another scaffold capable of introduction into the
vitreous via minimally invasive injection using a 22-gauge
applicator [7]. However, unlike Iluvien, Ozurdex is com-
posed of degradable poly(lactide-co-glycolide) [10], thereby
allowing scaffold degradation and clearance from the eye
Figure 2 Potential sites for placement of a drug releasing scaffold in the eye. An illustration of the numerous potential sites for placement
of a drug releasing scaffold for sustained ocular delivery. Reproduced with permission from Nature Publishing Group [3].
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and body without the need for secondary surgical inter-
vention [11].
With recent advances in pharmaceuticals, including
regulatory approval of multiple pharmacotherapies to
treat wet age-related macular degeneration (AMD), and
the increasingly elderly demographic at risk of degenera-
tive eye disorders, there has been renewed interest in
designing novel drug delivery platforms, particularly
nanocarriers, to address the limitations of posterior seg-
ment therapeutics [3]. Furthermore, scientific research is
continuing to shed new light on the fundamental bio-
chemical pathways implicated in retinal degenerative
diseases, which is leading to the discovery of new
pharmacological targets and the development of novel
therapeutics.
RNA interference and siRNA delivery
RNA interference (RNAi) is an evolutionarily conserved
mechanism that has been observed in most organisms
from plants to vertebrates. It is a mechanism that leads
to sequence-specific post-transcriptional gene silencing
that was first documented in animals by Andrew Fire
and Craig Mello in 1998, both of whom subsequently
received the Nobel Prize in Physiology or Medicine in
2006 [12,13].
RNA interference can provide a novel therapeutic mo-
dality to treat many human diseases by interfering with
disease-causing and disease-promoting genes in a se-
quence-specific manner. Elbashir et al. were the first to
demonstrate that small interfering RNA (siRNAs) can
induce the RNAi pathway in mammalian cells without
producing an adverse immune response [14]. This im-
mediately suggested that the RNAi pathway could poten-
tially be manipulated in humans for the treatment of
many human diseases. Theoretically, RNAi can be used
to selectively alter the expression of any transcribed
gene. This new paradigm in therapeutics allows one to
address disease states previously considered ‘undrug-
gable’ [15]. In addition, it creates new opportunities to
alter important cellular processes such as cell division
and apoptosis, both of which are significantly altered in
many cancers [16].
RNA interference is essentially a conserved cellular
mechanism that leads to post-transcriptional gene silencing,
which can be manipulated for therapeutic applications in
humans. Post-transcriptional gene silencing strategies can
be broadly divided into four types: 1) single-stranded anti-
sense oligodeoxynucleotides (ODNs)- synthetic molecules
that can specifically hybridize with complementary mRNA
and sterically inhibit protein translation, 2) ribozymes-
catalytically active small RNA molecules that can spe-
cifically recognize and cleave single-stranded regions
in RNA, 3) microRNA (miRNA)- endogenous, short
double-stranded non-coding RNA molecules that play an
important role in health and disease by modulating gene
expression, and 4) siRNAs- these 18–25 nucleotide long
duplexes are potent activators of the innate immune sys-
tem that have been shown to initiate sequence-specific
post-transcriptional gene silencing. Although all of these
strategies can potentially be applied to suppress mRNA
translation, it is generally accepted that siRNA technology
offers the best combination of specificity, potency and ver-
satility as a therapeutic [15]. In addition, siRNAs are easily
synthesized and do not require cellular expression systems
or complex protein purification systems, making this tech-
nology significantly more cost effective over other small
molecule therapeutics [12].
Small-interfering RNA mediates its post-transcriptional
gene silencing effects via the RNAi pathway. In brief,
when exogenous siRNA duplexes are introduced into
mammalian cells, the 5’-end is phosphorylated. This
duplex is then assembled into a multiprotein complex
called RNA-induced silencing complex (RISC), which
includes proteins such as Argonaute 2 (AGO2), Dicer,
TRBP (HIV-1 TAR RNA-binding protein) and PACT
(dsRNA-binding protein) [17]. The sense strand is then
cleaved and unwound, leaving only the antisense strand
associated with AGO2. Argonaute 2 is an endonuclease
that promotes hybridization of this antisense strand to
complementary cellular mRNAs and subsequent cleavage
of the mRNA target [17]. This results in ‘knocking down’
the translation of the target gene [18].
In designing siRNAs, the three most important attri-
butes to be taken into account are: potency (effectiveness
of gene silencing at low siRNA concentrations), specificity
(minimize homology to other mRNAs) and nuclease
stability (resistance against exonuclease and endonuclease
activity). Moreover, there are two types of off-target effects
that should be minimized: immune stimulation arising
from siRNA recognition by the innate immune system,
and unintended silencing of genes that share partial
homology with the siRNA [15,17].
It is clear that siRNA technology has a great thera-
peutic potential in medicine. However, one of the major
limitations for their application in vitro and in vivo is
the inability of siRNA to cross cell membranes and reach
the cytoplasm. The negative charges arising from the
phosphate groups in the siRNA backbone electrostati-
cally repel negatively charged cell membranes, therefore
limiting siRNA ability to diffuse across cell membranes.
In addition, other challenges common to most drug de-
livery systems, including high molecular weight, short
blood half-life, poor specificity and uptake in target tis-
sues, cellular toxicity, and undesirable off-target effects,
significantly hamper the successful application of siRNA
therapeutics in medicine [12]. Moreover, the intrinsic
physical barriers, efficient drug clearance mechanisms
and other complexities of ocular tissues such as the
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retina and the cornea pose a significant challenge to ocular
siRNA delivery. In order to address these problems, several
siRNA delivery strategies have been developed for in vitro
and in vivo applications.
Numerous non-viral carriers including natural and
synthetic polymers, polyplexes, liposomes, lipoplexes,
peptides, dendrimers and free nucleic acid pressurized
hydrodynamic injections, as well as virus-based vectors
and plasmids encoding for siRNA, have been proposed for
siRNA delivery. Although most of these strategies have
been attempted with various degrees of success in vitro
and in vivo, strategies for targeted siRNA delivery that are
most relevant to ophthalmic applications will be reviewed.
Non-viral siRNA delivery systems
In an evolutionary sense, the prevalence of viral infec-
tion of cells has likely resulted in highly efficient cellular
and systemic defense mechanisms aimed at degrading
the naked siRNA molecule in vivo. Serum nucleases
such as eri-1 [19], renal clearance, and nontargeted bio-
distribution make intracellular targets extremely difficult
to access. Thus, the most prohibitive barrier faced by
siRNA therapeutic strategies is a delivery system [20].
Traditionally, engineered viral particles were tasked with
the delivery of nucleic payloads to the eye due to its rela-
tive immune-privilege status [21]. Several viral types,
particularly adenovirus (Ad), adenoassociated virus
(AAV), and lentivirus, are being actively investigated as
vectors for RNAi therapy [22]. Exotic modifications of
these viral vectors, such as self-complementary AAV
(scAAV) or helper-dependent adenovirus (HD-Ad), are
the current state-of-the-art in viral delivery, optimizing
the properties of earlier generations for ocular gene de-
livery [23]. However, viral vectors are seen as an accept-
able rather than perfect solution to nucleic acid delivery;
the potential for mutagenesis, limited loading capacities,
appropriate targeting, insertional predictability, high pro-
duction costs, and adverse immune reactivity severely limit
the practicability of viruses [24]. Alternatively, delivering
plasmid vectors expressing siRNA have been attempted
with success [25-27], but such DNA-based expression vec-
tors can potentially integrate into the host genome and in-
crease the chances of insertional mutagenesis [26,28].
Engineered, non-viral siRNA delivery systems are being
extensively studied because they are relatively safe and can
be easily modified with targeting ligands. These artificial
vectors are therefore seen as an attractive alternative
for viral delivery systems. There are four main types of
vectors that are convenient for non-viral siRNA delivery: 1)
polymeric, 2) lipid, 3) protein and 4) dendrimeric nano-
carrier delivery systems (Figure 3).
1) Polymeric nanocarriers
Although many types of polymers have been used to de-
liver oligonucleotides, much attention has focused on
using cationic polymers for two main reasons: 1) their
ability to electrostatically bind siRNA without the need for
covalent attachment or encapsulation, and 2) the ability of
amine containing cationic polymers to provide endosomal
buffering and escape for intracytosolic siRNA delivery.
Polyethylenimine (PEI) is perhaps the most investigated
synthetic cationic polymer for nucleic acid delivery due to
its uniquely high buffering capability at endosomal pH,
known as the ‘proton sponge’ effect, which releases nu-
cleic acid payloads into the cytoplasm after endocytosis
[29]. Grayson et al. have demonstrated that polyplexes of
PEI can effectively deliver siRNA to cells in vitro [30]. Kim
et al. were among the first to employ the use of pegylated
(PEG) PEI-siRNA cationic polyplexes targeted against vas-
cular endothelial growth factor-A (VEGFA), vascular
endothelial growth factor receptor-1 (VEGFR1) and/or
VEGFR2 to significantly reduce herpes simplex virus-
induced angiogenesis and stromal keratitis in murine ocu-
lar tissues in vivo [31]. Notably, these PEG-PEI-siRNA
polyplexes were effective in both local and systemic ad-
ministration of the formulation. Given that PEI-siRNA
has been successfully tested in vivo for the treatment of
Figure 3 Nanocarriers for ocular siRNA delivery. This illustration shows four types of pegylated nanocarriers for ocular siRNA delivery: A)
polymer, B) liposome, C) protein, D) dendrimer. The siRNA payload is typically entrapped, encapsulated or covalently bound to the nanocarrier
interior to preserve its bioactivity, reduce non-specific cellular uptake and prevent undesirable activation of the innate immune system.
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various diseases, it is a promising candidate as a nanocar-
rier for ocular siRNA delivery [32].
Alternatively, polymeric micelles have been extensively
used to deliver nucleic acids. These micelles are colloidal
suspensions of amphiphilic copolymers with particle sizes
ranging from 5–100 nm [12]. For siRNA delivery, it has
been suggested that PEG-polycation diblock copolymers,
lactosylated PEG-siRNA and PEG-poly(methacrylic acid)
blor siRNA encapsulation are well suited [12]. Interest-
ingly, Duan et al. have combined the use of a cationic ock
co-polymers fdiblock copolymer (PEI-PEG) with a natural
polysaccharide, chitosan, to make ‘ternary’ nanocarriers to
successfully deliver siRNA targeted against the IkB kinase
subunit mRNA to human Tenon’s capsule fibroblasts
in vitro [33]. The authors demonstrated that these bio-
degradable nanocarriers significantly enhanced siRNA de-
livery and were much less toxic than 25KDa PEI alone. In
addition, Ye et al. applied these ‘ternary’ siRNA nanocar-
riers targeting IkB kinase subunit mRNA in vivo in a mon-
key model of glaucoma filtration surgery and showed that
subconjunctival injection of these nanocarriers signifi-
cantly reduced scar tissue compared to controls [34].
Taken together, these results suggest that pegylated cat-
ionic nanocarriers may be suitable candidates for ophthal-
mic siRNA delivery.
2) Lipid nanocarriers
There are many types of lipid-based siRNA delivery
systems. However, the most common approaches in-
clude: 1) liposomal delivery, where siRNA is encapsu-
lated within vesicles composed of a phospholipid bilayer
and 2) lipoplexes, where siRNA complexes with cationic
lipids (such as 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphati-
dylethanolamine (DOPE), N-[1-(2,3-dioleyloxy)propyl]-N,
N,N-trimethylammonium chloride (DOTMA) and N,N-
dioleyl-N,N-dimethylammonium chloride (DODAC)) and
forms nanoscale complexes. Liposomes are probably the
most commonly used artificial gene delivery vector since
their ability to transport the preproinsulin gene to the liver
was demonstrated nearly 30 years ago [35]. Liu et al. have
successfully demonstrated that 132 nm pegylated lipo-
some-protamine-hyaluronic acid nanocarriers loaded with
siRNA targeted against VEGFR1 can not only enhance
VEGFR1 knockdown, but also accelerate intracellular de-
livery to human RPE cells over free siRNA in vitro [36].
After intravitreal administration, these nanocarriers were
also able to significantly reduce the area of choroidal
neovascularization (CNV) in a laser-induced murine
CNV model with minimal toxicity, suggesting their suit-
ability for clinical applications [36]. Lipid combinations
such as DC-Chol (3β-[N-(N′,N′-dimethylamino-ethane)
carbamoyl]-cholesterol) have also been used to deliver
siRNA successfully and may present opportunities to
combine desired features to create novel lipid-based
nanocarriers [37].
3) Protein nanocarriers
Protein-based siRNA delivery involves the formation of
‘proticles,’ where proteins are conjugated (electrostatically
or covalently) to siRNA for delivery. For example, albumin-
protamine-oligonucleotide forms nanocarrier complexes
(230–320 nm diameter), which can be safely delivered to
cells [38]. Recently, Johnson et al. have developed a novel
cell-penetrating peptide (CPP) for ocular delivery of small
and large molecules, including siRNA, fluorescent probes,
plasmid DNA and quantum dots to RPE, photoreceptor
and ganglion cells in vitro and in vivo [39]. Not only do the
authors report >50% transgene silencing after peptide-
siRNA delivery in human embryonic retinal cells in vitro,
but they also demonstrate that this peptide-based nanocar-
rier can transduce approximately 85% of the neural retina
within 2 h of intravitreal injection in vivo [39]. The lack of
toxicity, biodegradability and serum stability of these nano-
carriers makes them particularly advantageous as a delivery
vehicle [38]. However, protein-based nanocarriers have
been known to localize and degrade within endolysosomes
after cellular uptake [40]. This problem will likely require
additional nanocarrier design considerations such as
endosomal escape strategies for its successful applica-
tion in ocular conditions.
4) Dendrimers
Dendrimers represent a group of nanoscale materials
that are hyperbranched, monodisperse and have defined
molecular weights. Structurally, dendrimers are composed
of a central core, repeating units that make up the
branches, and surface functional groups [27]. Dendrimers
are synthesized in a step-by-step fashion by the sequential
addition of repeating units organized in concentric layers,
called generations, around the central core. High gener-
ation dendrimers have numerous cavities within their
hyperbranched structure to allow for the encapsulation of
therapeutic agents such as siRNA molecules. The most
common dendrimers used for siRNA delivery include poly
(amidoamine) (PAMAM) and poly(propylene imine) (PPI)
[41]. However, other types of dendrimers composed of
amine-containing cationic polymers such as poly-L-lysine
have been investigated for ODN (anti-VEGF) delivery to
RPE cells in vitro [42], and have demonstrated long-term
(4–6 months) inhibition (up to 95%) of laser-induced
CNV after intravitreal injection in a rat model, without
any observable adverse effects [43]. The major advantages
of dendrimers include biodegradability, ease of synthesis
and customizability, such that they can be synthesized in
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various sizes and differing number and type of surface
functional groups to optimize siRNA delivery. Recently,
Agrawal et al. have developed dendrimer-conjugated mag-
netofluorescent nanoworms called ‘dendriworms’ that sig-
nificantly enhance intracellular siRNA delivery in a mouse
model by optimizing endosomal escape [44]. Alternatively,
Han et al. have conjugated CPPs, such as HIV transactiva-
tor of transcription (TaT), to PAMAM dendrimers for
enhanced intracellular siRNA delivery in vitro and in vivo
[45]. Together, these results suggest that dendrimers are
ideally suited to serve as nanocarriers, which can be
loaded with siRNA and functionalized with PEG and tar-
geting ligands for clinical applications. However, at
present, there are no examples of dendrimeric siRNA de-
livery for ocular applications in the literature.
Despite the multitude of siRNA delivery strategies
available, the lack of safe and efficient delivery in vivo
has limited the clinical translation of siRNA therapeu-
tics. Although a few siRNA therapeutic drugs are cur-
rently under clinical trials (Table 1, [46-55]) for ocular
applications, none have yet been approved by the FDA.
Hence, there is a clear need to develop safe and effica-
cious methods of ocular siRNA delivery.
Chemically modified siRNAs
Various molecular locations on siRNA molecules can be
chemically altered to resist hydrolysis and enhance cellular
uptake. In order to increase the efficacy of siRNA delivery,
much research has focused on increasing the nuclease re-
sistance and therefore serum stability of siRNAs. Nucleases
such as eri-1 are involved in the degradation of unmodified
siRNA duplexes [19], which have been reported to have a
short serum half-life of about 3–5 min. However, it has
been shown that siRNA serum half-life can be extended
up to 72 h with fully modified duplexes [56].
Among the multitude of possible siRNA modifications,
there are two schools of thought regarding the best ap-
proach to developing chemically modified siRNA. In one
approach, it is believed that extensive chemical modifica-
tion of siRNA is most likely to lead to the greatest efficacy.
For example, Sirna Therapeutics has several patents and
products that favour extensive siRNA duplex modifica-
tions, where the sense and antisense strands have modi-
fied bases (2’-Fluoro-RNA pyrimidines (2’-F-RNA), DNA
purines), altered covalent links between the nucleotides
(phosphorothioate linkage (PS)) and inverted 5’ and 3’ aba-
sic end caps [17]. These extensive siRNA modifications
translated into increased potency and a much longer
serum half-life (48–72 h) in a Hepatitis B virus mouse
model [56]. In contrast, the other school of thought is fo-
cused on creating stabilized siRNAs with minimal modifi-
cations. For example, Alnylam Pharmaceuticals has many
siRNA products that are selectively modified (2’-sugar
modifications such as 2’-O-methyl or 2’-F-RNA) at
vulnerable sites, such as those susceptible to endonuclease
cleavage [15,17,57]. It is important to note that modifica-
tions to the RNA backbone can potentially impair siRNA-
induced silencing activity, thus many reported modifica-
tions have been limited to the sense strand [58,59]. How-
ever, the rules for predicting siRNA stability and potency
are still unclear since some studies have demonstrated
antisense modifications with preserved siRNA functional-
ity [60,61], while other studies have shown sense strand
modifications with reduced siRNA efficiency [62,63].
Various chemical modifications to the terminals, back-
bone, nucleobases and sugars of siRNAs can be implemen-
ted to protect the duplex from exonuclease degradation.
For example, the phosphodiester (PO4) linkages along the
RNA backbone can be replaced with PS or boranopho-
sphonate (PB) at the 3’ end [64-66]. It has been shown that
PS derived oligonucleotides stimulate the physical uptake
of siRNA in human cells [67], while siRNAs with PB back-
bone modifications have less cytotoxicity and a much
higher nuclease resistance than native siRNA. Such PB
siRNAs are at least 10 times more nuclease resistant than
unmodified siRNAs, and have recently been used to treat
patients with AMD. The process has reached Phase II clin-
ical trials, and it was found to have no observable side
effects [68]. Replacement of sugar moieties at the 2’-
hydroxyl group of the ribose backbone with 2’-O-methyl,
2’-fluoro, or 2’-methoxyethyl groups can further improve
in vivo stability [66,69]. Moreover, various molecules can
be conjugated to the 5’ or 3’ ends of the sense strand,
without affecting the activity of the antisense strand
needed for silencing [66]. This method can allow for cell
specific targeting or visualization of siRNA uptake and
distribution by introducing appropriate ligands and
fluorophores respectively. However, degradation of these
artificially altered siRNA molecules may result in metabo-
lites with unsafe or otherwise unwanted reactivity [66].
Chemical modification of siRNA can increase stability in
biological solutions, target specificity and potency [68].
However, the benefits of modification must be measured
against the cost and labour of the modification process, as
well as its effects on immune stimulation, which are gen-
erally difficult to predict and require empirical testing
in vivo.
Immune stimulation and other off-target effects of siRNA
delivery
In addition to the gene knockdown effects of the RNAi
pathway, there are many other potential consequences
that can be initiated by siRNA in vivo. Hence, these so
called ‘off-target effects’ need to be considered and eval-
uated in any siRNA delivery study. For example, it is
well known that double stranded RNA (dsRNAs) greater
than 30 bp are potent activators of the innate immune
response [70]. Although siRNA duplexes are shorter
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than 30 bp, many recent studies have begun reporting
off-target effects [58,71]. In general, RNAs are recog-
nized by three major types of immunoreceptors: Toll-
like Receptors (TLR), protein kinase R (PKR) and heli-
cases. Toll-like receptors are found on cell-surfaces
(TLR3) and in endosomes (TLR3,7,8), whereas PKR and
helicases (MDA5, RIG-I) are found in the cytoplasm
[72,73]. Immune recognition can lead to a host of down-
stream effects at the cellular level, including cytokine re-
lease, interferon response and changes in gene expression.
At the whole body level, the use of unmodified siRNAs
have been known to induce systemic toxicity, increase
serum transaminases, decrease body weight, lymphopenia
and piloerection [74]. Thus, proper siRNA design should
likely incorporate features to minimize the possibility of
undesirable immune activation.
Although immune activation is influenced by many
factors such as oligonucleotide length, sequence, chem-
ical modification, mode of delivery and immune cell type
involved, it has been previously shown that chemically
modified siRNAs can be synthesized so as to reduce
their immunostimulatory properties [74]. However, it is
interesting to note that immune stimulation may also
have desirable consequences, such as anti-angiogenesis
via the TLR3 pathway [72]. Although this type of thera-
peutic immune stimulation may be useful from the
standpoint of treating cancer, it can also have potentially
severe side-effects [73].
In addition to immune stimulation, other off-target
effects can originate from the partial hybridization of the
antisense strand of siRNA with an unintended mRNA.
This may lead to the cleavage and subsequent knock-
down of the wrong gene [75]. In addition, siRNAs can
have their sense strand incorporated into RISC, leading
to other off-target effects [75]. To address these pro-
blems, siRNA sequences can be carefully selected to
minimize complementarity with unwanted mRNAs, and
chemically modified siRNAs can be used to increase the
selective incorporation of the antisense strand into RISC
[62,76]. This highlights the importance of proper siRNA
design in mediating target gene knockdown.
Cellular uptake of nanocarriers and endosomal escape
strategies
Cells can uptake nanocarriers in many ways, including
phagocytosis, macropinocytosis, clathrin-mediated endo-
cytosis, non-clathrin-mediated endocytosis and caveolin-
mediated uptake [77]. Each of these pathways delivers
nanocarriers to specific cellular compartments, which
may help or hinder drugs (intracellular, membrane-
impermeable type) from reaching their target site. For
example, cationic-lipid-DNA complexes and nanocarriers
with ligands for glycoreceptors are internalized via clathrin-
mediated endocytosis and are destined for the lysosomal
compartment (Figure 4) [77]. In contrast, nanocarriers with
ligands such as albumin, folic acids and cholesterol are
taken up via caveolin-mediated endocytosis, while cell-
penetrating peptide (CPP) ligands such as the HIV transac-
tivator of transcription (TaT), facilitate uptake via macropi-
nocytosis [78,79]. In addition to the surface ligand, the size
Figure 4 Nanocarrier uptake and intracellular siRNA delivery. This illustration shows that uptake of antibody targeted nanocarriers (10–100 nm)
occurs via receptor-mediated endocytosis. The key step in cytoplasmic siRNA delivery involves low pH-triggered nanocarrier disassembly and
endosomal escape. A ‘smart’ nanocarrier can induce endosomal escape by lysing or fusing with endolysosomes upon acidification. The pH change can
also be used to trigger the dissociation of the nanocarrier, therefore releasing the siRNA cargo into the cytosol.
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and shape of nanocarriers can also influence the mechan-
ism and rate of uptake. Previous nanocarrier uptake studies
by Rejman et al. have shown that untargeted particles up to
200 nm are exclusively internalized via clathrin-mediated
endocytosis, while larger particles enter via a caveolin-
dependent pathway [80]. Furthermore, they report an in-
verse correlation between particle size and rate of uptake.
For example, as the particle size was raised from 50 nm to
100 nm, internalization was diminished by 3–4 times.
Interestingly, their data also suggests that cells have an
upper limit for the size of internalized particles, since 1 μm
particles were not taken up into mouse melanoma B16 cells
in vitro [80].
After internalization of nanocarriers into cells, many
studies have shown that large fractions of these nanocar-
riers can remain sequestered in trafficking vesicles and
endolysosomes [81]. This implies that some types of
nanocarriers may not be suitable for delivering mem-
brane-impermeable therapeutics (such as siRNA) to
intracellular targets. Moreover, a lysosomal localization
of unmodified naked siRNA will likely result in the deg-
radation of siRNA [79]. Hence, much research has fo-
cused on intracellular delivery strategies such as cationic
lipid transfection, microinjection and electroporation
[82]. However, most of these strategies are limited to
in vitro conditions due to their invasiveness, variable
transfection efficiency, complexity of the procedure and
potential for altering/disrupting cellular function. Recent
efforts have demonstrated that endosomal escape strat-
egies can be incorporated into nanocarrier design to sig-
nificantly enhance cytosolic delivery of siRNA [83]. Most
commonly, CPPs, pH responsive polymers, fusogenic
peptide sequences and hydrophobic molecules have been
used for nanocarrier endosomal escape [83]. Nanocar-
riers functionalized with CPPs such as the TaT, VP22,
penetratin and polyarginine have been shown to perme-
ate through the plasma membrane for direct cytoplasmic
delivery [83-86]. Alternatively, other pH-responsive
approaches tend to induce the ‘proton-sponge effect’ for
endosomal escape via the clever use of cationic proton-
able amine-containing polymers such as PEI [87]. In this
approach, PEI acts as a buffer against endolysosomal
acidification and causes the osmotic swelling and rup-
ture of endolysosomes, releasing the nanocarriers into
the cytosol (Figure 4) [88]. In contrast, other approaches
attempt to conjugate drugs to fusogenic peptide
sequences, such as GALA and KALA, or hydrophobic
molecules such that the nanocarrier can traverse mem-
branes [83]. For example, cholesterol-tagging has been
shown to improve cytosolic delivery of siRNA with min-
imal cytotoxicity [89].
Interestingly, lipid-based nanocarriers can also be engi-
neered to fuse with cell membranes, either avoiding endo-
cytosis completely or escaping endolysosomes without
inducing endolysosomal lysis. Although some studies sug-
gest that a net positive surface charge and a high cationic
lipid/siRNA molar charge ratio are important factors
required to facilitate efficient membrane fusion with lipid-
based nanocarriers, it has been reported that these factors
also seem to significantly increase toxicity [90]. Recently,
Leal et al. have reported the development of cationic lipo-
some (CL)-siRNA complexes with novel cubic phase
nanostructures, which offer a novel solution to lipid based
delivery. Cubic phase lipid delivery systems readily fuse
with cell membranes due to their high charge density and
positive Gaussian modulus, delivering their cargo through
transiently induced pores in the endosomal membrane,
which results in highly efficient gene silencing in vitro
with low toxicity [91,92]. In contrast, some studies have
successfully employed non-invasive physical methods to
enhance intracellular delivery of siRNA. For example, Du
et al. recently demonstrated that simultaneous administra-
tion of low intensity ultrasound or 15-20% microbubbles
can safely enhance the delivery efficiency of siRNA-loaded
polymeric nanocarriers to rat RPE-J cells in vitro [93]. It is
likely that a combination of approaches will need to be
tested to determine the optimal strategy for endosomal es-
cape for ocular siRNA delivery.
Development of a ‘universal’ nanocarrier for ocular siRNA
delivery
To achieve intracellular ocular siRNA delivery via intra-
vitreal injection, a rational design of a nanocarrier is
required that is capable of overcoming the unique bio-
logical barriers present in the eye. A review of the litera-
ture suggests that several important features including
targeting, stealth, siRNA incorporation, size, shape and
surface characteristics will have to be taken into consid-
eration for the development of a ‘universal’ nanocarrier
for ocular siRNA delivery (Table 2). Turchinovich et al.
recently demonstrated efficient siRNA delivery into
mouse retina in vivo using a commercially available
transfection reagent [94]. However, this non-targeted
method mainly transfected the retinal ganglion cell layer.
This suggests that it is likely necessary to use targeting
molecules on nanocarriers to control the specific retinal
cell type being targeted for transfection. Other studies
by Aggarwal et al. have shown that nanocarriers exposed
to biological fluids in host tissues such as serum are im-
mediately coated with opsonins and other host proteins,
creating a ‘molecular signature’ that determines the
internalization pathway and fate of nanocarriers taken
up by phagocytic cells [95]. Given these observations,
many approaches to shield the nanocarriers from such
host-induced modification have been developed, among
which, a hydrophilic coat of PEG has demonstrated its
effectiveness in vivo. These PEG coated ‘stealth’ nanocar-
riers have been shown to significantly reduce non-
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specific cellular uptake and opsonization by phagocytic
cells [96].
Moreover, the use of a nanocarrier allows for the control
of immune stimulation. Kleinman et al. have shown that
siRNA can directly mediate CNV suppression in vivo via a
non-RNAi mediated mechanism involving cell-surface re-
ceptor TLR-3 [72]. A therapeutic siRNA shielded from the
ocular environment can perhaps avoid such immune
stimulation effects of siRNA. However, in some cases, it
might be desirable to induce a potentially beneficial im-
mune stimulation effect such as angiogenesis suppression.
Given the versatility of nanocarrier systems, it is likely
possible to design a carrier that exposes chemically modi-
fied, stabilized siRNA to ocular fluids to mediate innate
immune stimulation and trigger the TLR-3 pathway for
angiogenesis suppression.
A review of successful siRNA delivery nanocarriers
in vivo strongly suggests that a four component core-shell
delivery system is ideal: 1) core- composed of a biodegrad-
able material that entraps, encapsulates or covalently binds
siRNA, 2) shell- composed of a hydrophilic polymer such
as PEG or a self-protein such as albumin for stability, pro-
tection and surface charge modification, 3) drug- chem-
ically modified siRNA for enhanced stability, potency,
specificity and efficacy, 4) targeting ligand- antibody,
aptamer, peptide, lectin or other small molecules present
on the nanocarrier surface for selective delivery to target
cells (Figure 5). In addition, the size, shape and surface
characteristics of the nanocarrier are key elements that con-
trol their biological interactions. Although the ideal size
and shape of nanocarriers for ocular drug delivery have not
been systematically tested, the diffusion of nanocarriers
through solid tumor models suggest that smaller carriers
are preferred over larger ones. Wong et al. have recently
provided proof-of-principle that gelatin nanocarriers can be
designed to change their particle size from 100 nm to
10 nm upon reaching the tumor microenvironment,
responding to locally produced matrix metalloproteinase-2
(MMP-2), and can thus penetrate deeper into the tumor
tissue [97]. Although most studies involving nanocarrier
biodistribution and cellular uptake have been elucidated
using spherical nanocarriers, recent studies suggest that the
shape of nanocarriers can significantly influence their bio-
logical interactions [79,98]. Particularly, a recent study
showed that positively charged cylindrical particles with an
aspect ratio of 3 (150 nm x 450 nm) were internalized four
times more rapidly by HeLa cells than cylindrical particles
with an aspect ratio of 1 (200 nm x 200 nm) [98]. This sug-
gests that it is important to consider the size as well as the
shape of the nanocarrier in their design. Nanocarrier
Figure 5 Schematic of a four-component ‘universal’ nanocarrier for ocular siRNA delivery. This illustration highlights the salient features of
a four-component, targeted core-shell nanocarrier for ocular siRNA delivery.
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biodistribution and uptake in biological systems can also be
controlled by manipulating their surface characteristics.
The predominant strategy for improving the stability of
nanocarriers in biological solutions has involved the graft-
ing of PEG to the surface to render them more hydrophilic
and neutral in charge [79]. Some studies suggest that the
addition of self-proteins such as albumin via adsorption or
covalent modification may reduce non-specific cellular up-
take and opsonization [99,100]. Taken together, these data
suggest that it is important to optimize the size, shape and
surface characteristics for the development of a ‘universal’
nanocarrier for ocular siRNA delivery.
The proposed four-component nanocarrier system
provides a customizable platform for the development of
a ‘smart’ drug delivery system that can be engineered to
enhance endosomal escape, control siRNA release intra-
cellularly and manipulate the innate immune response.
Particularly, a core-shell nanocarrier structure allows for
the incorporation of specific endosomal escape strat-
egies, which can be activated upon endocytosis. For ex-
ample, the core and shell components can be joined
with a cleavable linker that is sensitive to endolysosomal
stimuli such as acidic pH and acid-activated proteases.
This design effectively allows for the de-shielding of the
nanocarrier core, containing siRNA, to induce endoso-
mal destabilization, or to directly traverse the endosomal
membrane if the core has a hydrophobic composition.
The reducing environment of the cytosol can also be
used to further stimulate the dissociation of siRNA from
the nanocarrier core via the incorporation of disulphide
bonds. The first successful systemic delivery of siRNA
via a targeted nanocarrier in humans serves to confirm
these important parameters in nanocarrier design [101].
Conclusions and future directions
Given that we currently lack an ideal siRNA delivery system
for ocular disorders, it is instructive to consider the nucleo-
tide delivery strategies found in nature. For example, viruses
are essentially targeted biological nanocarriers for the local
or systemic delivery of nucleic acids, known to be the
causative agents of various human diseases. A virion is in-
deed a smart nanocarrier, with several key features: envir-
onmental stability, monodispersity, bioresponsiveness,
biodegradability, immune modulation properties, endoso-
mal escape capabilities, intracellular replicative capacity,
and targeted and localized DNA/RNA intracellular delivery
to specific cells for controlling gene expression. To this ex-
tent, Breitbach et al. have recently shown that a modified
oncolytic pox virus administered intravenously in human
subjects can selectively target cancer cells in solid tumors,
without any observable clinical effects on normal cells
[102]. This 300 nm enveloped virus delivered ds-DNA to
target cells in a dose-dependent manner, similar to that
observed in the recent Phase I clinical trial with siRNA-
nanocarrier technology [101]. A nature-inspired nanocar-
rier design can potentially provide structural insights into
developing the optimal solutions to some of the major bar-
riers in ocular and systemic siRNA delivery.
Many groups have employed ‘smart’ nanocarriers or
‘synthetic viruses’ that mimic isolated aspects of viral nu-
cleotide delivery with varying degrees of success. For ex-
ample, Hu et al. developed a pH-responsive core-shell
nanocarrier designed to release various cargos including
proteins, viral particles and siRNA under endosomal acid-
ification [103]. However, most of these single-stimuli re-
sponsive nanocarriers are focused on either drug delivery
or for diagnostic purposes (imaging and detection), with-
out the ability to combine such useful features. Although
multiple stimuli-responsive nucleotide delivery systems
are currently under development to address this challenge,
a general strategy for intracellular nucleotide delivery has
not yet been established [104]. This may be due to the fact
that nucleotide delivery systems vary greatly in their com-
position, such that combining beneficial features of two
different nucleotide delivery systems into a hybrid system
may not always be possible. In designing a nucleotide de-
livery system, it is instructive to note that viruses sequen-
tially deploy specific strategies to overcome each barrier at
the tissue and cellular level for successful intracellular nu-
cleotide delivery. It follows that any clinically viable nu-
cleotide delivery system will have to take into account the
common barriers to siRNA delivery and incorporate spe-
cific strategies to overcome each of these barriers, while
being flexible enough to combine features that can be
adapted to several ocular conditions.
We envision that the ultimate ocular siRNA delivery
system would incorporate a combination of nature-
inspired desirable features: a biodegradable, multiple stim-
uli-responsive nanocarrier for controlled and localized
siRNA release targeted to specific cell types for manipulat-
ing gene expression of specific genes. When combined
with a drug delivery device, such a ‘smart’ nucleotide deliv-
ery system would not only address the current challenges
of ocular siRNA delivery, with improved biodistribution,
bioavailability and reduced toxicity, but also improve
therapeutic outcomes for the patient.
Abbreviations
AAV: Adenoassociated virus; Ad: Adenovirus; AMD: Age-related macular
degeneration; AGO2: Argonaute 2; BAB: Blood aqueous barrier; BRB: Blood
retinal barrier; CNV: Choroidal neovascularization; CPP: Cell-penetrating
peptide; DC-Chol: (3β-[N-(N′,N′-dimethylamino-ethane)carbamoyl]-cholesterol;
DODAC: N,N-dioleyl-N,N-dimethylammonium chloride; DOPE: 1,2-dioleoyl-sn-
glycero-3-phosphatidylethanolamine; DOTAP: 1,2-dioleoyl-3-
trimethylammonium-propane; DOTMA: N-[1-(2,3-dioleyloxy)propyl]-N,N,N-
trimethylammonium chloride; dsRNAs: Double stranded RNAs; EVA: Ethylene
vinyl acetate; FAc: Fluocinolone acetonide; FDA: US Food and Drug
Administration; 2’-F-RNA: 2’-Fluoro-RNA; HD-Ad: Helper-dependent
adenovirus; miRNA: microRNA; MMP-2: Matrix metalloproteinase-2;
ODNs: Oligodeoxynucleotides; PACT: dsRNA-binding protein; PAMAM: Poly
(amidoamine); PB: Boranophosphonate; PEG: Polyethylene glycol;
PEI: Polyethylenimine; PKR: Protein kinase R; PO4: Phosphodiester; PPI: Poly
Thakur et al. Journal of Biological Engineering 2012, 6:7 Page 13 of 16
http://www.jbioleng.org/content/6/1/7
(propylene imine); PS: Phosphorothioate linkage; PVA: Polyvinyl alcohol;
RISC: RNA-induced silencing complex; RNAi: RNA interference; RPE: Retinal
pigment epithelium; scAAV: Self-complementary AAV; siRNA: Small
interfering RNA; TaT: HIV transactivator of transcription; TLR: Toll-like
Receptors; TRBP: HIV-1 TAR RNA-binding protein; VEGFA: Vascular endothelial
growth factor-A; VEGFR1: Vascular endothelial growth factor receptor-1.
Competing interests
No competing interests to declare.
Authors’ contributions
AT, SF, AZ, KK and BM contributed towards writing and editing the
manuscript. GH and HS critically evaluated the manuscript for publication. All
authors read and approved the final manuscript.
Authors’ information
No information to share.
Acknowledgements
We would like to thank Prof. Mark Eiteman and the Journal of Biological
Engineering for generously waiving the manuscript publication fees.
Author details
1Institute of Biomaterials and Biomedical Engineering, University of Toronto,
Toronto, ON, Canada. 2School of Biomedical Engineering, McMaster
University, Hamilton, ON L8N 3Z5, Canada. 3Faculty of Medicine, University of
Manitoba, Winnipeg, MB, Canada. 4Faculty of Medicine, University of Toronto,
Toronto, ON, Canada. 5Department of Pathology & Molecular Medicine,
McMaster University, Hamilton, ON L8N 3Z5, Canada. 6Department of
Chemical Engineering, McMaster University, Hamilton, ON L8N 3Z5, Canada.
Received: 11 November 2011 Accepted: 26 April 2012
Published: 11 June 2012
References
1. Duvvuri S, Majumdar S, Mitra AK: Drug delivery to the retina: challenges
and opportunities. Expert Opin Biol Ther 2003, 3:45–56.
2. Del Amo EM, Urtti A: Current and future ophthalmic drug delivery
systems. A shift to the posterior segment. Drug DiscovToday 2008,
13:135–143.
3. Novack GD: Ophthalmic drug delivery: development and regulatory
considerations. ClinPharmacolTher 2009, 85:539–543.
4. Urtti A: Challenges and obstacles of ocular pharmacokinetics and drug
delivery. Adv Drug Deliv Rev 2006, 58:1131–1135.
5. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ,
Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, et
al: Ophthalmic drug delivery systems for the treatment of retinal
diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci
2010, 51:5403–5420.
6. Kang Derwent JJ, Mieler WF: Thermoresponsive hydrogels as a new
ocular drug delivery platform to the posterior segment of the eye.
TransAmOphthalmolSoc 2008, 106:206–213.
7. Lee SS, Robinson MR: Novel drug delivery systems for retinal diseases. A
review. Ophthalmic Res 2009, 41:124–135.
8. Kuno N, Fujii S: Biodegradable intraocular therapies for retinal disorders:
progress to date. Drugs Aging 2010, 27:117–134.
9. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG,
Tolentino M, Gupta A, Duarte L, Madreperla S, et al: Long-term benefit of
sustained-delivery fluocinolone acetonide vitreous inserts for diabetic
macular edema. Ophthalmology 2011, 118:626–635. e622.
10. London NJ, Chiang A, Haller JA: The dexamethasone drug delivery
system: indications and evidence. Adv Ther 2011, 28:351–366.
11. Eljarrat-Binstock E: Pe'er J, Domb AJ: New techniques for drug delivery to
the posterior eye segment. Pharm Res 2010, 27:530–543.
12. Reischl D, Zimmer A: Drug delivery of siRNA therapeutics: potentials and
limits of nanosystems. Nanomedicine: Nanotechnology, Biology and
Medicine 2009, 5:8–20.
13. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and
specific genetic interference by double-stranded RNA in caenorhabditis
elegans. Nature 1998, 391:806–811.
14. Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes
of 21-nucleotide RNAs mediate RNA interference in cultured mammalian
cells. Nature 2001, 411:494–498.
15. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J: Interfering
with disease: a progress report on siRNA-based therapeutics. Nature Rev
Drug Discov 2007, 6:443–453.
16. Ahmed SU, Milner J: Basal Cancer Cell Survival Involves JNK2 Suppression
of a Novel JNK1/c-Jun/Bcl-3 Apoptotic Network. PLoS One 2009,
4:e7305.
17. Watts JK, Deleavey GF, Damha MJ: Chemically modified siRNA: tools and
applications. Drug Discovery Today 2008, 13:842–855.
18. Whitehead K, Langer R, Anderson D: Knocking down barriers: advances in
siRNA delivery. Nat Rev Drug Discov 2009, 8:129–138.
19. Kennedy S, Wang D, Ruvkun G: A conserved siRNA-degrading RNase
negatively regulates RNA interference in C. elegans. Nature 2004,
427:645–649.
20. Pirollo K, Chang E: Targeted delivery of small interfering RNA:
approaching effective cancer therapies. Cancer Res 2008, 68:1247–1250.
21. Mohan R, Tovey J, Sharma A, Tandon A: Gene therapy in the Cornea:
2005-present. Prog Retin Eye Res 2012, 31:43–64.
22. Couto L, High K: Viral vector-mediated RNA interference. Curr Opin
Pharmacol 2010, 10:534–542.
23. Wu L, Lam S, Cao H, Guan R, Hu J: Subretinal gene delivery using helper-
dependent adenoviral vectors. Cell Biosci 2011, 1:15.
24. Höbel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher H, Aigner
A: Polyethylenimine/small interfering RNA-mediated knockdown of
vascular endothelial growth factor in vivo exerts anti-tumor effects
synergistically with Bevacizumab. J Gene Med 2010, 12:287–300.
25. Hirano Y, Sakurai E, Matsubara A, Ogura Y: Suppression of ICAM-1 in retinal
and choroidal endothelial cells by plasmid small-interfering RNAs
in vivo. Invest Ophthalmol Vis Sci 2010, 51:508–515.
26. Conley S, Naash M: Nanoparticles for retinal gene therapy. Prog Retin Eye
Res 2010, 29:376–397.
27. Khar R, Jain G, Warsi M, Mallick N, Akhter S, Pathan S, Ahmad F: Nano-
vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics.
Indian J Pharm Sci 2010, 72:675–688.
28. Naik R, Mukhopadhyay A, Ganguli M: Gene delivery to the retina: focus on
non-viral approaches. Drug Discov Today 2009, 14:306–315.
29. Boussif O: Lezoualc'h F, Zanta M, Mergny M, Scherman D, Demeneix B,
Behr J: A versatile vector for gene and oligonucleotide transfer into cells
in culture and in vivo: polyethylenimine. PNAS 1995, 92:7297–7301.
30. Grayson A, Doody A, Putnam D: Biophysical and Structural
Characterization of Polyethylenimine-Mediated siRNA Delivery in Vitro.
Pharm Res 2006, 23:1868–1876.
31. Kim B, Tang Q, Biswas P, Xu J, Schiffelers R, Xie F, Ansari A, Scaria P, Woodle
M, Lu P, Rouse B: Inhibition of ocular angiogenesis by siRNA targeting
vascular endothelial growth factor pathway genes: therapeutic strategy
for herpetic stromal keratitis. Am J Pathol 2004, 165:2177–2185.
32. Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A:
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA
delivery to the lung. Eur J Pharm Biopharm 2011, 77:438–449.
33. Duan Y, Guan X, Ge J, Quan D, Zhuo Y, Ye H, Shao T: Cationic nano-
copolymers mediated IKKbeta targeting siRNA inhibit the proliferation of
human Tenon's capsule fibroblasts in vitro. Mol Vis 2008,
14:2616–2628.
34. Ye H, Qian Y, Lin M, Duan Y, Sun X, Zhuo Y, Ge J: Cationic nano-copolymers
mediated IKKβ targeting siRNA to modulate wound healing in a monkey
model of glaucoma filtration surgery. Mol Vis 2010, 16:2502–2510.
35. Soriano P, Dijkstra J, Legrand A, Spanjer H, Londos-Gagliardi D, Roerdink F,
Scherphof G, Nicolau C: Targeted and nontargeted liposomes for in vivo
transfer to rat liver cells of a plasmid containing the preproinsulin I
gene. PNAS 1983, 80:7128–7131.
36. Liu H, Liu Y, Ma Z, Wang J, Zhang Q: A Lipid Nanoparticle System
Improves siRNA Efficacy in RPE Cells and a Laser-Induced Murine CNV
Model. Invest Ophthalmol Vis Sci 2011, 52:4789–4794.
37. Zhang Y, Li H, Sun J, Gao J, Liu W, Li B, Guo Y, Chen J: DC-Chol/DOPE
cationic liposomes: a comparative study of the influence factors on
plasmid pDNA and siRNA gene delivery. Int J Pharm 2010,
390:198–207.
38. Lochmann D, Weyermann J, Georgens C, Prassl R, Zimmer A: Albumin-
protamine-oligonucleotide nanoparticles as a new antisense delivery
Thakur et al. Journal of Biological Engineering 2012, 6:7 Page 14 of 16
http://www.jbioleng.org/content/6/1/7
system. Part 1: Physicochemical characterization. Eur J Pharm Biopharm
2005, 59:419–429.
39. Johnson L, Cashman S, Kumar-Singh R: Cell-penetrating peptide for
enhanced delivery of nucleic acids and drugs to ocular tissues including
retina and cornea. Mol Ther 2008, 16:107–114.
40. Laufer S, Restle T: Peptide-Mediated Cellular Delivery of Oligonucleotide-
Based Therapeutics In Vitro: Quantitative Evaluation of Overall Efficacy
Employing Easy to Handle Reporter Systems. Curr Pharm Des 2008,
14:3637–3655.
41. Yuan X, Naguib S, Wu Z: Recent advances of siRNA delivery by
nanoparticles. Expert Opin Drug Deliv 2011, 8:521–536.
42. Marano R, Wimmer N, Kearns P, Thomas B, Toth I, Brankov M, Rakoczy P:
Inhibition of in vitro VEGF expression and choroidal neovascularization
by synthetic dendrimer peptide mediated delivery of a sense
oligonucleotide. Exp Eye Res 2004, 79:525–535.
43. Marano R, Toth I, Wimmer N, Brankov M, Rakoczy P: Dendrimer delivery of
an anti-VEGF oligonucleotide into the eye: a long-term study into
inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene
Ther 2005, 12:1544–1550.
44. Agrawal A, Min D, Singh N, Zhu H, Bhatia S: Functional delivery of siRNA in
mice using dendriworms. ACS Nano 2009, 3:2495–2504.
45. Han L, Zhang A, Wang H, Pu P, Jiang X, Kang C, Chang J: Tat-BMPs-PAMAM
conjugates enhance therapeutic effect of small interference RNA on
U251 glioma cells in vitro and in vivo. Hum Gene Ther 2010, 21:417–426.
46. A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With
Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular
Degeneration (AMD). [http://clinicaltrials.gov/ct2/show/NCT00363714]
47. A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-
Related Macular Degeneration. [http://clinicaltrials.gov/ct2/show/NCT00395057]
48. Kaiser P, Symons R, Shah S, Quinlan E, Nguyen Q: RNAi-based treatment
for neovascular age-related macular degeneration by Sirna-027. Am J
Ophthalmol 2010, 150:33–39.
49. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis
Therapy in Wet AMD (COBALT). [http://clinicaltrials.gov/ct2/show/NCT00499590]
50. Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular
Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus
Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization
(MONET Study). [http://www.clinicaltrials.gov/ct2/show/NCT00713518?
term= quark&rank = 7]
51. Prospective, Randomized, Multi-Center, Comparator Study Evaluating Efficacy
and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular
Edema (DEGAS). [http://www.clinicaltrials.gov/ct2/show/NCT00701181?
term= degas&rank = 1]
52. Development pipeline: PF-655. [http://www.quarkpharma.com/qbi-en/
products/53/]
53. Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve
Atrophy and Recent Onset NAION Patients. [http://clinicaltrials.gov/ct2/show/
NCT01064505]
54. Tolerance and Effect on Intraocular Pressure After Administration of SYL040012.
[http://clinicaltrials.gov/ct2/show/NCT00990743]
55. Tiemann K, Rossi J: RNAi-based therapeutics-current status, challenges
and prospects. EMBO Mol Med 2009, 1:142–151.
56. Morrissey D, Blanchard K, Shaw L, Jensen K, Lockridge J, Dickinson B,
McSwiggen J, Vargeese C, Bowman K, Shaffer C, et al: Activity of stabilized
short interfering RNA in a mouse model of hepatitis B virus replication.
Hepatology 2005, 41:1349–1356.
57. Pipeline: Development Programs.http://clinicaltrials.gov/ct2/show/
NCT00395057. [http://www.alnylam.com/Programs-and-Pipeline/index.php]
58. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I: Sequence-
dependent stimulation of the mammalian innate immune response by
synthetic siRNA. Nat Biotechnol 2005, 23:457–462.
59. Prakash T, Allerson C, Dande P, Vickers T, Sioufi N, Jarres R, Baker B, Swayze
E, Griffey R, Bhat B: Positional effect of chemical modifications on short
interference RNA activity in mammalian cells. J Med Chem 2005,
48:4247–4253.
60. Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk G, Giese K,
Kaufmann J: Structural variations and stabilising modifications of
synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003,
31:2705–2716.
61. Morrissey D, Lockridge J, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough
K, Machemer L, Radka S, Jadhav V, et al: Potent and persistent in vivo anti-
HBV activity of chemically modified siRNAs. Nature Biotechnol 2005,
23:1002–1007.
62. Samuel-Abraham S, Leonard J: Staying on message: design principles for
controlling nonspecific responses to siRNA. FEBS J 2010, 277:4828–4836.
63. Leuschner P, Ameres S, Kueng S, Martinez J: Cleavage of the siRNA
passenger strand during RISC assembly in human cells. EMBO Rep 2006,
7:314–320.
64. Hall AH, Wan J, Shaughnessy EE, Ramsay Shaw B, Alexander KA: RNA
interference using boranophosphate siRNAs: structure-activity
relationships. Nucleic Acids Res 2004, 32:5991–6000.
65. Choung S, Kim Y, Kim S, Park HO, Choi YC: Chemical modification of
siRNAs to improve serum stability without loss of efficacy. Biochem
Biophys Res Commun 2006, 342:919–927.
66. Shim M, Kwon Y: Efficient and targeted delivery of siRNA in vivo. FEBS J
2010, 277:4814–4827.
67. Overhoff M, Sczakiel G: Phosphorothioate-stimulated uptake of short
interfering RNA by human cells. EMBO Rep 2005, 6:1176–1181.
68. Behlke M: Chemical modification of siRNAs for in vivo use.
Oligonucleotides 2008, 18:305–319.
69. Jackson A, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Linsley P:
Position-specific chemical modification of siRNAs reduces "off-target"
transcript silencing. RNA 2006, 12:1197–1205.
70. Minks M, West D, Benvin S, Baglioni C: Structural requirements of double-
stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein
kinase of interferon-treated HeLa cells. J Biol Chem 1979, 254:10180–
10183.
71. Marques JT, Williams BRG: Activation of the mammalian immune system
by siRNAs. Nat Biotechnol 2005, 23:1399–1405.
72. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ,
Albuquerque RJC, Yamasaki S, Itaya M, Pan Y, et al: Sequence- and target-
independent angiogenesis suppression by siRNA via TLR3. Nature 2008,
452:591–597.
73. Judge A, MacLachlan I: Overcoming the innate immune response to small
interfering RNA. Human Gene Therapy 2008, 19:111–124.
74. Morrissey DV: Potent and persistent in vivo anti-HBV activity of
chemically modified siRNAs. Nature Biotechnol 2005, 23:1002–1007.
75. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet
G, Linsley PS: Expression profiling reveals off-target gene regulation by
RNAi. Nat Biotechnol 2003, 21:635–637.
76. Walton S, Wu M, Gredell J, Chan C: Designing highly active siRNAs for
therapeutic applications. FEBS J 2010, 277:4806–4813.
77. Zuhorn IS, Kalicharan R, Hoekstra D: Lipoplex-mediated transfection of
mammalian cells occurs through the cholesterol-dependent clathrin-
mediated pathway of endocytosis. J Biol Chem 2002, 277:18021–18028.
78. Torchilin V: Cell penetrating peptide-modified pharmaceutical
nanocarriers for intracellular drug and gene delivery. Biopolymers 2008,
90:604–610.
79. Petros R, DeSimone J: Strategies in the design of nanoparticles for
therapeutic applications. Nat Rev Drug Discov 2010, 9:615–627.
80. Rejman J, Oberle V, Zuhorn IS, Hoekstra D: Size-dependent internalization
of particles via the pathways of clathrin-and caveolae-mediated
endocytosis. Biochem J 2004, 377:159–169.
81. Fisher D, Ahlemeyer Y, Krieglstein B, Kissel T: In vitro cytotoxicity testing of
polycations: influence of polymer structure on cell viability and
hemolysis. Biomaterials 2003, 24:1121–1131.
82. Kim BYS, Jiang W, Oreopoulos J, Yip CM, Rutka JT, Chan WCW:
Biodegradable Quantum Dot Nanocomposites Enable Live Cell Labeling
and Imaging of Cytoplasmic Targets. Nano Letters 2008, 8:3887–3892.
83. Rajendran L, Knölker H, Simons K: Subcellular targeting strategies for drug
design and delivery. Nat Rev Drug Discov 2010, 9:29–42.
84. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y:
Arginine-rich peptides. An abundant source of membrane-permeable
peptides having potential as carriers for intracellular protein delivery. J Biol
Chem 2001, 276:5836–5840.
85. Ruan G, Agrawal A, Marcus AI, Nie S: Imaging and Tracking of Tat Peptide-
Conjugated Quantum Dots in Living Cells: New Insights into
Nanoparticle Uptake, Intracellular Transport, and Vesicle Shedding. J Am
Chem Soc 2007, 129:14759–14766.
86. Derossi D, Joliot A, Chassaing G, Prochiantz A: The third helix of the
Antennapedia homeodomain translocates through biological
membranes. J Biol Chem 1994, 269:10444–10450.
Thakur et al. Journal of Biological Engineering 2012, 6:7 Page 15 of 16
http://www.jbioleng.org/content/6/1/7
87. Duan H, Nie S: Cell-penetrating quantum dots based on multivalent and
endosome-disrupting surface coatings. J Am Chem Soc 2007,
129:3333–3338.
88. Thomas M, Klibanov A: Enhancing polyethylenimine's delivery of plasmid
DNA into mammalian cells. PNAS 2002, 99:14640–14645.
89. Gusachenko Simonova O, Kravchuk Y, Konevets D, Silnikov V, Vlassov VV,
Zenkova MA: Transfection Efficiency of 25-kDa PEICholesterol Conjugates
with Different Levels of Modification. J Biomater Sci Polym Ed 2009,
20:1091–1110.
90. Bouxsein N, McAllister C, Ewert K, Samuel C, Safinya C: Structure and gene
silencing activities of monovalent and pentavalent cationic lipid vectors
complexed with siRNA. Biochemistry 2007, 46:4785–4792.
91. Leal C, Bouxsein N, Ewert K, Safinya C: Highly efficient gene silencing
activity of siRNA embedded in a nanostructured gyroid cubic lipid
matrix. J Am Chem Soc 2010, 132:16841–16847.
92. Leal C, Ewert K, Shirazi R, Bouxsein N, Safinya C: Nanogyroids incorporating
multivalent lipids: enhanced membrane charge density and pore
forming ability for gene silencing. Langmuir 2011, 27:7691–7697.
93. Du J, Shi Q, Sun Y, Liu P, Zhu M, Du L, Duan Y: Enhanced delivery of
monomethoxypoly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly
l-lysine nanoparticles loading platelet-derived growth factor BB small
interfering RNA by ultrasound and/or microbubbles to rat retinal
pigment epithelium cells. J Gene Med 2011, 13:312–323.
94. Turchinovich A, Zoidl G, Dermietzel R: Non-viral siRNA delivery into the
mouse retina in vivo. BMC Ophthalmol 2010, 10:25.
95. Aggarwal P, Hall J, McLeland C, Dobrovolskaia A, McNeil S: Nanoparticle
interaction with plasma proteins as it relates to particle biodistribution,
biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009,
61:428–437.
96. Gref R, Minamitake Y, Peracchia M, Trubetskoy V, Torchilin V, Langer R:
Biodegradable long-circulating polymeric nanospheres. Science 1994,
263:1600–1603.
97. Wong C, Stylianopoulos T, Cui J, Martin J, Fukumura D: Multistage
nanoparticle delivery system for deep penetration into tumor tissue.
PNAS 2011, 108:2426–2431.
98. Gratton S, Ropp P, Pohlhaus P, Luft J, Madden V, Napier M, DeSimone J: The
effect of particle design on cellular internalization pathways. PNAS 2008,
105:11613–11618.
99. Yokoe J, Sakuragi S, Yamamoto K, Teragaki T, Ogawara K, Higaki K, Katayama
N, Kai T, Sato M, Kimura T: Albumin-conjugated PEG liposome enhances
tumor distribution of liposomal doxorubicin in rats. Int J Pharm 2008,
353:28–34.
100. Furumoto K, Yokoe J, Ogawara K, Amano S, Takaguchi M, Higaki K, Kai T,
Kimura T: Effect of coupling of albumin onto surface of PEG liposome on
its in vivo disposition. Int J Pharm 2007, 329:110–116.
101. Davis M, Zuckerman J, Choi C, Seligson D, Ribas A: Evidence of RNAi in
humans from systemically administered siRNA via targeted
nanoparticles. Nature 2010, 464:1067–1070.
102. Breitbach C, Burke J, Jonker D, Stephenson J, Haas A, Kirn D: Intravenous
delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in
humans. Nature 2011, 477:99–102.
103. Hu Y, Atukorale P, Lu J, Moon J, Um S, Cho E, Wang Y, Chen J, Irvine D:
Cytosolic delivery mediated via electrostatic surface binding of protein,
virus, or siRNA cargos to pH-responsive core-shell gel particles.
Biomacromolecules 2009, 10:756–765.
104. You J, Almeda D, Ye G, Auguste D: Bioresponsive matrices in drug
delivery. J Biol Eng 2010, 4.
doi:10.1186/1754-1611-6-7
Cite this article as: Thakur et al.: Strategies for ocular siRNA delivery:
Potential and limitations of non-viral nanocarriers. Journal of Biological
Engineering 2012 6:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thakur et al. Journal of Biological Engineering 2012, 6:7 Page 16 of 16
http://www.jbioleng.org/content/6/1/7
	





		 !
	
"##
$%
&'  (& !)*+,)!-(
				
	 !"	#$%	&!'''	#(%	)*	+,-	+..//,..'"
0,*!	,		*-	
		1234	5		1234	67	0+3*4	+,,	6	)
2*,	8	9+	+
0		+	./01+2
&301+,1+#		,4
#0	5.6 !) 7	8

%&	
9%&+
3:;%#/%
+<(+==<8=-)+/>)!)-?*)  (
0	3		+		:9)!)-?*)  (
@
!<4 !)(
.	&

,%
*<
A

10.1586/ERD.12.24 339ISSN 1743-4440© 2012 Expert Reviews Ltdwww.expert-reviews.com
Special Report
Stimuli-responsive materials have gained con-
siderable attention for their potential to create 
targeted, tunable and personalized therapeutics 
that respond directly to the physiologic environ-
ment. With recent advances in medical polymer 
technology, it is becoming increasingly possible 
to tailor drug-releasing scaffolds to produce on-
demand delivery of therapeutic payloads locally 
in response to physiological requirements [1]. 
Stimuli-responsive polymers, also termed intel-
ligent, smart, environmentally responsive and 
sensitive polymers, are a class of materials that 
undergo significant and rapid physicochemical 
changes in response to small changes in environ-
mental conditions. There are a number of differ-
ent classes of responsive polymers, which respond 
to a distinct set of stimuli, including light, pH, 
temperature, ultrasound, magnetism, electric 
field, enzymes, antibodies, or the presence of 
specific molecules, such as glucose [2]. In addi-
tion, the specific response varies depending on 
the system. Polymers may undergo changes in 
hydrophobic/hydrophilic balance, solubility, 
hydration, conformation, shape, degradation 
or micellization in response to the presence, or 
absence, of an external stimulus [2]. It is there-
fore possible to use these materials to generate 
drug delivery scaffolds that respond with predict-
able, controllable, predefined response profiles to 
impart a large degree of control and tunability 
over drug dosing. The ability to produce tar-
geted on-demand drug release has implications 
for a number of different clinical applications, 
including hormone replacement therapy, chemo-
therapy, rhythmic heart disorders, diabetes, birth 
control and posterior segment ocular drug deliv-
ery. Of the various stimuli-responsive materials, 
temperature-sensitive polymers are the most 
widely studied, and this special report, while 
not exhaustive, will focus on several of these 
materials that have particular importance in 
drug delivery applications. A list of natural and 
synthetic thermo responsive homopolymers and 
copolymers that are relevant to drug delivery is 
provided in TABLE 1.
Thermoresponsive polymers & their 
applicability for controlled release of 
drugs
Thermoresponsive polymers utilize subtle changes 
in temperature to trigger macroscopic changes 
in material properties. Polymers that possess 
a lower critical solution temperature (LCST) 
typically undergo a sol–gel phase transition when 
heated above their LCST, whereas polymers that 
become soluble upon heating are said to possess 
an upper critical solution temperature (UCST) 
[3]. Both systems can be exploited for drug 
delivery purposes. LCST copolymers can simply 
be mixed with drug as a liquid suspension at 
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The ability to undergo rapid changes in response to subtle environmental cues make stimuli- 
responsive materials attractive candidates for minimally invasive, targeted and personalized 
drug delivery applications. This special report aims to highlight and provide a brief description 
of several of the significant natural and synthetic temperature-responsive materials that have 
clinical relevance for drug delivery applications. This report examines the advantages and 
disadvantages of natural versus synthetic materials and outlines various scaffold architectures 
that can be utilized with temperature-sensitive drug delivery materials. The authors provide a 
commentary on the current state of the field and provide their insight into future expectations 
for temperature-sensitive drug delivery, emphasizing the importance of the emergence of dual 
and multiresponsive systems capable of responding precisely to an expanding set of stimuli, 
thereby allowing the development of disease-specific drug delivery vehicles.
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Table 1. A list of natural and synthetic thermoresponsive homopolymers and copolymers with their 
corresponding thermal phase transition temperatures.
Study (year) Name Abbreviation LCST/
UCST (°C)
Ref.
Synthetic homopolymers
Laukkanen et al. (2004) Poly(N-vinylcaprolactam) PVCL 31 [91]
Schild (1990) Poly(N-isopropylacrylamide) PNIPAAm 32 [92]
Cao et al. (2007) Poly(N-n-propylacrylamide) PNPAm 25 [93]
Poly(N,N-ethylmethylacrylamide) PEMA 70
Liu and Zhu (1999) Poly(N-ethylacrylamide) PEA 82 [94]
Geever et al. (2011) Poly(N,N-diethylacrylamide) PDEAAm ~28–32 [19]
Uguzdogan et al. (2005) Poly(ethoxypropylacrylamide) PEPA ~32 [95]
Yamazaki et al. (1998) Poly(N,N-bis(2-methoxyethyl) acrylamide) PBMEAm 49 [96]
Poly(N-(3-methoxypropyl)acrylamide) PMPAm >60
Persson et al. (2000) Poly(vinyl methyl ether) PVME 34 [97]
Yuk et al. (1997) Poly(2-dimethylamino)ethyl methacrylate) PDMA 50 [98]
Liu and Armes (2001) Poly(proprylene oxide) PPO 10–20 [99]
Chiu et al. (1986) Poly(2-ethyl-2-oxazoline) PEOZ ~62 [100]
Uyama and Kobayashi 
(1992)
Poly(2-isopropyl-2-oxazoline) PIPOZ ~36 [101]
Urban (2011) Polyphosphazenes ~25–99 [ 81]
Synthetic multi-block copolymers
Fusco (2006) Poly(ethylene oxide)-poly(propylene oxide)-
poly(ethylene oxide) (Pluronics®)
PEO–PPO–PEO 10–100 [102]
 L42† PEO4–PPO22–PEO4 37
 L62† PEO6–PPO34–PEO6 32
 L63† PEO9–PPO32–PEO9 34
Polyester/PEG block copolymers
Gao et al. (2010)   Poly(lactic acid-co-glycolic acid)-polyethylene 
glycol-poly(lactic acid-co-glycolic acid)
PLGA–PEG–PLGA ~37 [103]
Jeong et al. (1997)   Poly(ethylene glycol)–b-poly(D,L-lactic acid-co-
glycolic acid)–b-poly(ethylene glycol)
PEG–PLA–PEG ~37 [104]
Lutz et al. (2006)  Poly(oligo(ethylene glycol) methacrylate) POEGMA 26–90 [105]
Badi and Lutz (2009)   s-poly(ethylene glycol)-b-poly(2-(2-methoxy 
ethoxy) ethyl methacrylate-co-oligo(ethylene 
glycol) methacrylate)
sPEG-b-P(MEO2MA-co-OEGMA475) 35–41 [106]
Lutz et al. (2006)   Poly(2-(2-methoxyethoxy)ethyl methacrylate-
co-oligo(ethylene glycol) methacrylate)
P(MEO2MA-co-OEGMA)
5–8% OEGMA units per chain
32–37 [105]
Gong et al. (2009)   Poly(ε-caprolactone)-poly(ethylene glycol)-poly 
(ε-caprolactone)
PCL–PEG–PCL ~15–50 [107]
PCL1000–PEG1000–PCL1000 (15–35 wt%) ~18–25 [107]
PCL1000–PEG1500–PCL1000 (15–35 wt%) ~39–46
PCL1500–PEG1500–PCL1500 (15–35 wt%) ~37–45
Dayananda et al. (2008) PCL1950–PEG1750–PCL1950 (20 wt%) ~42 [108]
PCL2110–PEG2000–PCL2110 (20 wt%) ~44
†Pluronic nomenclature: The first letter in the copolymer name indicates that the physical state of the starting polymer is a liquid (L). The last number indicates the weight 
content of the PEO block (in terms of weight percent), while the remaining numbers give an indication of the molecular weight of the PPO block (taken from) [102].
Adapted from [111].
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room temperature and delivered via minimally invasivel injection 
techniques directly to hard-to-access target tissues within the 
body. Heating to physiologic temperature drives a sol–gel phase 
transition, which entraps the infused drug within a solid depot 
and can provide sustained release of therapeutic concentrations 
of drug directly at the site of interest [4]. Drug-releasing polymer 
systems possessing a UCST may employ temperature-induced 
swelling or scaffold destabilization to rapidly release drug at a 
target site [5]. Localized heating (tumor tissues) or the application 
of an externally applied stimulus (ultrasound, infrared laser and so 
on) may be utilized to induce the local destabilization of a UCST 
drug-releasing copolymer scaffold to produce targeted release [6,7].
Thermoresponsive drug delivery scaffolds offer numerous 
advantages, such as eliminating the need for invasive surgical 
implantation and the ability to bypass physiological barriers, 
allowing delivery to hard-to-access locations within the body [8]. 
Furthermore, drug encapsulation within a scaffold may protect the 
therapeutic agent from enzymatic or environmental degradation. 
The release rate can be tailored to locally produce persistent levels 
of therapeutically relevant concentrations of drug, thus over coming 
the ineffectiveness of simple injections, which are associated with 
an initial spike that may lead to toxic levels initially followed by a 
rapid decrease to levels that possess little to no therapeutic benefit 
(FIGURE 1) [8].
Synthetic thermoresponsive materials
Poly(N-isopropylacrylamide)
Polymer hydrogels that display reversible volume changes have 
gained considerable interest since Tanaka observed the tendency 
of polyacrylamide gels to undergo phase separation in response to 
temperature or fluid composition [9]. Poly(N-isopropylacrylamide) 
(PNIPAAm) is one of the most widely studied temperature-sensitive 
polymers; it exhibits a rapid sol–gel transition when heated above 
its LCST, approximately 32°C, allowing injection at room tem-
perature and scaffold formation at body temperature [4]. One of 
the major limitations of PNIPAAm is that it is nondegradable. 
Degradable drug delivery materials afford elimination of the scaf-
fold following exhaustion of the drug reservoir without the require-
ment for secondary surgical removal. Therefore, there has been an 
increased emphasis in recent years on introducing degradability 
into NIPAAm-based copolymers. Ultimately, it is desirable to pre-
serve the thermal phase transition properties of NIPAAm, while 
promoting the eventual degradation and clearance from the body 
following exhaustion of the therapeutic effect. In 1999, Neradovic 
et al. synthesized NIPAAm-based polymers with 2-hydroxyethyl 
 methacrylate–monolactate (HEMA– monolactate) [10]. As the 
hydro lytically labile lactate ester side groups were cleaved, the hydro-
philicity of the copolymer increased, raising the LCST. If the LCST 
is raised above body temperature, the thermoreversible NIPAAm-
based copolymers revert back into a hydrated liquid state, allowing 
uptake into systemic circulation and clearance from the body, as 
long as the molecular weight is below the renal filtration limit of 
30–50 kDa [11]. Yoshida et al. designed NIPAAm-based copolymers 
that were crosslinked with degradable poly(amino acids), which 
showed a similar clearance mechanism [12]. Guan et al. synthe-
sized a series of protein-reactive NIPAAm-based copolymers, pos-
sessing relatively high tensile strength that hydrolyze to produce 
soluble, nontoxic degradation products through copolymerization 
with HEMA–polylactide (HEMA–PLA), N-acryloxysuccinimide 
and acrylic acid [13]. Ma et al. further improved the mechanical 
properties through the incorporation of methacrylate–polylac-
tide (MA–PLA) and HEMA [14]. Cui et al. developed a series of 
slow-degrading NIPAAm-based copolymers through copolymeri-
zation with dimethyl-γ-butyrolactone acrylate (DBA) [15]. These 
Table 1. A list of natural and synthetic thermoresponsive homopolymers and copolymers with their 
corresponding thermal phase transition temperatures (cont.). 
Study (year) Name Abbreviation LCST/
UCST (°C)
Ref.
Natural polymers and derivatives
Chenite et al. (2000) and 
Molinaro et al. (2002)
Chitosan-glycerophosphate Chitosan-GP ~37 [50,51]
Persson et al. (2000) Methylcellulose MC 50 [97]
Schild (1990) Hydroxypropylcellulose HPC 42 [92]
Persson et al. (2000) Ethyl(hydroxyethyl)cellulose EHEC 65 [97]
Miyazaki et al. (1998)† Xyloglucan (with 44% removal of galactose) 22–27 [59]
Chilkoti et al. (2006) Elastin-like polypeptides ELP 0–100 [109]
Ge et al. (2010) ELP[V5A2G3-90] 49 [41]
Meyer et al. (2001) ELP[V5A2G3-150] 40 [48]
ELP [V5A2G3-160] 55
Urry et al. (1991) Poly(VPGVG) 27 [110]
†Pluronic nomenclature: The first letter in the copolymer name indicates that the physical state of the starting polymer is a liquid (L). The last number indicates the weight 
content of the PEO block (in terms of weight percent), while the remaining numbers give an indication of the molecular weight of the PPO block (taken from) [102].
Adapted from [111].
Temperature-sensitive polymers for drug delivery
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copolymers undergo a hydrolysis-dependent opening of the DBA 
lactone ring structure, capable of increasing LCST above body 
temperature without producing any degradation products [15,16]. 
The Sheardown group prepared bioactive NIPAAm/DBA copoly-
mers through copolymerization with N-acryloxysuccinimide [17] 
for posterior segment ophthalmic cell and drug delivery purposes. 
For a list of thermoresponsive homo-
polymers and copolymers of PNIPAAm, 
see [18]. There are many other exam-
ples of N-substituted thermoresponsive 
polyacrylamides that may be suitable for 
drug delivery, such as poly(N,N-diethyl-
acrylamide [19,20] and poly(N-vinyl capro-
lactam) [21]. For a comprehensive list, see 
[22]. Similar to PNIPAAm, linear polymers 
of poly(N,N-diethylacrylamide and poly 
(N-vinyl caprolactam) have LCST values of 
32°C [19] and 31°C [18], respectively.
Poly(ethylene oxide)-based 
thermoresponsive copolymers
Triblock copolymers possessing an A–B–A 
configuration of poly(ethylene oxide)–
poly(propylene oxide)–poly(ethylene 
oxide) (PEO–PPO–PEO), referred to as Pluronics or Poloxamers, 
are another family of thermogelling synthetic materials that have 
been extensively studied for their potential use as drug carriers 
[23]. Through manipulation of concentration, composition and 
molecular weight, these copolymers can be tuned to undergo 
reversible gelation at physiological temperature and pH [23]. The 
combination of hydrophilic ethylene oxide 
and hydrophobic propylene oxide units 
creates an amphiphilic copolymer that can 
self-associate into micelles under aqueous 
conditions when above a critical micelle 
concentration (CMC) (FIGURE 2). The CMC 
is highly temperature dependent, as below 
a critical micelle temperature, both ethyl-
ene oxide and propylene oxide blocks are 
relatively soluble in water [23]. As the tem-
perature of the system increases, the PPO 
chains become less soluble, resulting in 
micelle formation. Pluronic micelles typi-
cally possess a diameter ranging from 10 
to 100 nm and consist of a hydro phobic, 
PPO-rich core and a hydrated, hydro-
philic PEO-rich shell [24]. The PPO core 
is capable of incorporating up to 30 wt % 
of water-insoluble drugs, while the PEO 
corona maintains the micelles in a dis-
persed state and improves drug stability 
by shielding the reserves from undesirable 
interactions with cells and proteins [24]. 
However, these hydrogels tend to possess 
poor mechanical strength, limited stabil-
ity and high permeability, thereby limiting 
their effectiveness as sustained-release sys-
tems [24,25]. Cohn et al. have utilized a num-
ber of strategies to improve the mechanical 
integrity of PEO/PPO copolymers. Such 
strategies include the introduction of in situ 
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Figure 1. Representation of the ideal delivery profile in which drug 
concentration is maintained within the therapeutic window, below the toxic 
threshold, but high enough to exert a therapeutic effect.
Films
Interpenetrating networks
Triblock copolymers
Diblock copolymers
Thermoresponsive
polymer
architectures
Micelles Polymersomes
Bulk gels
Hydrophilic core and corona
Hydrophobic ring
Hydrophilic corona
Hydrophobic core
Figure 2. Illustration of some of the architectures that can be obtained using 
thermoresponsive copolymers for drug delivery applications. The architectures 
include bulk gels, micelles possessing a hydrophobic core and a hydrophilic corona, 
polymersomes that have a hydrophobic layer sandwiched between a hydrophilic core 
and corona, interpenetrating networks and polymer films.
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crosslinking end-groups, such as carbon-carbon double bonds [26], 
methacrylate groups [27] and triethoxysilane groups [27] and cova-
lently linking PEO and PPO using carbonyl chloride and diacyl 
chloride coupling agents [28]. In recent years, there has been an 
extensive investigation into the synthesis of copolymers of poly-
ethylene glycol (PEG) with degradable polyesters such as PLA, 
poly(lactide-co-glycolide) (PLGA) and poly(caprolactone) (PCL) 
to generate thermoresponsive copolymers with improved rigid-
ity that degrade in vivo, allowing their ultimate clearance from 
the body [28–30]. PEG-containing copolymers that have attracted 
significant interest include PLGA–PEG–PLGA, PEG–PLA–PEG, 
PCL–PEG–PCL and poly(oligo[ethylene glycol] methacrylate), 
to name a few [1].
Polyphosphazenes
Polyphosphazenes are a thermoresponsive family of hybrid 
organic–inorganic polymers. These polymers contain an inor-
ganic backbone consisting of alternating nitrogen and phospho-
rous atoms connected by alternating single and double bonds [31]. 
Attached to every phosphorous group are two organic groups that 
impart a high degree of versatility for modification and manipu-
lation of properties and functionality, which can be utilized to 
impart thermoresponsive properties [4]. Numerous approaches 
have been explored to develop hydrolytically susceptible copoly-
mers that have highly controllable degradation kinetics, capable 
of breaking down over periods ranging from hours to years [31–34]. 
Polyphosphazenes have demonstrated good compatibility with 
numerous cell lines in culture [35,36] and in vivo [37]. Furthermore, 
the degradation byproducts, namely ammonia, phosphate and 
alcohol, are well tolerated, and the copolymers can be designed to 
possess fast in situ gelation with tunable release kinetics, making 
polyphosphazenes attractive candidates for drug delivery [31,38]. For 
an in-depth review of polyphosphazenes, see [31].
Natural thermoresponsive materials
Elastin-like polypeptides
Elastin-like polypeptides (ELPs) are synthetic elastin-inspired 
polymers with a pentapeptide amino acid repeat structure, Val–
Pro–Gly–Xaa–Gly, where the Xaa guest residue can be any natu-
ral amino acid except proline [39,40]. Below the phase transition 
temperature (T
t
), ELPs exist as a clear homogeneous aqueous 
solution. When heated above their transition temperature, the 
solution becomes turbid through ELP coacervation into droplets 
[41]. The ELP droplet size and distribution can be manipulated 
through concentration and temperature [41], while the transi-
tion temperature can be adjusted by varying the concentra-
tion, molecular weight, salt content and ELP composition (i.e., 
through modifying the Xaa guest residue, using variable amino 
acid sequences or by functionalization with other proteins or 
polymers) [41]. ELPs are interesting candidates for drug delivery, 
as they possess tunable characteristics, are well tolerated in vivo 
and degrade into simple amino acid residues [42]. In addition, 
the molecular weight and composition of ELPs can be precisely 
controlled through genetic engineering approaches to form nar-
rowly dispersed polymers, which allows an increased level of 
control over drug-release performance [43]. Furthermore, ELPs 
can be expressed in high quantities from Escherichia coli and 
can be easily purified as a result of their thermogelling behavior 
[44]. The Chilkoti group has extensively studied ELPs for their 
ability to target tumor tissues [45–48]. In one strategy, the group 
passively targeted tumor tissues by employing drug-conjugated 
ELPs with a T
t
 that was well above physiologic temperature. The 
small, soluble, ELPs took advantage of the enhanced permea-
bility of tumor vasculature to accumulate within tumor tissues 
following systemic delivery [47]. In another approach, ELP–drug 
conjugates were designed to thermally target tumor tissues. The 
peptides were engineered to possess a T
t
 between 37 and 42°C 
and externally applied stimuli induced localized hyperthermia, 
causing the ELP–drug conjugates to aggregate and adhere to the 
vessel walls [48]. Mild hyperthermia was also used to drive the 
localized assembly of micelles that possessed a tumor-targeting 
ligand on the hydrophilic corona, leading to enhanced cellu-
lar uptake [46]. In another strategy, ELPs with a subphysiologic 
T
t
 were injected directly into tumorous tissues to produce a 
sustained-release drug depot directly within the tumor tissues 
for extended treatment [45].
Chitosan
Chitosan is a polysaccharide that is derived from chitin [4]. While 
on its own, chitosan is not thermoresponsive, it becomes thermo-
responsive when it is mixed with glycerophosphate (GP) [4]. At 
elevated temperatures, GP forms strong hydrogen bonds with 
chitosan, which leads to gel formation [4]. However,  chitosan/GP 
 mixtures tend to possess slow gelation rates. Therefore, for appli-
cations requiring more rapid gelation, the derivative chitosan 
chloride can be used to expedite the gelling process [49]. Chitosan 
scaffolds also suffer from relatively rapid release of loaded protein 
and drugs possessing low molecular weight; complete release is 
often achieved within several hours [4,50]. There are also concerns 
about the suitability of chitosan/GP hydrogels for in vivo appli-
cation as they have been shown to induce a relatively significant 
 inflammatory response [51].
Cellulose derivatives
Several cellulose derivatives, such as methylcellulose (MC) and 
hydroxypropylmethylcellulose, display LCST behavior that can 
be exploited for drug delivery and tissue engineering applications 
[52]. MC and hydroxypropylmethylcellulose display LCST val-
ues between 40–50°C and 75–90°C, respectively [53]. However, 
these values can be substantially lowered using both physical 
and chemical methods, such as the addition of NaCl or a reduc-
tion in the hydroxypropyl content [53,54]. At low temperatures, 
the macro molecules exist in a fully hydrated state with little 
 polymer– polymer interaction aside from physical entanglement 
[52]. Upon heating, intermolecular hydrophobic interactions 
between the methoxy groups result in gradual dehydration and gel 
formation [53]. Recently, a physical blend of hyaluronan and MC 
demonstrated rapid thermoreversible in situ gelation, degradability, 
good in vivo tolerance and potential for minimally invasive intra-
thecal drug delivery for spinal cord injuries [55,56]. Formulations 
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of hyaluronan and MC have also demonstrated favorable results 
as injectable cell scaffolds for retinal therapeutics [57].
Xyloglucan
In its native form, the xyloglucan polysaccharide does not form a 
gel [58]. However, Miyazaki et al. developed a thermally reversible 
xyloglucan hydrogel through partial degradation of xyloglucan from 
the seeds of Tamarindus indica [59]. When more than 35% of the 
galactose residues have been removed, xyloglucan exhibits tem-
perature -responsive behavior under dilute aqueous conditions and 
possesses a relatively high storage modulus [23,25]. Xyloglucan gels 
have been examined as drug delivery scaffolds for oral [60], ocular 
[61], rectal [59], percutaneous [62] and intraperitoneal [63] applications.
Polymer architecture
A crucial parameter to consider when designing in situ-forming 
drug delivery scaffolds is the type of polymeric architecture that 
will be most suitable for the intended application. In situ- forming 
hydrogels can form numerous scaffold architectures, such as inter-
penetrating networks (IPNs), micelles, polymersomes, films and 
other variations (FIGURE 2). There are two main types of gels: physi-
cal gels and crosslinked gels. Physical gels are formed through 
the physical entanglement of polymer chains or micelle ordering, 
whereas crosslinked gels are covalently bound [8]. Covalently linked 
thermoresponsive networks undergo a change in their degree of 
swelling in response to temperature, while physically linked gels 
undergo a sol–gel phase transition [8]. Covalently linked networks 
can either be formed in situ or prior to implantation. In situ 
crosslinking minimizes invasiveness of instillation, but requires 
the use of crosslinking chemistry that is safe in vivo.
IPNs consist of two or more polymer networks that are bound 
through physical entanglement such that the networks can only be 
separated through bond breakage. IPNs offer a powerful tool for 
drug delivery as each polymer in the network can introduce specific 
properties, such as temperature sensitivity, and new properties 
can arise from the interaction of the various polymers within the 
network. Furthermore, it is relatively easy to manipulate properties 
by varying the polymer ratio within the IPN and modifying the 
polymers within the network. Liu et al. have designed transparent 
silicone/PNIPAAm IPN materials which show temperature tran-
sitions that are useful for drug loading and that show particular 
promise for the delivery of hydrophobic drugs [Liu L, Sheardown H, 
Manuscript Submitted]. Semi-interpenetrating copolymer networks 
(semi-IPNs) contain at least one crosslinked polymer network, 
either linear or branched [64]. Kim et al. prepared thermoresponsive 
semi-IPNs based on chitosan and poly(acryl amide) in which the 
hybrid synthetic and natural copolymers displayed high swelling 
ratios that were dependent on temperature, pH, ion concentration 
and electric field [64]. Nanoparticle IPNs consisting of poly(acrylic 
acid) (PAA) and poly(acryl amide) display UCST behavior and 
rapidly swell in response to heating above a critical temperature 
[65]. Chen et al. prepared semi-IPN nanogels based on hydroxy-
propylcellulse, which possesses an LCST around 41°C, and PAA, 
which, as mentioned, possesses UCST behavior [66]. By varying 
the chemical composition and the degree of crosslinking, the phase 
transition properties of these hydroxypropylcellulse–PAA nano-
gel semi-IPNs could be shifted from UCST to LCST. IPNs and 
semi-IPNs of thermoresponsive copolymers offer a high degree of 
flexibility and can be tailored to provide variable release profiles 
to suit a broad range of applications.
As discussed in the section entitled poly(ethylene oxide)-based 
thermoresponsive copolymers, amphiphilic block copolymers can 
spontaneously assemble into micelles with a hydrophilic corona 
and a hydrophobic core. Therefore, micelles may be particularly 
useful for cancer therapeutics, as many chemotherapeutics are 
small hydrophobic compounds with a poor therapeutic index [44]. 
Micelle drug carriers can increase drug accumulation in tumor 
tissues, while minimizing off-target effects through the enhanced 
permeability and retention effect, which allows extravasation of 
the small drug carriers through the leaky tumor vasculature, as 
mentioned in the section entitled ‘Elastin-like polypeptides’ [44]. 
Quan et al. designed an elegant thermoresponsive micelle carrier 
for tumor-triggered drug release [67]. Upon encountering the subtle 
physiological changes in tumor physiology (pH 6.8, T > 37°C), 
PEGylated arginine–glycine–aspartic acid (RGD) peptides 
were deprotected, allowing internalization by RGD receptor 
over expressing tumor cells and destabilization of drug-loaded 
micelles for localized treatment. Wei et al. synthesized a series of 
NIPAAm-containing thermoresponsive shell crosslinked micelles 
[68]. They found that the crosslinked shell slowed drug release at 
temperatures below the LCST (25°C), but the rate accelerated 
dramatically above the LCST (37°C) as pNIPAAm gelation led 
to a  deformation of the micelle structure.
Polymersomes, also known as polymer vesicles, are similar to 
micelles in that they are self-assembling amphiphilic block copoly-
mers; however, they arrange to form a hydrophobic ring sand-
wiched between a hydrophilic core and corona [8]. The polymer-
some structure allows interior encapsulation of both hydrophilic 
and hydrophobic drugs, while the hydrophilic shell protects the 
entrapped drug from undesirable interactions and can help the 
drug delivery system to evade the immune system. The hydro-
philic corona can act as a rate-controlling membrane to modulate 
the release of drug from the hydrophobic ring, which in turn can 
serve to impede release from the hydrophilic core [69]. Li et al. 
synthesized thermoresponsive, self-assembling polymersomes 
consisting of diblock copolymers of poly(N-[3-aminopropyl]
methacrylamide hydrochloride) and PNIPAAm [70]. In aqueous 
conditions, the amphiphilic block copolymers existed as unimers 
at room temperature and transitioned to form vesicles when 
heated above their LCST, which could be adjusted between 30 
and 40°C by varying the composition. The vesicle shells were then 
crosslinked by polyelectrolyte complexation. Qin et al. prepared 
thermoresponsive, doxorubicin-containing PEG–PNIPAAm-
based polymersomes that self-associated upon heating above their 
LCST and could be destabilized, or ruptured, upon local cooling 
with either ice or penetrating cryoprobes [71]. These experiments 
demonstrate how temperature sensitivity can be utilized to create 
localized drug release following minimally invasive delivery. For 
an in-depth review of  stimuli-responsive polymersomes in targeted 
drug  delivery, see [72].
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Thermoresponsive films can also be used as coatings on medi-
cal implants to create a stimuli-responsive material capable of 
modulating the microenvironment surrounding the implant. For 
example, a rate-controlling thermoresponsive film may increase its 
release rate in response to slightly elevated increases in temperature 
due to localized inflammation.
Using thermoresponsive materials, there are numerous design 
architectures that can be generated, and researchers must decide 
which type is suitable for their intended application. For an 
 in-depth review on temperature-responsive polymer architecture, 
see [8] and [69].
Expert commentary
When designing drug delivery vehicles, an important design 
question to consider is whether to use natural or synthetic mate-
rials. Both choices possess inherent advantages and disadvan-
tages. While natural materials offer great potential for inherent 
bio compatibility, synthetic materials offer greater flexibility for 
manipulation and tuning of system performance. With natural 
materials, we are limited in our ability to modulate the material’s 
properties, unless we resort to the use of synthetic modification 
techniques. Furthermore, natural materials often possess indefinite 
composition, poor mechanical strength, variable and uncontrolla-
ble degradation kinetics, microbial contamination and compatibil-
ity issues [31]. Conversely, synthetic polymers allow a high degree 
of control over important design constraints, such as mechanical 
properties, degradation rates, pore size, morphology, scaffold shape 
and size, drug-release kinetics and biomimetic behavior [31]. It is 
the opinion of the authors that, moving forward, synthetic poly-
mers inspired by, and potentially augmented by, natural materials 
will provide valuable tools for the design of novel drug-releasing 
scaffolds. Patenaude et al. synthesized novel hybrids of natural and 
synthetic materials based on PNIPAAm and various carbohydrate 
polymers [73]. These studies demonstrated a high degree of control 
over copolymer properties, such as swelling, degradation, phase 
transition, and mechanical properties, effectively combining the 
desired performance features of both natural (degradation and 
biological interactions) and synthetic (compositional diversity and 
thermal sensitivity) materials. TABLE 2 lists some of the advantages 
and disadvantages of natural and synthetic materials for medical 
application.
The current state of temperature-sensitive drug delivery 
co polymers offers minimally invasive implantation of sustained-
release scaffolds to hard-to-access regions within the body through 
simple injection and in situ gelation. Furthermore, through uti-
lization of the subtle temperature increase in tumor tissues, it is 
possible to tailor scaffolds to undergo a sol–gel phase transition 
upon encountering a tumor, thus targeting the subtle physiological 
differences and providing localized dosing. Several strategies, such 
as localized ultrasound application, can induce subtle temperature 
increases that lead to directed accumulation of drug carriers that 
possess gelling temperatures slightly above physiologic tempera-
ture, and penetrating cryoprobes can induce localized cooling to 
destabilize drug carriers. Thus, temperature-sensitive drug delivery 
scaffolds are particularly interesting for cancer therapeutics and 
applications where minimally invasive procedures are crucial, such 
as spinal cord [56] and ocular cell and drug delivery purposes [74]. 
However, temperature-responsive copolymers alone are limited in 
their ability to respond to the abundance of subtle differences that 
characterize specific diseased states. Therefore, when used in con-
junction with additional stimuli-responsive materials, the degree 
of control vastly increases, as dual or multiresponsive materials 
can respond with controllable properties to a number of different 
physiological states.
There are two classifications of stimuli-responsive materials 
that can be used to further functionalize temperature-sensitive 
drug delivery scaffolds: materials that respond to internal stimuli 
present in the in vivo environment, and those that respond to 
externally applied stimuli. Light, magnetism, electrical impulses 
and ultrasound are examples of stimuli that can be externally 
applied to manipulate and regulate the performance of implanted 
scaffolds [75]. Ionic strength, pH, enzymes, antigen–antibody 
 interactions, or the presence of specific chemicals are examples 
of internal stimuli that may drive a behavioral change in an 
Table 2. A list of some of the advantages and disadvantages of using naturally derived and synthetic 
materials in medical applications.
Natural materials Synthetic materials
Advantages Inherent biocompatibility
Safe degradation byproducts
Defined cellular and biological interactions
Natural materials are well suited to ‘nature-mimicking’ 
strategies popular in tissue engineering
Can provide a close approximation of native 
extracellular matrix
Synthetic flexibility and compositional diversity
High degree of control over performance parameters, such as 
molecular weight, mechanical properties, elasticity, stimulus-
response, release profile, degradation kinetics and so on
Easily sterilized
Disadvantages Limited number of natural polymers, therefore 
restricted range of attainable properties
Batch-to-batch variability with indefinite composition
Poor mechanical strength
Can illicit an immune response
Biological contamination
Sterilization can be difficult
Carbon–carbon backbone is not inherently degradable, thus 
degradation strategies are often required, which can induce 
inflammation and cytotoxicity
Often engineered in attempt to ‘mimic’ biological tissues, however, 
unable to recreate ‘true’ extracellular microenvironment
Can illicit a foreign body reaction
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implanted scaffold [76]. Internal stimuli have the ability to act as 
a negative-feedback loop and generate a direct response to the 
surrounding physiologic environment. By contrast, externally 
regulated stimuli-responsive materials require active manipula-
tion from an outside source to generate a change in performance 
properties. While internal stimuli may provide better on-demand 
release profiles and tighter regulation of the pathological state, 
materials requiring external stimuli afford physicians a greater 
degree of control over the dosing parameters, which is partic-
ularly important should complications arise. For an in-depth 
review of recent advances and future perspectives of various 
 stimuli-responsive materials, see [75–77].
Thermoresponsive & externally regulated stimuli 
responsive systems
There are many examples of dual thermo- and externally regu-
lated copolymer systems. Temperature- and light-responsive 
materials were prepared from photochromic derivatives of ELP, 
in which one azobenzene moiety was incorporated for every 
30 amino acid residues [78]. Irradiation at 350 nm induced a 
trans–cis isomerization, which increased the hydrophilicity of 
the material and shifted the phase transition temperature from 
32–42°C. Irradiation with a longer wavelength was found to 
reform 50% of the hydrophobic trans isomer, thus driving 
phase separation. Such a system could be used to generate a 
pulsed-release profile for on-demand release. Zrinyi synthesized 
thermo- and magneto-responsive polymer beads by incorpo-
rating magnetic nanoparticles into crosslinked PNIPAAm and 
poly(vinyl alcohol) hydrogels [79]. In uniform magnetic fields, 
the gel beads arranged into linear, chainlike structures. However, 
in nonuniform fields, the gels formed random aggregates. This 
study demonstrates the ability to externally mani pulate scaf-
fold architecture with externally applied magnetism. This con-
cept could be extended to manipulate gates in a channeled 
drug-release scaffold, thus creating on–off capabilities and a 
pulsatile release profile. Kim et al. prepared thermo- and electro-
responsive IPNs from poly(vinyl alcohol) and PNIPAAm [80]. 
Electro-responsive materials tend to swell, shrink or bend in 
response to an applied electric field and are typically comprised 
of polyelectrolyte hydrogels [81]. As the charged ions are guided 
towards the cathode or anode side of the gel, deformation of the 
polyelectrolyte occurs [81]. Ultrasound is a noninvasive stimulus 
that has been shown to influence drug-release properties within 
the body by accelerating degradation in degradable polymers 
and enhancing the permeation of drug in both eroding and non-
eroding scaffolds [81]. Ultrasound can be used to disrupt micelle 
architecture through acoustic destabilization, thus inducing 
release of the therapeutic payload [81,82]. It can also be used to 
induce localized heating and aggregation of thermoresponsive 
drug scaffolds.
Thermoresponsive & internally regulated  
stimuli-responsive systems
Thermoresponsive copolymers have also been combined 
with a number of materials that respond to internal stimuli. 
pH-responsive systems have received considerable attention owing 
to the significant variation of pH within the different locations of 
the body. In the GI tract, the stomach has an acidic pH between 
1 and 3, whereas the pH in the duodenum ranges from 4.8 to 
8.2 [3]. Cancer tissue has a slight acidic extracellur pH between 
6.5–7.2, whereas normal tissues and blood possess a pH around 
7.4 [3]. Furthermore, intracellular variations in pH can be 
exploited for targeted delivery; the early endosome, late endo-
some and lysosome have pH values of 6.0–6.5, 5.0–6.0 and 
4.5–5.0, respectively [3]. pH-responsive polymers contain weak 
acids or weak bases, such as carboxylic acids or amines, and thus 
undergo changes in their ionization state in response to changes in 
pH [3]. Changes in the ionization state can lead to conformational 
changes, such as micelle formation or disruption, or changes in 
the swelling properties of crosslinked gels [2]. Ionizable polymers 
possessing a dissociation constant (pKa) that closely matches 
the pH of the target tissues can utilize the conformational pH-
induced changes to release drug at a specific location. There are 
many examples of thermo- and pH-responsive polymers systems. 
Brazel and Peppas described the synthesis and characterization of 
temperature- and pH-responsive hydrogels of methacrylic acid 
and PNIPAAm [83] and Leung et al. synthesized microgels with 
a thermoresponsive core and pH-sensitive shell [84]. These stud-
ies demonstrate the potential to target tissues based on their pH 
and are particularly interesting for cancer therapeutics as tumor 
tissues possess an elevated temperature and a slightly acidic pH. 
In addition to pH, antigen-responsive materials are capable of 
undergoing significant property changes in response to highly 
specific stimuli recognition. Lu et al. reported the synthesis of 
thermo- and antigen-responsive hydrogels from the combination 
of a polymerizable antibody Fab′ fragment, which was prepared 
from an antifluorescein mono clonal antibody, with NIPAAm 
and N,N ′-methylenebis(acrylamide) [85]. The resulting hydro-
gels underwent significant reversible volume changes in response 
to both temperature and the presence of antigens. Glucose-
responsive copolymers are of considerable interest for their abil-
ity to detect glucose levels and deliver insulin as required [81]. 
Glucose-responsive polymers typically function either through 
enzymatic oxidation of glucose via glucose oxidase, through 
glucose binding with concanavalin A or through reversible 
bond formation with boronic acids [81]. Thermo- and glucose- 
responsive copolymers have been synthesized from comb-type 
graft co polymers of PNIPAAm-co-3-acrylamidophenylboronic 
acid) [86], and through covalently linking glucose oxidase to 
copolymers of NIPAAm, methacrylic acid and octadecylacrylate 
and subsequently immobilizing to the surface of liposomes [87]. 
Such scaffolds could introduce sustained-release scaffolds that 
detect blood sugar levels and modify their insulin-release profile 
accordingly, thus decreasing the frequency of insulin injections 
and allowing tighter regulation of blood sugar levels.
While temperature-sensitive materials have tremendous poten-
tial for targeted drug delivery, combination with dual and multi-
responsive polymer systems has the potential to unleash and help 
realize the true capabilities of these drug release scaffolds to create 
personalized and on-demand release profiles.
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Five-year view
It is becoming increasingly possible to synthesize drug delivery 
scaffolds consisting of multiple stimuli-responsive materials that 
can locally release a multitude of different pharma ceuticals on 
demand in response to internal physiological feedback and 
externally applied signals. Such control will allow drastically 
improved manipulation of the microenvironment of diseased 
tissues and improve the regulation of systemic conditions. As 
our understanding of the physiological signature of different 
diseases increases, so too will our ability to design drug-releasing 
scaffolds that produce a predictable and controllable response 
to disease-specific stimuli. As mentioned, temperature-sensitive 
systems alone are limited in their ability to respond to the sur-
plus of stimuli that characterize a specific disease. Therefore, 
the true power of thermoresponsive drug-releasing scaffolds 
will be realized when they are combined with additional stim-
uli-responsive materials. Such dual and multi responsive drug 
delivery scaffolds are beginning to emerge in the literature as 
temperature- sensitive polymers are combined with materials 
capable of external regulation through stimuli such as light [88], 
magnetism [89] and ultrasound [90]. However, a new generation 
of stimuli-responsive materials is emerging, wherein the iden-
tification of differ entiating environmental factors characteriz-
ing various conditions is allowing the use of intricate internal 
stimuli to manipulate polymer properties to create a predefined 
response to disease-specific environmental cues, thus provid-
ing on-demand, personalized treatment. A thermoresponsive, 
 glucose-sensitive copolymer that forms an insulin-loaded 
scaffold upon injection into the body with release that is dic-
tated by blood sugar levels would mimic the body’s natural 
regulation mechanism and help provide tighter regulation of 
blood sugar levels for diabetic patients. The generation of such 
nature-mimicking scaffolds will be driven by the improved 
understanding of biochemical pathways implicated in various 
diseases. Better characterization of the chemical signature of 
various diseases expands the engineer’s toolbox for designing 
novel scaffolds capable of providing personalized treatment. 
Thus, future generations of drug delivery scaffolds will require 
a multidisciplinary approach to harness the true potential of 
stimuli-responsive materials.
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Key issues
s  Temperature-sensitive drug delivery scaffolds allow minimally invasive instillation of sustained-release scaffolds for localized or systemic 
treatment.
s  Encapsulation within a scaffold protects pharmaceuticals from undesirable interactions and enzymatic or environmental degradation. 
Furthermore, the scaffolds can be designed to generate sustained drug release, maintaining concentrations within the therapeutic 
window and avoiding complications frequently associated with simple injections.
s  There are numerous temperature-responsive polymers and architectures to choose from when designing drug delivery scaffolds. 
Several design choices include whether to use degradable versus nondegradable scaffolds, natural versus synthetic materials and which 
architecture (simple hydrogel aggregates, interpenetrating networks, micelles, polymersomes, films and so on) is best suited for the 
intended application.
s  Synthetic materials offer a high degree of flexibility, allowing manipulation of mechanical properties, degradation rates, pore size, 
morphology, scaffold shape and size, and drug release kinetics, whereas natural materials often possess uncontrollable degradation 
kinetics, microbial contamination and compatibility issues. Ultimately, combinations of natural and synthetic materials may overcome the 
limitations while capitalizing on the strengths of both types of materials.
s  Temperature-sensitive drug delivery scaffolds are particularly well suited for delivery of chemotherapeutics. Scaffolds designed with a 
gelling temperature slightly above physiologic value utilize the subtle temperature increase in tumor tissues to drive scaffold formation 
and accumulation in tumor vasculature and the surrounding tissues.
s  In situ gelling temperature-sensitive drug delivery scaffolds have tremendous potential for hard-to-access complications requiring 
minimally invasive techniques, such as ocular and spinal cord therapeutics.
s  Combining temperature-sensitive polymers with additional stimuli responsive materials imparts the ability to respond to numerous 
external and internal stimuli, such as light, magnetism, electrical impulses, ultrasound (external) and ionic strength, pH, enzymes, 
antigen–antibody interactions or specific chemicals (internal). Such dual and multiresponsive drug delivery scaffolds offer a significant 
level of control over dosing characteristics and treatment personalization.
s  The continued identification of differentiating environmental factors characterizing specific diseases will allow the development of 
increasingly intricate scaffolds capable of responding to disease-specific cues to provide negative feedback that attempts to mimic the 
body’s natural regulation mechanisms.
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Abstract: Genetically modified cells encapsulated in alginate-
poly-L-lysine-alginate (APA) are being developed to deliver
therapeutic products to treat a variety of diseases. The char-
acterization of the encapsulated cells thus becomes para-
mount. This study reports a novel method to assess the
viability, granularity and proliferation of encapsulated cells
based on flow cytometry. The in vitro viability of encapsu-
lated G8 murine myoblasts secreting canine FVIII (cFVIII)
measured by flow cytometry was comparable to the tradi-
tional trypan blue exclusion method and both correlated with
cFVIII secretion levels. In contrast, after implantation into
mice, only viability measured by flow cytometry correlated
with cFVIII secretion. Further, flow cytometry analysis of
encapsulated cells maintained in vitro and in vivo revealed a
greater fraction of granular cells compared to free cells, sug-
gesting that encapsulation influences the morphology (cyto-
plasmic composition) of cells within APA microcapsules.
Interestingly, the proliferation study showed that encapsu-
lated cells proliferate faster, on average, and were more het-
erogeneous in vivo compared to in vitro culture conditions,
suggesting that encapsulated cell proliferation is complex
and environment-dependent. In conclusion, we show that
flow cytometry analysis allows for a more consistent and
comprehensive examination of encapsulated cells to aid in
the development of cell therapy protocols. VC 2010 Wiley Periodi-
cals, Inc. J Biomed Mater Res Part B: Appl Biomater 94B: 296–304,
2010.
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INTRODUCTION
Implantation of microencapsulated cells is a strategy for the
continuous delivery of therapeutic protein products, with
the potential to treat a wide variety of diseases.1 Genetically
modified cells are immune-isolated within polymeric and
biocompatible devices with pore sizes that prevent immune
cell-mediated destruction of the enclosed cells after their
implantation in vivo.2 In addition, previous studies have
shown improved viability of some types of encapsulated
cells compared to free cells, attributing this to the increased
local concentration of growth factors secreted by encapsu-
lated cells.2–4 Alginate-poly-L-lysine-alginate (APA) microcap-
sules have a polyanionic core formed by calcium alginate
with a polycationic membrane composed of poly-L-lysine to
control permeability and increase strength. The poly-L-lysine
is further coated with alginate to improve biocompatibility.5
Alginate-based microcapsules have been used to encapsulate
a wide variety of living cells engineered to deliver a variety
of proteins, including coagulation factor VIII, for the treat-
ment of the bleeding disorder, hemophilia A.5,6
Viability of the encapsulated cells is a key parameter for
interpreting the secretory ability of the encapsulated cells.
Therefore, it is critical in cell and gene therapy experiments
to use highly reliable and accurate determinations of cell vi-
ability. Previous studies employing encapsulated G8 murine
myoblasts of fetal origin for FVIII delivery, primarily used
the dye-exclusion method to assess cell viability,7–11 based
on selectively staining dead cells with trypan blue. However,
the determination of live and dead cells is based on a small
sampling of the total number of cells, and can be quite sub-
jective, varying significantly depending on what is perceived
by the examiner to be a healthy cell.12 Moreover, stained
smaller cell fragments may distort an accurate determina-
tion, and is thus subject to inconsistency.12 All things con-
sidered, this method of measuring cell viability is highly ex-
aminer dependent. Similar limitations exist with other dye-
exclusion viability tests such as eosin Y, alamar blue, nigro-
sine, ethidium bromide, alcian blue, among many others.
These viability methods also rely on cells having compro-
mised membranes, and face many of the same problems as
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trypan blue exclusion, namely reliability, subjectivity and
are limited to assessing a small sample of cells.13,14
In this study, we compared a flow cytometry-based
method of viability analysis with trypan blue exclusion. Cur-
rent assays for viability, such as trypan blue, can only report
the percentage of living cells, but not the health of these liv-
ing cells. Flow cytometry has four significant advantages
over other viability assays: (1) It is able to analyze thou-
sands of particles per second, ensuring a representative
sampling of experimental cell populations; (2) It offers a
multi-parameter analysis of cell viability and health; (3) It is
able to distinguish between implanted cells and host cells in
a heterogeneous population of cells; and (4) The measures
are objective and easily quantifiable.
Flow cytometry can objectively identify living cells based
on fluorescent intensity of the fluorochrome-labeled cell, cell
size as determined by the degree of forward scattering (FS),
and also the proportion of the living cells that are granular
(and morphologically distinct, as determined by the degree
of side scattering) (SS) of the cells.15 The degree of side scat-
ter on a flow cytometry plot is related to the cytoplasmic
complexity of the cell (i.e., shape of the nucleus, the amount
and type of cytoplasmic granules or the membrane rough-
ness). In essence, side scatter is a measure of the relative
granularity of the cell and thus, can be used as an indication
of its health.16–19 An extremely attractive benefit of flow
cytometry analysis is the ability to use selected cell surface
markers to discriminate host (recipient) cells that may con-
taminate the encapsulated cells upon their retrieval, thus
increasing the accuracy of this technique. Moreover, it allows
for an additional level of analysis for cellular morphology
(granularity), which other methods of viability cannot assess.
Along with cell viability, cell proliferation is another indica-
tor of normal cell behavior that can be studied using flow
cytometry. Proliferation of certain cell lines, such as myoblasts,
is limitedwithin the microcapsule.20,21 Availability of the cell di-
vision tracking dye, carboxyfluorescein diacetate succinimidyl
ester (CFSE), makes it possible to examine the number of cell
divisions during proliferation.22 CFSE is a simple and sensitive
tool for analyzing multiple parameters of cells. This dye, which
is retainedwithin cells, allows for one to examine specific popu-
lations of proliferating cells and the dye can survive in cells for
7–10 successive cell generations. Once the CFSE molecule dif-
fuses into cells, its acetate groups are cleaved by intracellular
esterases, converting it into a fluorescent membrane-imperme-
able dye. Since CFSE is retained by the cell in the cytoplasm,
each round of cell division decreases the relative fluorescence
intensity of the dye by half.22 Encapsulation may affect the pro-
liferation behavior of cells. Studying the changes in proliferation
between free cells, encapsulated cells in vitro and encapsulated
cells in vivo may provide additional insights into how to opti-
mize encapsulated cell secretion.
A hurdle for the use flow cytometry to analyze APA
encapsulated cells is the complete removal of the capsule
material before analyzing cells. Here, we present a modified
technique to de-encapsulate cells suitable for flow cytometry.
Our data provide new insight into the behavior of encapsu-
lated mouse fetal myoblasts genetically modified to secrete
canine FVIII (cFVIII). This novel analysis may be extended to
other cells being used in cell and gene therapy strategies.
MATERIALS AND METHODS
Cell culture
G8 is a fetal skeletal myoblast cell line derived Swiss Web-
ster mice (ATCC, Rockville, MD; CRL-1456). G8 cells were
transduced with pLenti-EF1-a-BDD-cFVIII as previously
described.23 G8 cells were cultured on 0.01% collagen
coated plates in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 1.59 g/L sodium bicarbonate
(NaHCO3), 20% fetal bovine serum (FBS), 1% streptomycin
(100 lg/mL) and penicillin (100 lg/mL) at 37C in 5%
CO2. Cells were subcultured at 80% confluency.
Microencapsulation
Cell encapsulation technique has been described.6 Briefly,
cells were harvested, counted, and resuspended in 1.7% low
viscosity (LV) sodium alginate (Improved Kelmar, ISP Algi-
nates, San Diego, CA) to a concentration of 5 106 cells/
mL. The cell/alginate suspension was extruded at 0.9 mL/
min through a 0.35 mm needle in an electrostatic encapsula-
tor (Nisco Engineering, Zurich, Switzerland) at 7 kV. Extru-
sion of the cell/alginate suspension into a gelling solution of
1.1% CaCl2 formed beads with a diameter of 360 (626) lm.
Alginate was then cross-linked with 0.05% poly-L-lysine for 6
min, and further coated with 0.03% alginate for 2 min. The
unpolymerized core of alginate was then dissolved with so-
dium citrate for 6 min. Microcapsules were cultured in vitro
in DMEM under cell culture conditions described earlier.
Microcapsules to be studied in vivo were incubated overnight
in serum-free media before being implanted into mice to
minimize serum-induced antigenic response.
De-encapsulation of APA capsules
A protocol from de Groot et al. was optimized to completely
remove the alginate-poly-L-lysine-alginate layer and release
the enclosed cells for viability staining.24 A sample of 150
lL of capsules was added to 10 mL of 0.25% trypsin/EDTA
(Gibco, Burlington, Canada) in a sterile centrifuge tube. The
capsules were placed in a gently shaking water bath at 37C
for 30 min. After the incubation, the capsules were broken
and any remaining cell clumps dislodged by gently pipetting
the suspension 2–3 times. Cells were pelleted by centrifuga-
tion and re-suspended in 0.5% BSA in PBS (Ca2þ and Mg2þ
free) for cell staining. Free cells subjected to the same pro-
cedure were used as control.
Trypan blue exclusion
A sample of microcapsules (10 lL) were placed on micro-
scope slide and were crushed by a glass cover slip to
release the cells, which were subsequently stained with try-
pan blue (Invitrogen, Burlington, Canada). Live (transparent)
and dead (blue) cells were assessed in a given field of view
and quantified by light microscopy.
Flow cytometry
Flow cytometry analysis was carried out using Cytomics
Flow Cytometer 500 (Beckman-Coulter) with the CXP
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software provided. Free or de-encapsulated cells were
stained with 1 lL of 50 nM Calcein (Invitrogen, Burlington,
Canada), at room temperature in the dark for 20 min, and
filtered (40 lm filter), before they were analyzed for viabil-
ity by flow cytometry. For proliferation studies cells were
stained with 2.5 nM carboxyfluorescein succinimidyl ester
(CFSE) division tracking dye for 10 min at room tempera-
ture, and the reaction stopped with an excess of wash buffer
(5% FBS in Ca2þ/Mg2þ free PBS). The newly labeled cells
were re-suspended in media or mixed with alginate for
encapsulation. Flow cytometry was used to analyze the
CFSE-labeled cells.
Flow cytometry measures of cell ‘‘health’’ were cali-
brated against free G8 cells that had been cultured in vitro
and harvested without being subjected to the mock de-
encapsulation procedure. The normal cell size distribution
and Calcein-labeling intensity was defined in these healthy
cells, and cell viability was calculated using these two pa-
rameters. Gated regions on the forward scatter/side scatter
(FS/SS) plot were established based on two parameters: cell
size (forward scatter) and granularity (side scatter). Box A
included cells greater than 17 lm, box B included cells
between 5–17 lm and box F included a fraction of the cells
in box A that were considered granular (Figure 1). The cell
size cut-offs were determined by the location of the largest
population (>90%) of freshly cultured free cells defined in
the FS/SS cell density plot, using flow count beads of
known size. The granularity (box F) cut-off defined the top
5th percentile of all side-scattered cells that were located in
box A. Cell viability was calculated by determining the per-
centage of all cells in box A that were brightly-labeled (in-
dicative of living cells) with Calcein, as a fraction of total
cells (box A and box B) analyzed. The vast majority of
freshly cultured free cells were consistently located within
one bright population peak. Brightly-labeled cells were
defined as the percentage of all cells located within the
bright population peak of the Calcein-staining histogram.
This distinct bright population peak was selected manually,
providing values consistently with a standard deviation of
less than 5% for repeat measurements (Figure 1).
The cut-offs for all boxes were uniquely defined for G8
myoblasts and were held constant in all conditions tested
(free cells, encapsulated cells and implanted encapsulated
cells). It is important to note that without defined cut-offs
for cell size and Calcein-labeling intensity, small brightly-
labeled cell fragments would be included in the count for
FIGURE 1. Flow cytometry-based viability for free G8 cells exposed to the trypsin/EDTA de-encapsulation procedure. (i) The FS/SS plot of Calcein-
labeled G8 cells. Box A (>17 lm) represents live cells (green cells in green box), box B (5–17 lm) represents dead cells (red) and abnormally small
cells and fragments (grey), and box F represents the proportion of cells in box A that were considered granular. The dimensions of all the boxes
were held constant when calculating cell viability in all experiments. (ii) The fraction of cells in box A that are brightly labeled with Calcein (live
cells in C bracket). The total viability [V ¼ (98.8%/100)  93.7%] and granularity [G ¼ (98.8%/100)  5.0%] of cells was then calculated. The dimly la-
beled dead cells appear in the D bracket. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
FIGURE 2. Representative FS/SS plots of nonimplanted encapsulated G8-cFVIII cells cultured in vitro. Samples of G8 cells were de-encapsulated
on day 0, 1, and 7, and their viability assessed by flow cytometry. Viability significantly (p < 0.05) decreases over the week, as indicated by the
increased movement of live cells (green) from box A into box B. Granularity also increases (p < 0.05) over the week, as indicated by the move-
ment of cells into box F. (Data presented from 30,000 events collected). [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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viability. Approximately 30,000 events were counted per
sample of cells. By flow cytometry, brightly labeled (with
Calcein) cells larger than 17 lm were considered alive,
while the remaining cells were considered dead (Figure 1).
Animal experimentation
C57BL/6 mice were purchased from Charles, River (Mon-
treal, Canada), while FVIII-deficient mice are bred at
McMaster University’s Central Animal Facilities (CAF). A
total of 20  106 cells each (4 mL) of microcapsules per
mouse were injected intra-peritoneally (IP) using a G18
catheter under anaesthesia with isofluorane (Bimeda-MTC,
Animal Health, Richmond Hill, Canada) in a small anaes-
thetic machine (Med-Vet Aesthetic System, Toronto, Canada).
Blood samples were taken weekly by retro-orbital bleeding
with sodium citrate as anticoagulant (1:9 ratio). Mouse
plasma was obtained by centrifugation (13,000g at 4C for
10 min), and stored at 70C until used. All of the animal
procedures in animals were performed in accordance with
McMaster University’s Animal Ethics Guidelines.
ELISA assay for cFVIII measurement
Canine FVIII secretion was quantified using a cFVIII-specific
ELISA kit (Affinity Biologicals, Hamilton, Canada), using nor-
mal pooled canine plasma (Central Animal Facilities, McMas-
ter University) to generate the standard curves.
RESULTS
Viability of free G8 myoblasts
After establishing the appropriate flow cytometry settings
(materials and methods) for running G8 cells and running a
sample of 30,000 cells, we calculated that freshly cultured
free G8 cells have a viability of 92.6% (Figure 1). The cells
located in box F indicated that 4.9% of living free cells in
box A were granular, indicating a morphologically distinct
subpopulation of live cells. It was imperative that the cells
were released from the capsule material before flow analy-
sis could be performed. However, cell de-encapsulation tech-
niques may negatively affect cell viability. Although the de-
encapsulation procedure used in this study has been tested
before,24 its effects on myoblasts were investigated. As a
control, a sample of free G8 cells were subjected to the
same de-encapsulation procedure that was used for encap-
sulated cells, while a negative control sample was not sub-
jected to trypsin/EDTA. Cell viability was then assessed by
flow cytometry. The viability of free cells exposed to the
trypsin/EDTA de-encapsulation procedure (92.6%, Figure 1)
or free cells exposed to normal cell culture conditions in
media without trypsin/EDTA (90.1%, data not shown) was
not significantly different (p > 0.05) from that of the viabil-
ity of encapsulated cells on day 0 (90.9%, Figure 2). This
indicated that the de-encapsulation procedure did not
adversely influence the viability of cells as measured by this
method. In addition, we tested and confirmed this result in
blood outgrowth endothelial cells (BOECs) (data not shown)
as well.
FIGURE 3. Comparison of viability calculated using flow cytometry (black bar) and trypan blue (white bar) for free G8-cFVIII cells cultured in
vitro. Viability determined using flow cytometry is significantly (p < 0.05) different from viability determined by trypan blue. (Error bars indicate
standard deviation; n ¼ 3).
FIGURE 4. Murine myoblasts enclosed within APA microcapsules
(approximately 300–400 lm in diameter).
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When the viability of free G8 myoblasts as analyzed by
flow cytometry and trypan blue exclusion was compared,
flow cytometry-based viability produced a more consistent
(smaller standard deviations) result (92.6% 6 1.2%) than
trypan blue exclusion (97.3% 6 2.7%). Importantly, the
results obtained by the two methods were significantly dif-
ferent (p < 0.05, Figure 3), with the viability values
obtained from trypan blue exclusion being higher.
Viability of nonimplanted encapsulated G8-cFVIII cells
Once the flow cytometry parameters for assessing cell viabil-
ity were identified, myoblasts were encapsulated and cul-
tured in vitro (Figure 4). Samples of G8-cFVIII cells were
then de-encapsulated on day 0, 1, and 7, labeled with Calcein
and the cell viability calculated by flow cytometry. Cell viabil-
ity significantly decreased from 90.9% on day 0 to 56.1% on
day 7, while at the same time cell granularity (box F)
increased from 7.1 to 12.6% from day 0 to day 7 (Figure 2).
Since G8 myoblasts were engineered to secrete FVIII
continuously, cFVIII secretion rate (mU/mL of capsules/day)
by encapsulated cells was determined and used as another
indication of cell viability. Canine FVIII secretion decreased
from 306.9 mU/mL capsules/day to 78.3 mU/mL capsules/
day by day 7 (p < 0.05), agreeing with both trypan blue
exclusion and flow cytometry-based viability techniques
(Figure 5). Although the average viability calculated using
flow cytometry was consistently higher than viabilities cal-
culated using trypan blue exclusion, the difference was not
statistically significant (p < 0.05). In addition, we observed
similar trends in the data comparing flow cytometry-based
and trypan blue-based viabilities using BOECs (data not
shown), thereby confirming our results.
Viability of implanted encapsulated G8-cFVIII cells
It is also important to monitor the viability and morphology
of encapsulated cells following their implantation in vivo.
However, such determination can be challenged by potential
contamination of the sample with host cells surrounding the
microcapsules. Thus, the application of flow cytometry in
such conditions was investigated and compared to trypan
blue exclusion. A group of C57BL/6 mice were implanted
with encapsulated G8-cFVIII myoblasts. After 6 weeks, mice
were sacrificed, microcapsules retrieved and cultured in
vitro. At various time points, samples of cultured microcap-
sules were de-encapsulated, labeled with Calcein and ana-
lyzed by flow cytometry. Initial cell viability on explantation
FIGURE 5. Relationship between cFVIII secretion rate of non-implanted encapsulated G8-cFVIII cells and viability. Secretion rate (n), trypan blue-
based viability (~) and flow-based viability (l) all significantly (p < 0.05) decreased from day 0 to day 7. Trypan blue-based viability and flow
cytometry-based viability were not significantly (p < 0.05) different. Solid and dashed lines represent the linear regression fit of data presented.
(Error bars indicate standard deviation; n ¼ 3). [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
FIGURE 6. Representative FS/SS plots of encapsulated G8-cFVIII cells retrieved 6 weeks postimplantation in mice. The recovered G8-cFVIII cells
were subsequently cultured in vitro, and samples de-encapsulated on day 0, 1, and 7 to assess their viability using flow cytometry. Viability sig-
nificantly increases over the week, as indicated by the movement of cells into box B. Granularity slightly increases over the week, as indicated
by the movement of cells into box F. (Data presented from >25,000 events collected). [Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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(day 0) was 34.9% and this significantly increased during 7
days of culture to 69.2%, while granularity (box F) of live
cells slightly increased from 7.6 to 9.2% from day 0 to day
7 (Figure 6). The increase in viability of encapsulated myo-
blasts cultured in vitro after retrieval was consistent in all
data collected (n ¼ 3), but the granularity changes were not
statistically significant (p > 0.05). In contrast, trypan blue-
based viability values were significantly different from those
yielded by flow (p < 0.05).
When the viability measured by trypan blue and flow
cytometry were compared to cFVIII secretion, it was inter-
esting to find that the trend displayed in flow cytometry-
based viability values positively correlated with the average
cFVIII secretion rate (Figure 7), while trypan blue-based
viability was negatively correlated with the secretion rate.
Host cells could potentially contaminate the sample of
retrieved microcapsules. In particular, professional antigen
presenting cells (APCs) such as macrophages or dendritic
cells have often been reported to adhere to retrieved micro-
capsules.1,6 Thus, in the interest of accuracy, it was impor-
tant to discriminate between encapsulated and host cells
postretrieval. Therefore, four days after retrieval, de-encap-
sulated cells were stained with anti-CD86 (BD, Franklin
Lakes, NJ), a surface marker specific to APCs. No significant
staining of CD86 was found, suggesting the absence of anti-
gen presenting cells in the sample (Figure 8).
Granularity of implanted and nonimplanted
encapsulated G8-cFVIII cells
In addition to cell viability, flow cytometry can be used to
assess other parameters of cell behavior. In flow cytometry,
side scatter is a measure of the relative granularity of the
cell and thus, can be used as an indication of its health. In
heterogeneous cell samples, granularity can be used as a pa-
rameter to morphologically distinguish a subpopulation of
cells. Granularity of cells was assessed by setting a thresh-
old (box F) at the extreme end of the forward scatter/side
scatter flow cytometry plot (Figure 2) and comparing the
relative percentage of cells that appear above this threshold
at various time points. The granularity of live free cells
(based on cell size and labeling intensity criteria) remained
relatively constant for exponentially growing cells in vitro
(Figure 9). In contrast, both implanted and non-implanted
encapsulated cells had a significantly (p<0.05) higher gran-
ularity (fraction of live cells in box F) than free cells. There
was no significant difference between implanted and non-
implanted encapsulated myoblasts at various time points
examined. However, we observed that the granularity of G8-
cFVIII cells significantly (p<0.05) increased from day 0 (day
of encapsulation) to day 7 upon encapsulation and mainte-
nance in vitro (Figure 9). A similar increase in the granular-
ity of non-implanted encapsulated cells was also observed
in BOECs (data not shown) at equivalent time points.
Proliferation of nonimplanted encapsulated
G8-cFVIII cells
To study the proliferation behavior of encapsulated cells,
G8-cFVIII cells were labeled with CFSE, subsequently encap-
sulated and cultured in vitro for 7 days. A subset of CFSE-
labeled free cells was also kept in vitro as a control. At
FIGURE 7. Relationship between cFVIII secretion rate and viability of encapsulated G8-cFVIII cells cultured in vitro after being retrieved from
mice. Secretion rate (n) did not significantly increase from day 0 to day 7. Flow-based viability (l) significantly (p < 0.05) increased from day 0
to day 7. Trypan blue-based viability (~) did not significantly decrease from day 0 to day 7. Trypan blue-based viability and flow-based viability
were significantly (p < 0.05) different. Solid and dashed lines represent the linear regression fit of data presented. (Error bars indicate standard
deviation; n ¼ 3). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
FIGURE 8. CD86 staining of de-encapsulated cells postimplantation.
The lack of CD86 expression (black) indicates that no CD86 expressing
cells were present on the retrieved capsules. White curve represents
the isotype control.
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various time points cells were analyzed by flow cytometry
for proliferation. Encapsulated cells cultured in vitro prolif-
erated slower (on average) with a doubling time of 1.41
days, while free cells proliferate with a doubling time of
0.59 days (Figure 10). Encapsulated cells also appeared to
have multiple sub-populations growing at slightly different
rates compared to free cells. In contrast, free cells appeared
to divide in synchrony.
The proliferation behavior of encapsulated cells in vivo
was also examined. A group of C57BL/6 mice were
implanted with CFSE-labeled encapsulated G8-cFVIII cells
for 7 days. A sample of the prepared microcapsules was
kept in vitro as a control. On day 7 mice were sacrificed,
and microcapsules were retrieved and cultured in vitro. The
cell proliferation of the implanted microcapsules was com-
pared with the sample kept in vitro. Encapsulated cells pro-
liferated slightly faster (on average) in vivo, with a doubling
time of 1.02 days, while non-implanted encapsulated cells
maintained in vitro proliferate with a doubling time of 1.20
days (Figure 11). In addition, implanted-encapsulated cells
appeared to have a greater range in the rate of cell prolifer-
ation, as indicated by the presence of large distinct subpo-
pulations compared to non-implanted encapsulated cells. On
day 11, some of the sub-populations in the implanted-
encapsulated cells appeared to have become less distinct to
the main population of dividing cells.
DISCUSSION
In any microencapsulation-based cell therapy strategy, the
accurate assessments of the viability and proliferation of the
encapsulated cells are essential for predicting the potential
long-term secretion profiles of the therapeutic products.
This is the first study to use flow cytometry to evaluate the
viability of cells enclosed in alginate-poly-L-lysine-alginate
(APA) microcapsules. We developed a flow cytometry-based
assay to examine the viability, granularity, and proliferation
of cells within the microcapsules, using myoblasts as a
model. Our data indicate that flow cytometry yields more
consistent viability values than trypan blue, and correlate
with cFVIII secretion levels. This could be explained by the
fact that trypan blue dye only stains cells with compromised
cell membranes.25 In contrast, Calcein stains live cells based
on the enzymatic activity of ubiquitously expressed intracel-
lular esterases. Since dead and unhealthy cells have lower
levels of active esterases, they are weakly stained with Cal-
cein. Thus, Calcein fluorescence intensity provides a more
accurate estimate of cell viability. A key factor in this tech-
nique is the appropriate setting for cell size cut-offs in the
flow analysis to exclude small brightly labeled cell frag-
ments from the viability count. It is important to note that
in this study the cell size and Calcein-labeling intensity cut-
offs were optimized for G8-myoblasts, and although it can
be generalized, the parameters are expected to a certain
degree be cell line dependant. An additional advantage of
this method is that it allows one to determine cell viability
without the need for any additional cell surface markers.
When the viability of non-implanted encapsulated cells
wasmeasured using flow cytometry and trypan blue exclusion,
we found that viability values correlated with each other and
with the cFVIII secretion rates, although trypan-based viability
was lower than flow cytometry-based viability. This may be
due to the more subjective nature of trypan blue staining,
where clumps of proliferating cells are generally excluded
from the viability estimate due to the difficulty in assessing
cell boundaries. Thus, non-aggregated cells are preferentially
counted using trypan blue, which perhaps includes a greater
proportion of dead cells that reduces the overall viability of
encapsulated cells. In addition, our in vitro data comparing
flow cytometry-based viability and trypan blue exclusion was
confirmed using blood outgrowth endothelial cells (BOECs).
We also compared the viability of encapsulated cells
implanted into mice, retrieved 6 weeks postimplantation, and
found that flow cytometry-based viabilities were significantly
FIGURE 9. Comparison of the granularity of (n) nonencapsulated
(free), (l) nonimplanted encapsulated and (^) implanted-encapsu-
lated G8 cells. Nonimplanted encapsulated cells were cultured in vitro,
while implanted-encapsulated cells were retrieved 6 weeks postim-
plantation (on day 0) and subsequently maintained in vitro and de-
encapsulated on day 0, 1 and 7 to assess their granularity (percentage
in box F) using flow cytometry. Free cells had a significantly (p <
0.05) lower granularity compared to non-implanted encapsulated and
implanted-encapsulated cells. (Error bars indicate standard deviation;
n ¼ 3). [Color figure can be viewed in the online issue, which is avail-
able at www.interscience.wiley.com.]
FIGURE 10. Proliferation of nonimplanted encapsulated (black) and free (white) G8-cFVIII cells cultured in vitro. Encapsulated CFSE-labeled G8-
cFVIII cells proliferated slower (on average) than free cells. Representative data presented.
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different from trypan blue-based viabilities. However, flow-
based viability positively correlated with the cFVIII secretion
rate. Given that the average viability of a population of cells is
expected to correlate with their average secretion rate, the
observed correlation between encapsulated cell viability and
cFVIII secretion rate is only supported by flow cytometry
data26,16 (Figure 7). It is also important to note that previous
studies have shown that FVIII is able to efficiently diffuse
through APA microcapsules in a linear fashion, suggesting
that the capsular material is not significantly influencing the
average secretion rate. These studies confirm the permeabil-
ity of the capsules to FVIII, thus validating the correlation
between cell viability and secretion.6
In addition, the trypsin/EDTA de-encapsulation procedure
separated aggregates of proliferating cells into a single cell
suspension (data not shown), allowing an accurate analysis by
flow cytometry, yet without significantly (p > 0.05) affecting
cell viability. Furthermore, 30,000 cells were analyzed by
flow compared to the several dozen cells that may be counted
by trypan blue. The much larger sample size also resulted in
significantly smaller standard deviations (p < 0.0001) than
those of trypan-based viabilities. The limited sample size fea-
sible and the operator-dependent nature of trypan blue, con-
tribute to more inconsistent viability results. Taken together,
this study suggests that the trypsin/EDTA de-encapsulation
procedure in conjunction with flow cytometry analysis pro-
vides a more objective and consistent estimate of encapsu-
lated cell viability than the traditional trypan blue method.
To address the possibility that host contaminating APCs
might potentially be included in our flow cytometry-based
viability estimates of encapsulated G8-cFVIII cells, we
stained for the presence of the costimulatory molecule
CD86 (B7-2), expressed on the cell-membrane of APCs.27
The absence of cells expressing CD86 among the retrieved
myoblasts indicated that there was no APC contamination
from the host (Figure 8).
Of note, encapsulated G8 cells were significantly more
granular (p < 0.05) than free cells. Granularity is a measure
of the internal composition of cells based on their light-scat-
tering (quantified by the degree of side-scatter in flow
cytometry) properties of their intracellular structures.17
Free cells have a range of granularity (cytoplasmic heteroge-
neity) (Figure 5), a reflection of their normal physiology,
which increases upon encapsulation as measured by the
percentage of cells in box F (Figures 2 and 6). This indicates
that a fraction of live encapsulated cells are morphologically
distinct, perhaps representing cells with an altered cFVIII
secretion rate. Accumulation of FVIII proteins in the endo-
plasmic reticulum activates the unfolded protein response
(UPR), leading to oxidative stress and apoptosis.28–30 It is
possible that the additional stress of encapsulation itself
may have resulted in a greater fraction of cells that are
more granular. In agreement with this explanation, Sandhu
et al. have shown a correlation between the b-galactosidase
secretion of cells and their granularity.16 This study also
demonstrated a positive correlation between the number of
viral particles within an infected cell and its granularity.16
Hence, in our study, FVIII secretion provided a unique op-
portunity to characterize encapsulated cells.
Our proliferation studies show that encapsulated myo-
blasts proliferated in vitro 2.4-fold slower on average than
their free cell counterparts, perhaps attributable to the lack
of a proper attachment support of alginate for prolifera-
tion.31–33 The heterogeneous proliferation findings would
suggest the presence of subpopulations of myoblasts prolif-
erating at slightly different rates (Figure 10). In contrast, free
cells proliferated faster and in synchrony, probably due to
the high capacity of the tissue culture-treated surfaces to
promote cell adhesion, which allows cells to space them-
selves uniformly and to adopt an adherent morphology.
Interestingly, encapsulated cells that were implanted into
mice proliferate 1.2-fold faster on average than non-
implanted encapsulated cells (Figure 11), and had multiple
subpopulations of cells, proliferating at different rates. These
observations suggest that the proliferation behavior of
encapsulated cells in vivo differs from that of encapsulated
cells maintained in vitro. It is also possible that the large sub-
populations observed in implanted microcapsules represent
differentiated myoblasts. In vivo, the proinflammatory envi-
ronment created around the site of implantation may have
induced the differentiation of G8 myoblasts into myotube-
like non-proliferative cells,34,35 thus creating the distinct
large subpopulation. These data suggest that the prolifera-
tion behavior of encapsulated cells is environment-depend-
ent. Given the limited space within microcapsules, it is
expected that the proliferation behavior may also have a sig-
nificant impact on cell viability and consequently their secre-
tion rate.36 The findings from this study support our previ-
ous findings7,10 and highlight the advantageous characteristic
of myoblasts of differentiating into non-proliferative myo-
tubes upon nutrient or cell confluency stress. In contrast to
the behavior of proliferative cells such as fibroblasts that can
fill the entire capsular space, the proliferation of encapsu-
lated myoblasts is rather limited and will cease when nutri-
ent diffusion is compromised. Therefore, due to the differen-
tiation of myoblasts, capsules are not filled to capacity with
cells and can not break as a result of cell proliferation, as
we have determined monitoring encapsulated myoblasts
retrieved from mice 7 months after their implantation.7
As a future challenge, the volume of implanted micro-
capsules would have to be significantly reduced before
FIGURE 11. Proliferation of implanted-encapsulated (black) and non-
implanted encapsulated (white) G8-cFVIII cells. Implanted capsules
were retrieved after 7 days and cultured in vitro until day 11.
Implanted-encapsulated CFSE-labeled G8-cFVIII cells proliferate
slightly faster (on average) than non-implanted encapsulated cells.
Representative data presented from one implantation.
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human trials can be considered. A volume of 4 mL of micro-
capsules used in this study in mice would corresponds to
several liters when scaled up to human size, a clearly
impractical volume.
In conclusion, we propose a novel flow cytometry-based
assay to characterize the viability, granularity and prolifera-
tion of APA encapsulated cells, which provides a more reli-
able estimation of viability than trypan blue, and could be
of interest in many applications in cell and gene therapy.
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Abstract A flow cytometry-based cytotoxicity
(FCC) assay was developed using a single fluorophore,
calcein-acetoxymethyl diacetylester (calcein-AM), to
measure NK cell-mediated cytotoxicity. Non-adherent
human K562 and U937 target cells were individu-
ally labelled with calcein-AM and co-incubated with
effector NK cells to measure calcein loss, and
therefore calculate target cell cytotoxicity. This FCC
assay also provided a measure of sample viability.
Notably, cell viability measured by traditional calcein/
7-amino-actinomycin D (7-AAD) double labelling
and Trypan Blue methods were comparable to the
viability calculated using calcein-loss FCC. This FCC
assay may also be used with various effector and target
cell types and as a multi-parameter tool to measure
viability and immunophenotype cells for tissue
engineering purposes.
Keywords Calcein  Cell-mediated cytotoxicity 
Flow cytometry  Natural killer cells  Viability
Introduction
Cell-mediated cytotoxicity assays are indispensable in
immunology to quantify effector cell [cytotoxic
T-lymphocytes (CTLs), natural killer (NK) cells and
natural killer T cells (NKT)] function involved in the
defence against virally infected cells, allogeneic cells
and tumors. Although there are many different assays
to measure cytotoxicity, the chromium (51Cr)-release
assay (CRA) is considered the ‘gold standard’ for
measuring the cytolytic activity of effector cells
(Ozdemir 2011). Unfortunately, CRA has many
disadvantages, primarily related to the use of radioac-
tivity, low sensitivity to apoptotic cell death and speed
of analysis (Kim et al. 2007).
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The limitations of the CRA has inspired several
groups to develop flow cytometry-based cytotoxicity
(FCC) assays, which incorporate multi-parameter high-
speed analysis at the single-cell level (Papadopoulos
et al. 1994; Kasatori et al. 2005; Zimmermann et al.
2005;Klo¨ß et al. 2007; Cao et al. 2010). Flow cytometry
allows for the simultaneous measurement of cytotoxic
effector cell activation, cell frequency and phenotype, as
well as target cell death, in the same sample. In addition,
there is a good correlation between the results obtained
from FCC assays and the results of the 51Cr-release and
ELISpot assays (Burkett et al. 2005; Zaritskaya et al.
2010). However, most FCC assays require multiple cell
labels and/or cell surface markers with extensive cell
manipulation. Together, these factors contribute to
increased cost and limit the widespread applicability
of these assays. In order to address these limitations, we
developed an alternative FCC assay that requires only
one commonly used fluorophore, calcein-AM, for the
determination of NK cell-mediated cytotoxicity of
human target cells. Our assay relies on the conversion
of a membrane permeable lipophilic compound (calce-
in-AM) to a brightly fluorescent, membrane imperme-
able compound (calcein) via the action of ubiquitously
expressed intracellular esterases (Bratosin et al. 2005;
Gantenbein-Ritter et al. 2008). In a cell-mediated
cytotoxicity assay, killed calcein-labelled target cells
are either completely or incompletely lysed (mainly
perforin and granzymemediated necrosis), or remain as
one entity with a compromised cell membrane (mainly
TNF-a, TRAIL and Fas ligand- mediated apoptosis),
where calcein is free to diffuse outside the cell
(Zaritskaya et al. 2010). Thus, the physical size of dead
cells, their internal composition (granularity) and cal-
cein staining intensity distinctly varies from healthy/
living cells. These distinguishing characteristics were
used to calculate NK-specific target cell cytotoxicity.
In the absence of effector cells, we also measured the
viability of cells using this method. Our measured
viability values were validated against other established
assays for viability.
Materials and methods
Cell lines and cell culture
U937 is a histiocytic lymphoma-derived monocyte-like
human cell line (ATCC,CRL-1593.2). K562 is a human
chronic myelogenous leukemia cell line (ATCC, CCL-
243). U937 and K562 cell lines were cultured in RPMI
1640 (Invitrogen, Burlington, Canada) with 10% (v/v)
heat-inactivated FBS, 1% penicillin/streptomycin 0.1%
gentamycin and 0.1% fungizone in 0.2 lmvented tissue
culture flasks at 37C (humidified, 5% CO2). All other
media additives were purchased from Sigma–Aldrich.
Suspension cells were subcultured every 3–4 days.
Lymphocytes were cultured in U937 media, with
50 lM 2-mercaptoethanol 1 mM sodium pyruvate and
0.1 mM non-essential amino acids. We refer to this
media as lymphocyte media (LM). Cells were counted,
and viability was measured by Trypan Blue exclusion.
Enumerating target cell lysis in a cytotoxicity
assay using CountBright beads
CountBright beads (Molecular Probes) are small
(7 lm) fluorescent microspheres that were added to a
single-cell suspension in order to determine the
absolute cell count. In the CTL (cytotoxic T-lympho-
cyte) assay, we calculated the absolute number of
calcein-labelled target cells in control samples (U937
only) and compared themwith test samples (co-culture
of effector and calcein-labelled target cells) using
CountBright beads. Both the control samples and the
test samples initially contained the same number
(50,000) of calcein-labelled U937 target cells. Briefly,
CountBright beads were added to control and test
samples at the end of 4 h incubation in theCTL assay to
determine the absolute target cell count by flow
cytometry. These brightly fluorescent beads were
gated unambiguously in the forward scatter/side scatter
(FSC/SSC) plot to determine the bead count. Since the
concentration of beads and the ratio of the bead
solution to cell solution are known, the concentration
of cells was calculated according to the manufacturer’s
instructions (Molecular Probes).
CTL assay
The CTL assay was conducted as previously described
by our laboratory (Thakur et al. 2011). An E:T ratio of
4:1 was used in this assay (Fig. 1).
Positively selecting NK cells from fresh PBMCs
Peripheral blood mononuclear cells (PBMCs) were
isolated from whole blood collected from healthy
448 Biotechnol Lett (2012) 34:447–453
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human donors in this McMaster University Research
Ethics Board-approved study. The red blood cells
(RBC) were lysed using ammonium-chloride (ACK)
solution as previously described (Bossuyt et al. 1997).
After RBC lysis, the PBMCs were used as a source of
NK cells for the NK assay. Briefly, magnetic antibody-
coated beadswere used to positively selectCD56? cells
from PBMCs according to manufacturer’s instructions
(StemCell Technologies, Vancouver, Canada). After
separation, NK cells (CD56?) were resuspended in
4 ml LM.
NK assay
Freshly isolated NK cells (CD56? cells) were first
activated with 10 lg/ml Poly I:C (Sigma) and
50 U/ml rh IL-2 (Invitrogen) and incubated at 37C
(humidified, 5% CO2) in a 6-well tissue culture plate
for 48 h to increase their cytolytic activity. These
activated NK cells (lymphokine activated killer cells)
were then washed with PBS (Ca2? and Mg2? free).
Target cells were labelled with 100 nM calcein-AM
(Invitrogen) for 15–20 min at room temperature. The
cells were then washed with PBS (Ca2? and Mg2?
free) three times and finally resuspended in LM as
described above. The NK cells were then co-cultured
with target cells (NK cells: U937 or K562 cells) at
0.1:1, 0.25:1 and 1:1 in a 96-well round bottom plate in
triplicates. Cells were cultured in 200 ll LM. The
target cell number was held constant at 50,000 cells,
while the effector cell number was varied according to
the ratios. Control wells only contained the target cells
in LM. After incubating the co-culture for 4 h at 37C
(humidified, 5% CO2), 20 ll 7-AAD was added to
each well. This was followed by another incubation of
20 min at 22C (protected from light). The contents of
each well were added to 400 ll PBS (Ca2? and Mg2?
free) in separate flow cytometry tubes for analysis.
Flow cytometry data acquisition and analysis
A Beckman Coulter FC 500 system (Beckman Coulter
Inc., Mississauga, Canada) was used to acquire and
analyze the data with the CXP software provided.
Calcein was illuminated with an argon (488 nm) laser
and fluorescence was collected using a FITC filter set,
with the PMT collecting signals centered at 525 nm
(BP). 7-AAD was illuminated with an argon (488 nm)
laser and fluorescence was collected using an APC
filter set, with the PMT collecting signals centered at
675 nm (BP). Flow cytometry data analysis for the NK
assay was based on loss of calcein fluorescence from
target cells. Briefly, live target cells were gated based
on their calcein staining intensity and their relative
size (FSC) and granularity (SSC). In addition, the FSC
detection threshold voltages were optimized (via
CountBright beads) for the cell types used in this
study such that apoptotic and necrotic cells were
counted, but lysed cell fragments were not counted by
the flow cytometer. A live gate was created around the
normal FSC/SSC distribution of cells in the control
sample (no effector cells) to discriminate between
effector and target cells, and to allow intensity analysis
on healthy target cells. The population of healthy-
bright calcein stained target cells was first determined
in the control sample, which contained the same
number of cells (50,000) as the test samples, but
without any effector cells. After co-incubating effector
and target cells (test sample), the population of
healthy-bright calcein stained target cells was deter-
mined again. The difference between the two values
(control and test sample) gives the specific (effector
cell-mediated) target cell death [Eq. 1, calculating
percent specific death in cell-mediated cytotoxicity
assays (Thakur et al. 2011)]. We refer to this
calculation as the ‘Calcein-loss’ method for estimating
Fig. 1 Enumerating target cell lysis in a cytotoxicity assay
using CountBright beads. Comparison between calcein-labelled
target (U937) cell concentration in control samples (without
effector CTL cells, open square) and test samples [with effector
CTL cells, filled square] measured using CountBrigh beads.
Flow cytometry data presented from*30,000 events collected
per sample. (Error bars indicate standard deviation; n = 3;
* indicates significant (P\ 0.05) difference)
Biotechnol Lett (2012) 34:447–453 449
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specific cell death. A two-tailed Student’s t-test
was performed to determine statistical significance
between different E:T ratios and cell lines.
Specific death ð%Þ ¼ Ycontrol  100Xtest
Ztheoretical
 
ð1Þ
where Xtest = percentage of calcein-bright cells in
co-culture after incubation, Ycontrol = percentage of
calcein-bright cells in control, Ztheoretical = percent-
age of target cells in co-culture before incubation,
determined by the effector:target ratio.
Viability
Our calcein-loss FCC method of calculating specific
cell death relies on the measurement of viability in
controls and co-cultured samples. In order to validate
our calcein-loss FCC method, viability of control
samples were measured and compared to calcein/7-
AAD double labelling and Trypan Blue techniques.
The viability of a sample in the calcein-loss method
was determined by calculating the number of cells in
the live gate that are brightly labelled with calcein as a
fraction of the total number of cells (Fig. 2). Calcein/
7-AAD viability was determined by calculating the
fraction of Calcein labelled cells that were also
simultaneously labelled with 7-AAD, indicating late
apoptotic/necrotic dead cells with a compromised
cell membrane. In contrast, Trypan Blue staining
was performed using a hemocytometer, where dead
necrotic cells and apoptotic cells with a compromised
cell membrane stain blue.
Fig. 2 NK assay using xalcein-loss technique. (i) The FSC/
SSC plot of calcein-labelled U937 target cells in the absence of
effector NK cells. The live cell bracket (green cells) contains the
vast majority ([95%) of healthy/live cells, while the dead cell
bracket (red cells) contains the vast majority ([85%) of
unhealthy/dead cells in the sample. (ii) Histogram represents
the fraction of cells in the live bracket that are brightly
(‘Bright’) and dimly (‘Dim’) labelled with calcein. The brightly
labelled fraction in the live cell bracket (Ycontrol = (100%/
100) 9 87.3%) was then calculated. This value also represents
the viability of the sample. (iii) FSC/SSC plot of calcein-
labelled U937 target cells in the presence of effector NK cells
at E:T ratio of 1:1. (iv) The brightly labelled fraction in the
live cell bracket of this coculture (Xtest = (96.5%/100) 9 10%)
was then calculated. The specific death was calculated to be 68%
using Eq. 1
450 Biotechnol Lett (2012) 34:447–453
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Results
Determination of target cell lysis in a cytotoxicity
assay
A prime objective of our flow cytometry-based cyto-
toxicity assays was to determine whether calcein-
labelled target cells were being lysed in a necrotic
process induced by effector cells as opposed to staying
intact with a compromised cell membrane in an
apoptotic process. In order to determine the fraction
of cells undergoing necrosis/lysis by effector cells, we
calculated the absolute number of calcein-labelled
target cells in control samples (U937 only) and
compared themwith test samples (co-culture of effector
and target cells) using CountBright beads. The result
shown in Fig. 1 suggests that there was a significant
(P\ 0.05) loss of calcein-labelled target cells in the
cytotoxicity assay. Only 43% of the target cells
(including healthy and apoptotic/necrotic cells) were
counted after incubation with CTLs. The remaining
necrotic/lysed cells were detected at low FSC and
widely distributed over the SSC axis in the FSC/SSC
plot.
Determination of viability and cytotoxicity using
the Calcein-loss method
In order to determine specific cell cytotoxicity, the
viability of the control sample (containing only target
cells) and test sample (effector and target cells) was
calculated (Fig. 2i, ii). In the control sample, 87% of
cells lie within the live cell gate in the FSC/SSC plot
and 100% of the cells within this live gate were
brightly stained for calcein, indicating live cells. By
contrast, in the test sample only 10% of cells lie within
the live gate (Fig. 2iii, iv), with 96.5% of those being
brightly labelled with calcein. The specific cell
cytotoxicity was determined by comparing the viabil-
ity of the control and test sample, while accounting for
the E:T ratio (Eq. 1).
Comparison of viability determined using
calcein-loss, calcein/7-AAD and Trypan
Blue techniques
The calcein-loss method yields a viability that is
comparable, albeit significantly (P\ 0.05) lower than
with the calcein/7-AAD and Trypan Blue methods
(Fig. 3). However, viability values were consistent, as
indicated by the small standard deviations. Viability
values determined using calcein/7-AAD and Trypan
Blue were not significantly (P[ 0.05) different.
Trypan Blue viability averages were found to have
the largest standard deviations of the three techniques.
These observations were confirmed in both K562 and
U937 cell lines.
Calcein-loss FCC assay in K562 and U937 cells
The FCC assay using the calcein-loss method shows a
significant (P\ 0.05) increase in the specific cell
death of target cells with increasing E:T ratios. This
consistent increase in the specific cell death was
comparable between K562 and U937 cell lines
(Fig. 4).
Discussion
Our results indicate that the calcein-loss FCC method
provides a reliable estimate of NK cell-mediated
cytotoxicity that was consistent across both cell lines
used in this study. To our knowledge, no other FCC
method uses only a single fluorophore to measure
specific cell death via necrosis and apoptosis. Our
method of analysis defines dead cells as those which
have a compromised cell membrane. An apoptotic/
necrotic dead cell with a compromised cell membrane
is measured by the loss calcein intracellular staining
and the change in its size and granularity, while
Fig. 3 Comparison of viability calculated using calcein/
7-AAD, calcein-loss and Trypan Blue techniques in K562
(open square) and U937 (filled square) cell lines. Viability
determined using Calcein-loss is significantly (P\ 0.05) dif-
ferent in U937 (*) and K562 (*) cell lines. Viabilities
determined using calcein/7-AAD and Trypan Blue are not
significantly (P[ 0.05) different in both cell lines. Error bars
indicate standard deviation; n = 3. Flow cytometry data pre-
sented from*30,000 events collected per sample
Biotechnol Lett (2012) 34:447–453 451
123
completely lysed necrotic cells are quantified by the
reduction in the expected number of cells counted in
the flow cytometer (Bertho et al. 2000; Thakur et al.
2010). This is inherently more sensitive than relying
on the ability of a second dye such as 7-AAD or
ethidium bromide to label cells with a damaged cell
membrane.
Techniques that rely on double labelling of specif-
ically killed target cells, such as Cell Tracker Orange/
7-AAD previously used by other groups, may not be
suitable for use in cytotoxicity assays since they fail to
count early apoptotic and completely lysed necrotic
cells (Kim et al. 2007). Data presented here (Fig. 1)
indicate that a significant fraction (57%) of specific cell
death values (at high E:T ratios) measured in a CTL
assay can be attributed to the necrosis/lysis of target
cells, which result in necrotic cells and cell fragments
that fall below the cell counting limit normally set in
flow cytometry. Since CTLs and NK cells rely on
similar mechanisms to induce cell-mediated cytotox-
icity, it is likely that this result can be extended to NK
assays as well. Thus, methods relying exclusively on
double labelling of target cells may not be suitable for
the assessment of viability and cytotoxicity. However,
double labelling of target cells can be easily adapted in
our calcein-loss assay to distinguish between apoptosis
and necrosis. For example, apoptosis and necrosis can
be quantified by the addition of dyes such as 7-AAD
and annexin V. Target cells double labelled with
Calcein and annexin V (preferentially binds cell
membrane phosphatidylserine) will represent early
apoptotic cells, while target cells double-labelled with
Calcein and 7-AAD will represent late apoptotic/
necrotic cells with a compromised cell membrane.
Completely lysed necrotic target cells can be quantified
by comparing the absolute number of target cells in
controls (target cells only) and test samples (effector
and target cells). The reduction in the target cell
number in the test sample would provide a direct
measure of the completely lysed necrotic target cells.
Calcein-based viability assays are becoming
increasingly popular in tissue engineering due to
labelling sensitivity, reproducibility, stability of fluo-
rescence in the physiological pH range and their
versatility (Gantenbein-Ritter et al. 2008). Viability
measurements using the calcein-loss method were
found to be consistent across both U937 and K562 cell
lines. In comparison to Trypan Blue, the calcein-loss
method yielded viabilities with smaller standard
deviations. However, our method of analysis likely
underestimates the viability since the live gate was
restricted by size and granularity in the FSC/SSC plot
(Fig. 2). When compared to viability estimates mea-
sured by Trypan Blue and calcein/7-AAD, we calcu-
late that our calcein-loss method underestimates the
viability by 10% at the most (Fig. 3). We found that
expanding the live gate to encompass more cells
corrects this viability estimate, but a larger (less
stringent) live gate would likely decrease the accuracy
of the cytotoxicity measurements. A stringent live gate
was applied in this cytotoxicity assay, since cell size
(FSC), granularity (SSC) and calcein staining intensity
are all parameters that are expected to change when
target cells are killed/compromised by effector cells.
The specific cell death value was calculated by
comparing controls and co-cultured samples, both of
which had the same live gate and Calcein staining
intensity cut-offs, making it a reliable estimate of
cytotoxicity (Fig. 4). Our data show that the specific
cell death values are consistent across both cell lines
tested at various E:T ratios and are in agreement with
previously published NK cytotoxicity values (Papad-
opoulos et al. 1994; Kasatori et al. 2005).
Conclusion
We have developed a flow cytometry-based cytotox-
icity assay using a single fluorophore, calcein-AM, to
measure NK cell-mediated cytotoxicity as well as
viability of cell samples. This method can also be
Fig. 4 Comparison of NK cytotoxicity (specific cell death)
using calcein-loss technique in K562 (open square) and
U937 (filled square) cell lines at three different E:T ratios.
Specific cell death values increased with the E:T ratios in both
cell lines. Specific cell death values were also significantly
(P\ 0.05) different between all E:T ratios in both cell lines.
Error bars indicate standard deviation; n = 3. Flow cytometry
data presented from*30,000 events collected per sample
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adapted in multi-colour flow cytometry to simulta-
neously immunophenotype cells in cytotoxicity assays
with multiple effector and target cell types. Further-
more, this assay can be conveniently applied in tissue
engineering, where cell morphology, spatial distribu-
tion and viability are all important parameters that can
be assessed using a single fluorophore.
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Abstract
The immune response to allogeneic cells in tissue-engineered constructs is a major barrier to their
successful application in the treatment of many human diseases. Specifically, the T cell-mediated
immune response, initiated through the recognition of cell surface MHCI molecules, is the primary
cause of acute cellular allograft rejection. In this study, we altered expression of MHCI through
viral immunomodulatory mechanisms to examine whether allogeneic cells could be made to ‘mimic’
viral evasion of a host CTL response. We demonstrate the successful application of a retroviral
vector in vitro to overexpress the Kaposi’s sarcoma-associated herpesvirus immunomodulatory
protein, MIR2, in human monocyte-like myeloid progenitor cells. This approach led to differential
downregulation of cell surface MHCI, ICAM-1 and B7–2 molecules. We also demonstrate that
downregulation of immunoactive molecules has the functional effect of significantly reducing T
cell-mediated cytotoxicity without altering NK-mediated cytotoxicity in vitro. These results provide
proof-of-concept that viral immune evasion strategies allow cell-based tissue-engineered constructs
to delay or even prevent acute cellular immune rejection in vivo. Importantly, this methodology could
facilitate the development of universal donor cells for tissue engineering applications. Copyright ©
2011 John Wiley & Sons, Ltd.
Received 14 March 2010; Accepted 8 July 2010
Keywords tissue engineering; transplantation; immune response; MHC class I; gene therapy; Kaposi’s
sarcoma-associated herpesvirus; retroviral gene expression
1. Introduction
The immune response to allogeneic cells within tissue-
engineered constructs has been recognized as a significant
barrier to their widespread application in humans (Langer
et al., 1993; Jones, 2008). The objective of our work was
to engineer human cells that could resist rejection by
reducing expression of major histocompatibility complex
class I (MHCI) molecules. Experiments by George Snell
and colleagues identified the MHC complex as a locus
*Correspondence to: Kim Jones, Department of Chemical
Engineering, McMaster University, Hamilton, Ontario L8N 3Z5,
Canada. E-mail: kjones@mcmaster.ca
of polymorphic genes, which code for the targets of
allograft recognition (Hurme et al., 1978; Snell, 1979).
Since MHCI molecules are expressed on all nucleated
cells, they can be recognized by alloreactive T cells
and evoke immune responses to virtually all tissue
types. Acute cellular rejection is due to activation
of alloreactive CD8+ T cells, which proliferate and
differentiate into effector cytotoxic T lymphocytes (CTLs)
that specifically kill allogeneic cells (Abbas et al., 2000).
Hence, the MHCI recognition capability of T cells
responding to the allograft is the most significant
event leading to acute cellular rejection (Lechler et al.,
2005).
Copyright © 2011 John Wiley & Sons, Ltd.
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Recognizing this important aspect of immune rejection,
several studies have attempted to reduceMHCI expression
(Markmann et al., 1992; Osorio et al., 1994a, 1994b).
However, a global reduction of MHCI molecules has
been shown to increase the susceptibility of cells to
natural killer (NK) cells of the innate immune system
(Iannello et al., 2006). In humans, many of the MHCI
alleles, including human leukocyte antigen B (HLA-B)
and HLA-C, are recognized by NK cell inhibitory receptors
(Abbas et al., 2000). In the absence of MHCI molecules,
NK cells are activated by ubiquitously expressed cell
surface receptors such as MICA, MICB and AICL
(Welte et al., 2006; Thomas et al., 2008; Nathan et al.,
2009). This results in the specific lysis of cells lacking
MHCI molecules, which immediately suggests that a
general downregulation of MHCI molecules is unlikely
to significantly protect allogeneic cells from the immune
response. Given that allogeneic stem cells are a promising
tissue engineering cell source, many groups have shown
that stem cells exhibit immune privilege characteristics,
primarily due to their low MHCI expression and their
lack of MHCII expression (Li et al., 2004; Wu et al.,
2008). However, recent studies by Drukker et al. (2002)
suggest that stem cell-derived cells do not retain their
immune privilege characteristics. For example, human
embryonic stem cells (hESCs) upregulate their expression
of MHCI upon differentiation by about 10-fold, sufficient
to provoke an acute immune response (Drukker, 2008).
Overall, these observations suggest that it will be
necessary to modulate MHCI molecules expressed on
hESC-derived cells to induce active tolerance in the host
for these transplanted cells to be successful in tissue-
engineering applications.
In preparing a tissue-engineered construct, the cells
required are sourced in advance. This provides the
opportunity to use genetic engineering to manipulate
these cells, such that they evade or suppress the
immune response. Viruses have evolved complex genetic
mechanisms to evade and suppress detection by the
immune responses of the host (Iannello et al., 2006).
A tissue-engineered allogeneic construct with cells
engineered to utilize these viral mechanisms could
elicit a similar response, whereby the construct would
not be recognized by the host immune system as
foreign. Here, we tested this novel approach by
transducing a model human progenitor cell line to
express an immunomodulatory protein, modulator of
immune recognition (MIR2), from Kaposi’s sarcoma-
associated herpesvirus (KSHV). This 29 kDa protein
is known to downregulate the cell-surface expression
of MHCI, ICAM-1, B7–2 and other immunoactive
molecules (Ishido et al., 2000b; Coscoy et al., 2001a,
2001b; Lodoen et al., 2005; Sanchez et al., 2005; Welte
et al., 2006; Thomas et al., 2008). In this study, we
demonstrate the immunoprotective effect of MIR2–GFP
fusion protein (56 kDa) (Sanchez et al., 2002; Cadwell
et al., 2005) expression against allogeneic CTLs and NK
cells, using flow cytometry-based in vitro cytotoxicity
assays.
2. Materials and methods
2.1. Cell line and cell culture
The histiocytic lymphoma-derived monocyte-like myeloid
progenitor human cell line U937 (ATCC No. CRL-
1593.2) was cultured in RPMI 1640 (Invitrogen Canada
Inc., Burlington, ON, Canada) containing 10% v/v
heat-inactivated FBS (PAA Labs Inc.), 1% Penn/Strep
(Invitrogen), 0.1% Gentamycin (Invitrogen) and 0.1%
Fungizone (Invitrogen). Cells transduced with MIR2–GFP
(U937-MIR2–GFP) or LacZ (U937-LacZ) cells were
cultured in G418 sulphate (1 mg/ml during initial
selection or 250 μg/ml for maintenance; Invitrogen)-
supplemented media. Human leukocytes (CTLs and
NK cells) were maintained in U937 cell culture
medium supplemented with 50 μM 2-mercaptoethanol
(Invitrogen), 1 mM sodium pyruvate (Invitrogen) and
0.1 mM non-essential amino acids (Invitrogen).
2.2. Retroviral vector preparation
and transduction
The Viraport™ gene expression system was employed
to make the MIR2–GFP retrovirus (Stratagene, La
Jolla, CA, USA). The MIR2–GFP cDNA (kind gift of
Dr Laurent Coscoy, University of California, Berkeley,
CA, USA) was cloned into pFB-Neo using BamHI and
HindIII restriction sites. Viral particles were generated
by co-transfecting pFB-Neo-MIR2–GFP and the retroviral
component plasmids pVPack-GP and pVPack-VSV-G into
293T cells, using ExGen500 (Fermentas Canada Inc.,
Burlington, ON, Canada) according to the manufacturer’s
protocols. U937 cells were subsequently transduced to
generate U937-MIR2–GFP cells, which were selected and
maintained in G418 media. This procedure was repeated
to generate U937 control cells transduced with LacZ
(U937-LacZ).
Transduced U937 cells strongly expressed GFP (flu-
orescence microscopy data not shown), indicating the
expression of the chimeric MIR2–GFP protein. This con-
firmed that VSV-G pseudotyped MMLV was suitable to
deliver genes to U937 cells. Similarly, LacZ transduced
cells expressed β-galactosidase (data not shown). Further-
more, the viability of transduced cells (U937-MIR2–GFP,
97.7%; U937-LacZ, 97.4%) was not significantly different
from the viability of untransduced U937 cells (98.5%), as
measured by 7-AAD staining.
2.3. Microscopy
Fluorescent images were collected using a Leica DM
IRE2 inverted fluorescence microscope system (Leica
Microsystems, Richmond Hill, ON, Canada) with a
standard GFP filter set in conjunction with OpenLab
imaging software (Improvision Inc., Waltham, MA, USA).
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2.4. Flow cytometry
A Beckman Coulter FC500 system (Beckman Coulter
Canada Inc., Mississauga, ON, Canada) was used to
analyse cells with the CXP software provided. Cells
were stained with anti-HLA-ABC-PE, anti-CD54-PE, anti-
CD56-PE and anti-CD8-PC7 (Beckman Coulter), anti-HLA-
E (MEM-08; Abcam Inc., Cambridge, MA, USA), anti-
CD86-PE and anti-mouse IgG1-APC secondary antibody
(BD, Franklin Lakes, NJ, USA). Prior to antibody staining
of cells, cell surface Fc receptors were blocked with
heat-inactivated horse serum (Sigma) for 10 min at
room temperature. After incubating cells with antibody
for 30 min on ice, the cells were washed twice in
PBS and passed through a 40 μm cell strainer to
remove any cell clumps. Antibodies were used at
the manufacturer’s recommended concentrations. Cell
viability was assessed by 7-AAD staining (Beckman
Coulter).
2.5. CTL assay
Peripheral blood mononuclear cells (PBMCs) were
isolated from whole blood, collected from human donors
by ammonium chloride (ACK) lysis of red blood cells.
This study was approved by the Research Ethics Board
at McMaster University and blood collection was done by
a licensed phlebotomist. Human CD8+ T cells were then
negatively isolated using the EasySep Human CD8+ T Cell
Enrichment Kit (Stemcell Technologies, Vancouver, BC,
Canada). Isolated (‘responder’) cells were then stimulated
with mitomycin C-treated (25 μg/ml) U937 (‘stimulator’)
cells at a responder : stimulator ratio of 2 : 1 in vitro.
This co-culture was incubated in lymphocyte medium
supplemented with 10 U/ml recombinant human IL-2
(Invitrogen) at 37 ◦C (humidified, 5% CO2) for 96 h in
upright 75 cm2 tissue-culture flasks to allow the responder
population (CD8+ T cells) to proliferate and differentiate
into effector CTLs. In setting up the CTL assay, appropriate
effector (CTLs):target (U937-MIR2–GFP or U937-LacZ)
ratios were determined (2 : 1 and 10 : 1) and the target
cell number was held constant at 50 000 cells, while
the effector cell number was varied. The appropriate
number of target cells were centrifuged at 200 × g for
5 min and resuspended in medium and labelled with
100 nM Calcein-AM (Invitrogen) for 15–20 min at room
temperature. The cells were washed three times with PBS
(Ca2+- and Mg2+-free) and suspended in lymphocyte
medium at the desired concentration. The co-culture
was performed in 96-well round-bottomed tissue culture
plates. Each effector : target ratio had three repeats for
each of the target cell lines. Control wells contained
calcein-labelled target cells without effector cells. After
incubating the co-culture for 4 h at 37 ◦C (humidified, 5%
CO2), the contents of each well (200 μl) were added to
400 μl PBS (Ca2+- and Mg2+-free) in preparation for flow
cytometry.
2.6. NK assay
Human PBMCs were used as a source of NK cells.
Briefly, NK cells were positively selected from PBMCs
using the EasySep Human CD56 Selection Kit (Stemcell
Technologies, Vancouver, BC, Canada). Human CD56+
NK cells were then activated with 10 μg/ml Poly I : C
(Sigma-Aldrich Canada Ltd, Oakville, ON, Canada) and
50 U/ml recombinant human IL-2 (Invitrogen) at 37 ◦C
(humidified, 5% CO2) in a six-well tissue culture plate
for 48 h to enhance their cytolytic ability. After activation
of NK cells, appropriate effector (NK cells):target (U937-
MIR2–GFP or U937-LacZ cells) ratios were determined
(0.1 : 1, 0.25 : 1 and 1 : 1) and the co-culture was set up
in a manner similar to the CTL assay.
2.7. Data analysis
The percentage of specifically killed target cells was
calculated based on loss of calcein fluorescence from
target cells after co-incubation with effector cells. Briefly,
live target cells were gated based on their calcein staining
intensity and their relative size (FSC) and granularity
(SSC). A live gate was created around the normal
FSC/SSC distribution of cells in the control sample (no
effector cells) to discriminate between healthy bright
calcein-stained target cells and dead (dim) cells/debris.
The population of healthy bright calcein-stained target
cells was first determined in the control sample, which
contained the same number of cells (50 000) as the test
samples but without any effector cells. After co-incubating
effector and target cells (test sample), the population of
healthy bright calcein-stained target cells was determined
again. The difference between the two values (control
and test sample) was the percentage specific death
(equation 1); any differences observed between the test
and control groups were determined using Student’s t-
test; p < 0.05 was considered statistically significant:
Specific death (%) = Ycontrol −
[
100Xtest
Ztheoretical
]
(1)
where Xtest = percentage of calcein-bright cells in co-
culture after incubation, Ycontrol = percentage of calcein-
bright cells in control sample and Ztheoretical = percentage
of target cells in co-culture before incubation, determined
by the effector : target ratio.
3. Results
3.1. Characterization of cell surface molecules
in transduced cells
In order to determine the effect of MIR2–GFP expres-
sion on cell surface immunoactive molecules, U937-
MIR2–GFP and U937-LacZ cells were stained with anti-
bodies specific to HLA-ABC, CD54, CD86, HLA-E and
Copyright © 2011 John Wiley & Sons, Ltd. J Tissue Eng Regen Med (2011).
DOI: 10.1002/term
A. Thakur et al.
Figure 1. Cell surface characterization of U937-LacZ and U937-MIR2–GFP cells. HLA-ABC, CD54 and CD86 were all downregulated
(shaded curves) in U937-MIR2–GFP cells. Expression of MIR2–GFP was quantified by GFP fluorescence, while antibodies were used
to quantify all other markers. Mean fluorescence intensity (MFI) values for the shaded curves are indicated at the bottom right
corner of each graph, while MFI values of unlabelled cells (white curves) are indicated as MFIcontrol. Representative data presented
from 100000 cells analysed per sample; n = 2 replicates
HLA-DR. The detection of one strong GFP peak [mean
fluorescence intensity (MFI) = 14.9] in U937-MIR2–GFP
cells indicated a clonal population. This peak was 145-
fold above control cells (MFI = 0.103) (Figure 1A). In
Figure 1B, HLA-ABC expression was shown to be down-
regulated to 10% (MFI = 3.47) in U937-MIR2–GFP cells
compared to the control mean fluorescence intensity value
observed for mock transduced cells (MFI = 35.5). We
Copyright © 2011 John Wiley & Sons, Ltd. J Tissue Eng Regen Med (2011).
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Figure 2. Trend showing MIR2–GFP dose–response effect on
HLA-ABC expression. Figure depicts a decreasing trend in the
cell surface HLA-ABC level with increasing levels of MIR2–GFP
expression (MFI of GFP) as measured by flow cytometry in each
of the seven U937-MIR2–GFP clones (♦). Untransduced U937
cells () and U937-LacZ cells (ž) have high levels of HLA-ABC
expression. Line of best fit data presented from 100000 cells
analysed per sample; n = 1 replicate
also noted that CD54 expression was downregulated to
1% (MFI = 0.218), while CD86 was downregulated to
37% (MFI = 0.298) of control MFI values (Figure 1C,
D). Cell surface levels of HLA-E and HLA-DR were unde-
tectable in both U937-MIR2–GFP and U937-LacZ cells
(data not shown). Transduced U937-LacZ cells did not
significantly differ from untransduced U937 cells in their
expression of cell surface markers, including HLA-ABC
(MFI = 34.3), CD54 (MFI = 12.5) and CD86 (MFI =
0.708).
3.2. MIR2–GFP expression decreases surface
HLA-ABC in a dose-dependent manner
The relationship between MIR2–GFP expression and the
level of HLA-ABC downregulation was determined by
collecting GFP fluorescence data from various clones of
MIR2–GFP expressing cells. These data were plotted
against cell surface HLA-ABC expression data from the
same clones.We observed a negative relationship between
the expression level (MFI) of MIR2–GFP and the cell
surface amount of HLA-ABC (Figure 2). In addition, there
was a non-linear relationship between the expression level
of MIR2–GFP and HLA-ABC.
3.3. Retroviral transduction results in long-term
MIR2–GFP expression
In order to assess the long-term stability of MMLV-based
retroviral transduction, the MIR2–GFP expression level
and the corresponding HLA-ABC level was measured
after a clonal population of U937-MIR2–GFP cells was
maintained in active culture for 100 days. After 100 days,
the GFP signal decreased 2.48-fold to 40.3% (MFI =
14.1 ± 2.6) of its original day 0 value (MFI = 35 ± 2),
while the relative HLA-ABC level increased 2.42-fold from
8.4% (MFI = 1.46 ± 4.24) to 20.3% (MFI = 3.53 ± 3.52)
Figure 3. Effect of MIR2–GFP on HLA-ABC expression in
transduced cells over 100 days. The black bars show the
percentage of day 0 MFI for MIR2–GFP expression in
U937-MIR2–GFP cells. The white bars show the percentage
of HLA-ABC MFI measured in U937-MIR2–GFP cells relative
to its value measured in U937-LacZ cells on day 0. These
measurements were acquired from a clonal population of
U937-MIR2–GFP cells in active culture for 100 days. Data
presented from 100000 cells analysed per sample; n = 3
replicates; ∗, significant difference (p < 0.05); error bars
indicate SD
Figure 4. CTL assay. Specific lysis of calcein-labelled target cells
[U937–LacZ (white bars) or U937–MIR2–GFP (black bars) cells]
in control samples (without CTLs) and test samples (with CTLs)
with varying effector : target ratios. ∗p < 0.05 between cell lines
for both effector : target ratios; error bars indicate SD; n = 3
replicates
of its value measured in U937-LacZ cells on day 0
(MFI = 17.4 ± 3.5) (Figure 3).
3.4. U937-MIR2–GFP cells evade CTL-mediated
cytotoxicity
A CTL assay was used to compare the immune evasion
of U937-MIR2–GFP cells relative to U937-LacZ cells, as
measured by specific cell lysis of target cells. In this assay,
flow cytometry measurements confirmed that CD8+ CTLs
comprised approximately 77% of the live effector cell
population (data not shown). The CTL assay showed a
statistically significant decrease in the specific lysis of
target cells transduced with MIR2 at two different ratios
(Figure 4). At the 2 : 1 E : T ratio, there was a 52% reduc-
tion in the specific lysis of MIR2 cells, whereas at the 10 : 1
E : T ratio there was a 31% reduction. This dose–response
effect shows that MIR2 expression confers a significant
protective effect against CTL-specific cell lysis.
Copyright © 2011 John Wiley & Sons, Ltd. J Tissue Eng Regen Med (2011).
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Figure 5. NK Assay. Specific lysis of calcein-labelled target cells
[U937–LacZ (white bars) or U937–MIR2–GFP (black bars) cells]
in control samples (without NK cells) and test samples (with
NK cells) with varying effector : target ratios. No significant
difference between cell lines (p < 0.05); error bars indicate
SD; n = 3 replicates
3.5. U937-MIR2–GFP cells evade NK-mediated
cytotoxicity
The NK assay was used to compare the immune evasion
of U937-MIR2–GFP cells relative to U937-LacZ cells, as
measured by specific cell lysis of target cells by NK cells. In
this assay, flow cytometry measurements confirmed that
CD56+ NK cells comprised 90% of the live effector cell
population (data not shown). Although this population
of CD56+ cells included a small fraction of NKT (CD56+,
CD3+) cells, previous studies have demonstrated that
this population does not influence the function of CD56+
cells in this assay (Bonavida et al., 1994; Arrenberg et al.,
2009). The NK assay showed no statistically significant
difference in the specific cell lysis of target cells transduced
with MIR2 when compared to target cells transduced with
LacZ at various E : T ratios (Figure 5).
4. Discussion
In tissue engineering, the immune response to allogeneic
cells is a major barrier impeding the successful trans-
plantation of tissue-engineered constructs. We propose a
method to engineer immune acceptance, such that allo-
geneic cells are selectively modified, using viral strategies
that evade the alloimmune response while retaining nor-
mal immune function. To our knowledge, this is the first
study showing that a multifunctional viral immunomod-
ulatory protein differentially downregulates cell surface
molecules in allogeneic cells and results in CTL evasion,
without altering NK-specific target cell lysis in vitro.
Recently, another research group suggested that viral
stealth mechanisms can be exploited for stem cell
transplantation. Lee et al. (2005) transfected human
cytomegalovirus (hCMV) US genes into human neuronal
stem cells (hNSCs) and downregulated surface MHCI
molecules by 20–50%. Another study by the same group
transfected hCMV US genes into a human breast luminal
epithelial cell line, which is known to have stem cell
properties, and achieved a 40–60% downregulation of
cell surface MHCI molecules (Kim et al., 2005). However,
their approach only attempted to globally downregulate
MHCI molecules. Given that cell surface MHCI molecules,
especially HLA-C and HLA-E, also serve to negatively
regulate NK cells, a global downregulation of all types
of MHCI molecules is likely to make the cells more
susceptible to NK-mediated cytotoxicity (Yokoyama et al.,
1993; Lanier, 2005; Iannello et al., 2006). Hence, an
increase in NK-mediated cytotoxicity could potentially
negate the protective effect of reduced MHCI levels on
allogeneic cells from host CTL activity. This presents
a potential barrier for the application of global MHCI
reduction techniques for the purposes of allogeneic cell
transplantation in tissue-engineered constructs. In our
study, expression of MIR2 had the effect of protecting
allogeneic cells against CTL cytotoxicity without altering
the susceptibility of allogeneic cells to NK-mediated cell
lysis. This presents a significant advancement in the
application of MHCI reduction techniques as a means
of evading acute cellular immune rejection for allogeneic
cell-based tissue-engineered constructs.
Human U937 cells were used as a model human
progenitor cell line, since they are known to express
relatively high levels of MHC class Ia (HLA-ABC),
ICAM-1 (CD54) and co-stimulatory molecules such as
B7–2 (CD86), similar to the expression profile of stem-
cell derived cells (Drukker et al., 2002; Mar´ın et al.,
2003). Our cell surface characterization of MIR2–GFP-
transduced U937 cells showed that MIR2 differentially
downregulates immunoactive molecules, such that CD54
levels are decreased to 1%, HLA-ABC levels are decreased
to 10% and CD86 levels are decreased to 37% of mock-
transduced cells (Figure 1). Although we could not detect
cell surface HLA-E in U937 cells, previous groups have
detected low levels of HLA-E (Mar´ın et al., 2003). It
would be expected that HLA-E levels would remain
unaltered in MIR2–GFP-transduced cells (Iannello et al.,
2006). In addition, we observed that the expression
of MIR2 downregulated surface HLA-ABC in a dose-
dependent manner (Figure 2). Overall, these proof-of-
concept results suggest that MIR2 can significantly reduce
cell surface expression of MHCI, CD86 and ICAM-
1 in human progenitor cells. Of particular interest,
U937 myeloid progenitor cells have been used in tissue
engineering to study monocyte/macrophage responses to
decellularized pericardial biomaterials (Ariganello et al.,
2009, 2010), poly(ethylene glycol) matrices (Zuckerman
et al., 2009) and RGD-grafted gelatin matrices (Gao et al.,
2007). Recent work by Roh et al. (2010) highlights
the importance of mononuclear cell involvement in the
development of tissue-engineered vascular grafts. In this
study, Roh et al. reported that transplanted biodegradable
scaffolds seeded with bone marrow mononuclear cells
formed into living blood vessels via an inflammatory
process of vascular remodelling (Cho et al., 2009; Roh
et al., 2010). This immediately presents an opportunity
where genetically modified monocytes/macrophages can
be employed to direct inflammation, the foreign body
Copyright © 2011 John Wiley & Sons, Ltd. J Tissue Eng Regen Med (2011).
DOI: 10.1002/term
MIR2 expression decreases the alloimmune CTL response
reaction and wound healing, to ultimately control tissue
regeneration (Anderson et al., 2008). Therefore, U937
cells expressing lower levels of immunoactive molecules
may provide a relevant model for future studies in tissue
engineering involving immune cell activation and tissue
remodelling in response to biomaterials.
In genetically engineering cells for allogeneic trans-
plantation, it is important that the introduced viral gene
be expressed for a sufficient length of time in order
for it to be useful as a general strategy. In this study,
retrovirally-transduced U937 cells stably expressed func-
tional MIR2–GFP for at least 100 days, as confirmed
by the low cell surface levels of HLA-ABC (Figure 3).
Moreover, we found that reduced MIR2–GFP expression
over time still resulted in significant downregulation of
HLA-ABC (Figures 2, 3). The level of HLA-ABC expres-
sion after 100 days suggests that even a reduced amount
of MIR2 expression is sufficient to maintain a long-term
state of HLA-ABC downregulation. Although this result
is promising, safety studies of long-term MIR2 expres-
sion using retroviral gene expression systems are likely
required to validate its efficacy in vivo. Clinical trials have
reported adverse events caused by γ -retroviral vector inte-
gration, leading to insertional mutagenesis (Howe et al.,
2008), clonal expansion of transduced cells (Hacein-Bey-
Abina et al., 2003) and two cases of myelodysplasia (Stein
et al., 2010). Hence, there has been an impetus towards
developing safer integrating vectors for gene therapy.
Recently, studies by Montini et al. (2006) have demon-
strated low genotoxicity of lentiviral vector integration
in haematopoietic stem cell gene transfer. Although it
is believed that lentiviral vectors may lower the chances
of adverse events, a recent case of clonal expansion of
lentiviral transduced cells in a β-thalassemia clinical trial
has renewed safety concerns (Kaiser, 2009). Fortunately,
newer targeted gene transfer technologies are being devel-
oped to lower the risk of adverse events in vivo. For
example, self-inactivating (SIN) vectors integrate into the
transduced cell genome with deleted 3′ and 5′ long termi-
nal repeats (LTRs) and rely on internal cellular promoters
for transgene expression (Nienhuis et al., 2006, 2008; Per-
sons, 2010). Moreover, others groups have showed that
‘insulator elements’ can be added to the 3′ LTR during
vector assembly to block enhancer activity, thus reducing
the genotoxicity of vector integration (Evans-Galea et al.,
2007). Finally, in the event of unexpected allogeneic cell
behaviour post-transplantation, Bonini et al. (2007) have
developed ‘suicide’ vectors that provide a mechanism by
which transduced cells can be selectively killed by admin-
istering a drug. Given that viral gene delivery vectors can
be modified with such safety features, the results from
our study suggest that VSV-G pseudotyped MMLV-based
retroviral gene delivery vectors may be suitable for some
cell types in tissue engineering.
In addition to concerns about adverse events associated
with gene delivery, it is conceivable that long-term MHCI
downregulation may also increase the risk of pathogen
propagation in transplanted allogeneic donor cells.
However, the MHCI expression profile in MIR2-expressing
cells suggests that peptide presentation mechanisms
are not completely removed, therefore minimizing the
risk of pathogen propagation. Perhaps the greatest
benefit of expressing MIR2 is its ability to differentially
downregulate immunoactive molecules, including MHCI,
such that only peptide presentation via HLA-A and HLA-
B gene products are significantly reduced, while leaving
other HLA peptide presentation mechanisms relatively
unaffected. We expect that this will reduce the overall
acute allogeneic immune response from CTL and NK cells,
while preserving some of the MHCI peptide presentation
routes (via HLA-C) for pathogen detection. Furthermore,
this method of donor cell antigen modification does not
alter the host or its immune system from mounting
a systemic immune response. Taken together, donor
cell antigen modification with MIR2 presents a unique
opportunity to produce allogeneic cell-based tissue-
engineered constructs for transplantation that minimize
the potential for adverse events in vivo.
Results from the CTL and NK assays in our study
suggest that MIR2–GFP expression protects U937 cells
against the cytotoxic effects of allogeneic CTLs without
altering NK-specific target cell lysis in vitro. Specifically,
MIR2 expression reduced MHCI and ICAM-1 levels, which
contributed to the decrease in CTL-mediating killing of
target cells (Figure 4). Since CD8+ CTLs recognize MHCI
and adhere to target cells using ICAM-1, it is expected
that any decrease in the cell surface expression of MHCI
or ICAM-1 would hinder target recognition and binding
capability of CTLs. Immune evasion of MIR2-expressing
target cells in our study strongly support this notion.
Unlike the CTL response, NK cell cytolytic activity is
inversely proportional to the amount of MHCI present
on the cell surface. As the MHCI levels decrease on the
cell surface, a greater percentage of the target cells are
specifically killed by NK cells (Iannello et al., 2006). How-
ever, in this study we did not observe any significant
increase in NK-mediated cytotoxicity of U937-MIR2–GFP
cells and U937-LacZ cells, despite the downregulation of
MHCI (Figure 5). Our results suggest that MIR2 expres-
sion maintains constitutive protection against NK-specific
cell lysis, while significantly reducing CTL cytotoxicity
against allogeneic cells. Hence, MIR2 expression presents
a distinct advantage over previously employed tech-
niques for global MHCI reduction to evade acute cellular
immune rejection of allogeneic cells. However, a num-
ber of factors could have contributed to the unaltered
level of NK-specific target cell lysis. First, cell-surface
HLA-C, which is weakly affected by MIR2 expression,
might have been sufficient to negatively regulate NK
cell specific lysis of target cells (Ishido et al., 2000a,
2000b). Second, the strong downregulation of ICAM-1
(CD54) might have significantly lowered the capacity of
NK cells to adhere to MIR2-expressing cells, resulting
in decreased NK-specific cell lysis. Third, MIR2-mediated
downregulation of other U937 cell surfacemolecules, such
as MHCI-related chains (MICA, MICB) and activation-
induced C-type lectin (AICL), might have reduced the
activation signal necessary for NK cell activation (Welte
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et al., 2006; Thomas et al., 2008; Nathan et al., 2009). It
is likely that a combination of the above factors resulted in
the observed protective effect of MIR2 expression against
NK cell-specific lysis of target cells.
Our method of modifying cell surface molecules has
other benefits with respect to the alloimmune response.
Differential downregulation of MHCI molecules by MIR2
implies that there is a significant reduction of some classes
of MHCI molecules; it does not, however, remove all
MHCI molecules from being expressed. The relatively
unaltered expression of HLA-C and other non-classical
MHCI molecules, such as HLA-E, not only serves to
inhibit NK cell-mediated cytotoxicity but might also serve
to induce active host tolerance to the allograft. Many
studies have previously shown that some expression of
the immunoantigen is beneficial to maintaining active
tolerance. A study by Faustman et al. (1991) showed
that incomplete masking of MHCI molecules using
antibodies can potentially lead to tolerance in murine
hosts. This study indicates that donor MHC density was
important in inducing tolerance. Hence, our differential
downregulation approach to MHCI modulation may
effectively create a greater window of opportunity for
the induction of systemic tolerance.
In summary, donor antigen modification using viral
immunomodulatory strategies to evade the immune
response against allogeneic cells represents a new
paradigm in the field of tissue engineering. This method
of selective immunosuppression may also pave the way to
generating universal donor cells. An immediate advantage
of universal donor cells in tissue engineering is that they
would enable the development of off-the-shelf technology,
which could function immediately in any individual. Fur-
thermore, this technology would provide an alternative
to isogenic stem cell technology, which is often labori-
ous and requires time to create, differentiate and expand
isogenic stem cells for applications in tissue engineering.
We believe that viral strategies of immune evasion can be
successfully employed to extend the life of a cell-based
tissue-engineered construct in an allogeneic host.
5. Conclusion
Expressing a viral immunomodulatory protein, MIR2, in
a model human cell line differentially downregulated cell
surface levels of MHCI, ICAM-1 and CD86 molecules,
which simultaneously resulted in the evasion of acute
cellular rejection mediated by allogeneic CTLs without
altering NK cell-mediated cytotoxicity. This strategy
immediately provides a method for the creation of
universal donor cells that could be transplanted into any
allogeneic individual.
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Suppression of the MHC Class I-Mediated Alloimmune 
Response in Human Cells Using a Single-Step Retroviral 
Transduction Protocol to Express KSHV’s Stealth Protein MIR2 
Abstract
The host immune response is a significant barrier 
to allogeneic transplantation, and this problem af-
fects almost all types of cell-based, tissue-engineered 
constructs. In this paper, we test whether a single 
dose of a retroviral vector is sufficient to transduce 
a population of human cells to express viral immu-
nomodulatory proteins to suppress the acute cellu-
lar alloimmune response in vitro. We overexpressed 
Kaposi’s Sarcoma-Associated Herpes Virus (KSHV) 
modulator of immune recognition (MIR2) protein 
in human monocyte-like progenitor cells (U937) us-
ing the moloney murine leukemia virus (MMLV) to 
transduce cells in a single transduction step, with-
out any cell selection or amplification. We used 
fluorescence microscopy and flow cytometry to 
characterize the heterogeneously transduced MIR2-
expressing U937 cells and found that approximately 
80% differentially downregulated cell surface levels 
of Major Histocompatibility Class I (MHCI) and 
ICAM-1 molecules, which resulted in a significant 
(30%) reduction in cytotoxic T-lymphocyte (CTL)-
mediated killing of target cells, without altering 
natural killer (NK)-mediated target cell lysis in vitro. 
Our results provide a proof-of-principle that the use 
of viral immunomodulatory mechanisms in a single-
step transduction approach can significantly mini-
mize the acute cellular alloimmune response medi-
ated via CTLs and NK cells. We propose a single-step 
ex vivo gene delivery strategy using retroviral vectors 
that can potentially be implemented in donor or-
gans, tissues and cell-based tissue engineered con-
structs to extend the life of allogeneic cells in vivo. Corresponding Author:
Ajit Thakur, Institute of Biomaterials and Biomedical Engineering
Email: thakurajit@gmail.com
Introduction
Diabetes, chronic renal failure, ischemic heart disease, end-stage liver disease and many others are all incur-able diseases with a known solution: organ transplan-
tation. However, transplanted organs or grafts from a human 
donor (allogenic transplants) have a limited life-span in the 
recipient due to the immune response against the foreign 
cells. Immunosuppressive drugs provide a short-term solution 
(80-95% 1-year graft survival) in cardiac, renal, lung, liver and 
pancreatic transplantation.1 However, immunosuppression is a 
systemic approach that suppresses the body’s immune system, 
therefore rendering the individual susceptible to opportunis-
tic infections. Moreover, long-term immunosuppressive drug 
therapy is associated with the risk of severe side effects, such as 
cytotoxicity, hypertension and cardiovascular disease.1 
In addition to the potential for graft rejection, significant 
organ-donor shortages represent a major challenge for the 
wide spread implementation of organ transplantation as a solu-
tion for numerous diseases. The extensive list of requirements 
for ensuring compatibility between the donor and recipient 
further reduces the total number of organs available for trans-
plantation. Fortunately, the field of tissue engineering offers 
many potential solutions to these medical challenges. Tissue 
engineered constructs can be used as a biological substitute in 
almost any tissue in the body; hence, their structure and com-
position can be specifically tailored to the application. How-
ever, implantation of cell-based tissue-engineered constructs 
must overcome the same fundamental challenge surrounding 
all allogeneic cell, tissue and organ transplantation: immune 
rejection. 
The immune response to allogeneic grafts involves compo-
nents of both the innate and adaptive immune system. How-
ever, the T-cell response of the adaptive immune system is con-
sidered to be the most important determinant of acute cellular 
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rejection.2,3 The T-cell response occurs due to the recognition 
of ‘non-self’ alloantigens present on the allograft. Experiments 
by George Snell and colleagues identified the Major Histocom-
patibility Complex (MHC) as the locus of polymorphic genes, 
which code for the targets of allograft recognition.4,5 Since 
Major Histocompatibility Complex Class I (MHCI) molecules 
are expressed on all nucleated cells, they can be recognized by 
alloreactive T cells and evoke immune responses in virtually 
all tissue types. This response typically leads to the activation 
of alloreactive CD8+ T cells, which proliferate and differenti-
ate into effector cells known as CD8+ cytotoxic T lymphocytes 
(CTLs). These CTLs have potent cytolytic activity and specifi-
cally target and eliminate allogeneic cells.2 Hence, the MHCI 
recognition capability of T cells responding to the allograft is 
the most significant event leading to acute cellular rejection.
Recognizing this important aspect of immune rejection, 
many previous studies have attempted numerous techniques 
to reduce MHCI expression.6,7 However, a global reduction of 
MHCI molecules has been shown to increase the susceptibil-
ity of cells to natural killer (NK) cells of the innate immune 
system.6 Cell surface MHCI acts as a ligand for NK cells and 
provides an inhibitory signal and decreases their cytolytic activ-
ity against allogeneic cells. In humans, many of the Class I al-
leles, including HLA-B and HLA-C loci, are recognized by NK 
cell inhibitory receptors.2 In the absence of MHCI molecules, 
NK cells are activated by ubiquitously expressed allogeneic cell 
surface ligands, such as MICA, MICB and AICL.8,9 This results 
in the specific lysis of cells lacking MHCI molecules. Therefore, 
it is clear that a general downregulation of MHCI molecules is 
unlikely to significantly protect allogeneic cells from the im-
mune response, and that a more elegant method is required.   
The immune response is arguably the most significant barri-
er to allogeneic transplantation and this problem affects almost 
all types of cell-based, tissue-engineered constructs. Hence, it is 
imperative that such tissue-engineered constructs address this 
important challenge. In preparing a tissue-engineered con-
struct, the cells required are sourced in advance. This provides 
the opportunity to use genetic engineering techniques to ma-
nipulate these cells in a fashion that may allow them to evade or 
suppress the immune response. Viruses have evolved complex 
genetic mechanisms to evade and suppress detection by the 
immune responses of the host. A tissue-engineered allogeneic 
construct with genetically engineered cells that utilizes these 
viral immune evasion mechanisms might potentially elicit a 
similar response and not be recognized by the host immune 
system as ‘foreign,’ thus preventing rejection. Previous work by 
our group has shown that clonally selected subpopulations of 
allogeneic cells employing viral immune evasion mechanisms 
can indeed suppress the alloimmune response against CTLs 
and NK cells.7 However, our approach involved multiple steps 
post-transduction, including clonal cell expansion, character-
ization and selection, which required several weeks to imple-
ment.7 Given that organs and tissues harvested from human 
donors have an extremely limited shelf-life, an alternative, ac-
celerated approach is required to make our immune evasion 
strategy more applicable to the clinical transplantation of or-
gans, tissues and cell-based, tissue-engineered constructs.
In this paper, we examine the feasibility of applying viral 
immune evasion mechanisms to genetically engineer cells in a 
single-step transduction method, without cell expansion or se-
lection, to suppress the immune rejection of allogeneic model 
human progenitor cells (U937). In summary, we genetically 
engineered allogeneic cells using a single dose of a retroviral 
vector moloney murine leukemia virus (MMLV) to express 
an immunomodulatory protein called modulator of immune 
recognition (MIR2) from Kaposi’s Sarcoma-Associated Herpes 
Virus (KSHV). This multifunctional protein is known to dif-
ferentially downregulate the cell surface expression of MHCI, 
ICAM-1 and other molecules.7 In addition, MIR2 also decreas-
es the expression of NK cell activation ligands (MICA, MICB), 
which are ubiquitously present on most cell types. We tested 
the effectiveness of using a single dose of retroviral vector to 
transduce allogeneic cells with MIR2 before challenging them 
against CTLs and NK cells. The immunoprotective effect of 
MIR2 expression against allogeneic CTLs and NK cells was test-
ed using an in vitro cytotoxicity assay in conjunction with flow 
cytometry. Our results provide a proof-of-principle that this 
single-step method of employing viral immune evasion strate-
gies can potentially be applied in the clinical transplantation 
of organs, tissues and cell-based, tissue-engineered constructs 
to delay or even prevent acute cellular immune rejection upon 
implantation into an allogeneic host.
 
Materials and Methods
Cell Line and Cell Culture
The histiocytic lymphoma-derived immortalized monocyte-
like myeloid progenitor human cell line (U937) was gener-
ously provided by Dr. Karen Mossman at the Centre for Gene 
Therapeutics, McMaster University, Hamilton, ON. Human 
U937 cells were cultured using standard culture conditions as 
described previously.10 
Retroviral Vector Construction and Transduction
In order to make the viral vector carrying the MIR2 gene, 
Stratagene’s Viraport™ retroviral gene expression system was 
employed. The MIR2-GFP fusion protein cDNA was a gift from 
Dr. Laurent Coscoy (University of California, Berkeley). Viral 
particles were generated according to the manufacturer’s in-
structions (Stratagene’s Viraport™). After transducing U937 
cells, they were cultured in non-selective media to maintain the 
composition of the MIR2-GFP-expressing heterologous popu-
lation (hereby referred to as U937-MIR2-GFP). This procedure 
was repeated to generate viral particles carrying the LacZ gene, 
which were subsequently used to generate U937 cells express-
ing -galactosidase enzyme. This cell line (hereby referred to 
as U937-LacZ) served as a control for comparison with U937-
MIR2-GFP.
     
Fluorescence Microscopy
All transmission light images were collected using an Axio-
vert 200 (Carl Zeiss MicroImaging, Inc., Germany) inverted 
fluorescence microscope. Images were acquired using AxioVi-
sion 3.1 (Carl Zeiss Vision, USA) software and processed with 
Adobe Photoshop.  Fluorescence images were collected using 
the aforementioned setup as well as with a Leica DM IRE2 in-
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verted fluorescence microscope system (Leica) in conjunction 
with Openlab imaging software (IMPROVISION).
 
Flow Cytometry
Cells were stained with fluorescently-labelled antibodies 
specific to cell surface markers of interest. A Beckman Coul-
ter FC500 system (Beckman Coulter Canada Inc., Mississauga, 
ON, Canada) was used to analyse the cells with the CXP soft-
ware provided. Data was analyzed as described previously.7,10 
The Student’s t-test was used to determine statistical signifi-
cance (p<0.05). 
CTL Assay
The CTL assay was used to measure the ability of target 
cells, such as U937-MIR2-GFP, to evade cytolysis by effector 
cells (CTLs) compared to control cells (U937-LacZ). In set-
ting up this assay, effector cells had to be isolated and differ-
entiated from human blood acquired from healthy graduate 
student volunteers. First, peripheral blood mononuclear cells 
(PBMCs) were isolated from fresh, whole blood by exposing 
RBCs to hypotonic ammonium-chloride (ACK) solution. Sec-
ond, the Human CD8+ T Cell Enrichment Kit (StemCell Tech-
nologies) was used to isolate CD8+ T cells from PBMCs. Third, 
these negatively isolated CD8+ T cells were stimulated with allo-
geneic ‘stimulator’ cells (U937-LacZ) in vitro to generate CTLs. 
Fourth, appropriate Effector (CTLs): Target (U937-MIR2-GFP 
or U937-LacZ) ratios were determined (2:1 and 10:1 respec-
tively) and the number of cells required was calculated. The 
target cell number was held constant, while the effector cell 
number was varied according to the predetermined ratios. In 
setting up the CTL assay, a sufficient number of target cells 
were labelled with 100 nM Calcein-AM (Invitrogen), which is 
a live cell fluorescent stain. After incubating the co-culture for 
4h at 37 °C (humidified, 5% CO2), 7-AAD (Beckman Coulter) 
was added to each well. Fifth, flow cytometry data analysis was 
based on the labelling intensity of the target cells with Calcein 
and 7-AAD. The percentage of specifically killed cells was calcu-
lated from the double-labelling of target cells with Calcein and 
7-AAD, and comparing this with background target cell death 
in control wells.10
NK Assay
The NK assay was used to measure the ability of target cells 
(U937-MIR2-GFP) to evade cytolysis by effector cells (NK cells) 
compared to control cells (U937-LacZ). In setting up this as-
say, effector cells had to be isolated and activated from human 
blood. First, PBMCs were isolated from fresh, whole blood as 
described in the CTL assay. Second, the Human CD56 Selec-
tion Kit (StemCell Technologies) was used to positively isolate 
NK cells. Third, NK cells were activated with 10 μg/ml Poly I:C 
(Sigma) and 50 U/ml rh IL-2 (Invitrogen) to enhance their 
cytolytic ability. Fourth, appropriate Effector (NK cells): Target 
(U937-MIR2-GFP or U937-LacZ) ratios were determined (0.1:1 
and 0.25:1) and the number of cells required was calculated. 
The NK assay was setup in a manner similar to the CTL assay. 
All studies were performed in accordance with the Research 
Ethics Board at McMaster University and blood collection was 
done by a licensed phlebotomist.
Results
Retrovirus can Efficiently Transduce Human U937 Cells 
with LacZ
The MMLV used in this study was pseudotyped, such that it 
expressed the vesicular stomatitis virus G (VSV-G) coat, which 
is known to have a broad specificity to almost any mitotic cell. 
In order to confirm that this VSV-G pseudotyped retrovirus 
was able to transduce U937 cells, a test transduction was setup. 
Retrovirus carrying the LacZ gene was generated and used to 
transduce U937 cells as described in the Materials and Methods 
section. Figure 1 shows blue staining of -galactosidase express-
ing cells, indicating that U937 cells were indeed transducible 
by VSV-G pseudotyped MMLV. The single dose transduction ef-
ficiency varied from 40-70% depending on the conditions. As a 
result, the transduction produced a heterogeneous population 
of cells with varying levels of -galactosidase-expressing cells. 
This population of cells was subsequently used as a transduc-
tion control to compare with U937-MIR2-GFP cells. 
Figure 1. Transduction of U937 cells using MMLV. Image shows 
-galactosidase staining (blue cells) of U937 cells, indicating that these 
cells are clearly transducible by retrovirus (MMLV).
After establishing the transducibility of U937 cells, MMLV 
carrying the MIR2-GFP gene was generated and used in sub-
sequent transductions. Figure 2 shows a strong GFP signal in 
transduced U937 cells, indicating the likely expression of the 
chimeric MIR2-GFP fusion protein. The single dose trans-
duction efficiency varied from 50%-80% depending on the 
conditions. In addition, the transduction produced a hetero-
geneous population of cells with varying levels of MIR2-GFP 
expressing cells, similar to the LacZ transduction.
Figure 2. MIR2-GFP expression in U937 cells after MMLV transduction. 
U937 cells express MIR2-GFP (green) after transduction with retrovirus. 
Images collected in transmission (A) and fluorescence (B) channels. 
Image C overlays the two channels. 
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MIR2-GFP expression downregulates cell surface HLA-
ABC and ICAM-1 
The expression of MIR2-GFP in U937 cells is expected to 
alter the cell surface expression of important immunoactive 
molecules such as HLA-ABC and ICAM-1 (CD54). In Figure 
3, the top panel depicts the normal distribution in the expres-
sion level of HLA-ABC and ICAM-1 in a heterologous popula-
tion of U937-LacZ cells. In contrast, the bottom panel shows 
that cell surface ICAM-1 is strongly downregulated, while 
HLA-ABC is moderately downregulated in U937-MIR2-GFP 
cells. The detection of GFP in only U937-MIR2-GFP cells con-
firmed that these cells were likely expressing the MIR2-GFP 
fusion protein, which produced the observed effects. Upon 
further analysis (via the CXP software) of the transduced cells 
expressing GFP, it was also noted that approximately 80% of 
live cells in the heterologous culture significantly downregu-
lated both cell surface HLA-ABC and ICAM-1. Only a small 
proportion (~10%) of the heterologous culture of trans-
duced cells expressed GFP without downregulating both cell 
surface HLA-ABC and ICAM-1. The remaining 5-10% of the 
heterologous culture did not express GFP and did not down-
regulate cell surface HLA-ABC or ICAM-1.
Figure 3. Cell-surface characterization of U937-LacZ and U937-MIR2-
GFP cells. This plot compares the relative amount of GFP, HLA-ABC 
and ICAM-1 (CD54) detected in each of the cell lines. GFP was quanti-
fied by its fluorescence, while fluorescently labelled antibodies were 
used to quantify the other markers. Flow cytometry data presented 
from 30,000 events collected per trial (n=3).
MIR2-GFP expression decreases CTL-induced specific 
cell death of U937 cells
The CTL assay determined the specific cell death of target 
cells transduced with MIR2 at two different Effector:Target 
(E:T) ratios (Figure 4). Specifically, at the 2:1 E:T ratio, there 
was a 30% reduction in the specific lysis of MIR2 cells. How-
ever, the protection conferred by MIR2 at the 10:1 E:T ratio 
was not significant. The control samples did not contain any 
effector cells and indicate the background levels of target cell 
death.
 
Figure 4. CTL Assay. Shows percent specific lysis of Calcein-labelled 
target cells (U937-LacZ [white bars] or U937-MIR2-GFP [black bars] 
cells) in control samples and test samples with varying Effector:Target 
ratios. (Statistics: p<0.05 between cell lines for 2:1 Effector:Target ra-
tio; error bars indicate standard deviation; n=3).
MIR2-GFP expression does not alter NK-induced spe-
cific cell death of U937 cells
The NK assay showed no statistically significant difference 
in the specific cell death of target cells transduced with MIR2-
GFP when compared to target cells transduced with LacZ at 
both E:T ratios (Figure 5). Moreover, it was noted that the 
increase in the specific cell death of target cells was associated 
with an increase in the E:T ratio. The control samples did not 
contain any effector cells and indicate the background levels 
of target cell death.
 
Figure 5. NK Assay. Shows percent specific lysis of Calcein-labelled 
target cells (U937-LacZ [white bars] or U937-MIR2-GFP [black bars] 
cells) in control samples and test samples with varying Effector:Target 
ratios. (Statistics: no significant difference (p>0.05) between cell 
lines; error bars indicate standard deviation; n=3).
 
Discussion
In tissue engineering, the immune response to allogeneic 
cells is a major barrier impeding successful transplantation 
of tissue-engineered constructs. Previous work by our group 
has demonstrated that clonally expanded allogeneic cells 
employing viral immune evasion strategies can significantly 
suppress the acute cellular alloimmune response mediated by 
CTLs and NK cells.7 However, this approach required mul-
tiple steps and several weeks of cell expansion, characteriza-
tion and selection before it could be implemented. In this 
paper, we test an alternative method to engineer immune ac-
ceptance, such that allogeneic cells are modified in a single 
step to employ viral strategies to suppress the acute cellular 
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alloimmune response. 
In our approach, we used a retroviral vector to deliver the 
MIR2-GFP chimeric viral gene to allogeneic cells in vitro. Our 
results show that a single dose of VSV-G pseudotyped MMLV 
is sufficient to transduce model human progenitor cells 
(U937 cells) and express the LacZ gene or the MIR2-GFP chi-
meric viral gene at a moderate transduction efficiency (40%-
80%) without the need for any cell expansion or selection 
before transplantation (Figures 1, 2). Furthermore, cell sur-
face characterization of MHCI and ICAM-1 expression con-
firmed that the levels of transduction efficiency achieved by 
a single dose of retroviral vector significantly (>90% decrease 
in mean fluorescence intensity) downregulated both MHCI 
and ICAM-1 in approximately 80% of the heterologous popu-
lation of transduced cells (Figure 3). However, approximately 
10% of the heterologous population of cells expressed GFP 
without downregulation of MHCI and ICAM-1. This effect is 
likely due to the insertional rearrangement of the transduced 
gene, which has been previously reported.2,6 In addition, Fig-
ure 3 suggests that this single-step transduction approach pro-
duced a heterogeneous expression of MIR2-GFP among the 
transduced cells. This effect is likely due to the varying trans-
gene copy-number in each transduced cell in the heterolo-
gous population and simulates the effect that is expected to 
occur during the transplantation of tissues which have been 
modified by retroviral vectors. It follows that our approach 
provides a more realistic measure of the effectiveness of this 
retroviral vector’s ability to transduce cells and tissues for 
transplantation between donor and recipient. In contrast to 
the present study, our previous work clonally expanded and 
selected subpopulations of transduced cells with the desired 
MIR2 expression level for enhanced suppression of the acute 
cellular alloimmune response mediated by CTLs and NK 
cells.7 Thus, our current study not only confirms the results 
of our previous work with amplified subpopulations of stably 
transduced MIR2-expressing cells, it also demonstrates the ef-
fectiveness of our retroviral gene-delivery approach over the 
short term, after a single-step transduction, without involving 
any cell expansion or selection.  
The results of the CTL assay suggest that MIR2-GFP ex-
pression in a heterologous population of cells confers a sig-
nificant (30%) protective effect against allogeneic CTLs at 
certain E:T ratios (Figure 4). It is also instructive to note that 
this statistically significant (p<0.05) decrease in CTL-specific 
cell lysis was measured in a heterologous population of trans-
duced cells, with approximately 20% of cells not downregu-
lating either MHCI or ICAM-1, and with widely varying levels 
of transgene expression (Figure 3). We have previously ob-
served CTL-specific cell lysis suppression in a heterologous 
culture of transduced cells ranging from 20-50%, depending 
on the transduction protocols employed (unpublished data). 
It follows that the suppression of the acute cellular alloim-
mune response can be significantly enhanced by optimizing 
transduction protocols and therefore improving the single-
step transduction efficiency. Furthermore, the MIR2-medi-
ated decrease in HLA-ABC (MHCI) and ICAM-1 levels are 
likely to have synergistically contributed to the decrease in 
CTL-mediated killing of target cells. Since CD8+ CTLs rec-
ognize MHCI and adhere to target cells using ICAM-1, it is 
expected that any decrease in the cell-surface expression of 
these molecule hinders the target recognition and binding 
capability of CTLs. This effect likely contributes to the ob-
served immune evasion of MIR2-expressing target cells. It is 
interesting to note that there was no protective effect at high 
E:T ratios. This suggests that there likely exists an upper limit 
for the protective effects of MIR2, which can be abrogated 
by significantly increasing the E:T ratio. However, E:T ratios 
above 10:1 are relatively high and may not be encountered by 
transplanted allogeneic cells in vivo. 
In the NK assay, no significant difference in specific cell 
death was observed between U937-MIR2-GFP cells and U937-
LacZ cells (Figure 5). Natural killer cell cytolytic activity is in-
versely proportional to the amount of MHCI present on the 
cell surface.6,7 As the MHCI levels decrease on the cell surface, 
a greater percentage of the target cells should be specifically 
killed by NK cells. In this experiment, U937 cells expressing 
MIR2 were shown to downregulate MHCI and ICAM-1 mol-
ecules, without increasing NK-mediated specific cell death of 
target cells in comparison to controls. Therefore, our results 
suggest that MIR2 expression confers a significant protective 
effect against NK specific cell death. A number of factors may 
have contributed to this observed protective effect, including 
the reduction of ICAM-1, which is involved in NK cell adher-
ence to target cells, and the MIR2-mediated downregulation 
of other U937 cell surface molecules, such as MICA, MICB 
and AICL that are involved in NK cell activation.11,12 
Our method of modifying cell surface molecules may 
also serve to increase the chances of inducing systemic tol-
erance against the allograft. Many studies have previously 
demonstrated that some expression of the immunoantigen is 
beneficial to maintaining active tolerance.6,13 For example, a 
study by Faustman and Coe showed that incomplete masking 
of MHCI molecules using antibodies can potentially lead to 
tolerance in murine hosts, indicating that donor MHC den-
sity was important in inducing tolerance.13 Given these obser-
vations, the expression of MIR2 in our present study might 
have the potential to induce a similar tolerance effect against 
allogeneic cells in vivo. MIR2 differentially downregulates 
MHCI molecules such that it significantly reduces cell surface 
expression of only some classes of MHCI molecules (HLA-A, 
HLA-B), without affecting other MHCI molecules (HLA-C, 
HLA-E). 7 The almost unabated expression of HLA-C and oth-
er non-classical MHCI molecules like HLA-E not only serve 
to inhibit NK cell-mediated cytotoxicity, but may also serve 
to induce active host tolerance to the allograft. Hence, our 
differential downregulation approach to MHCI modulation 
may effectively create a greater window of opportunity for the 
induction of systemic tolerance.
The results of our present study suggest that this immune 
evasion strategy can potentially be applied in the clinical 
transplantation of organs, tissues and cell-based tissue engi-
neering, since it can be effectively implemented in a single 
step without delay and provides an alternative to using sys-
temic immunosuppressive drugs. Moreover, this method to 
selectively modify donor antigens may also pave the way to 
generating ‘universal’ donor cells. An immediate advantage 
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of universal donor cells in tissue engineering is that it en-
ables the development of “off-the-shelf” technology, which 
can function immediately in any individual. Previous work 
by our group demonstrated that MIR2-expressing cells can 
maintain their immunoprotective effects against CTLs and 
NK cells over the long term, making this technique suitable 
for allogeneic cell-based product development.7 Given that 
we employed model human progenitor cells (U937 cells) 
that mimic the gene expression profile of stem-cell derived 
cells commonly used in tissue engineering,14,15 the results of 
our present study also suggest that our proposed strategy may 
provide an alternative to isogenic stem cell technology, which 
is often laborious and requires time to create, differentiate 
and expand isogenic stem cells for applications in tissue en-
gineering. It follows that this technology will enhance the 
development of semi-synthetic organs and therefore improve 
the availability of transplantable organs to better match de-
mand, which would significantly decrease the cost and delays 
incurred with current medical procedures involving donor 
organs.
Conclusion
We characterized the effect of a single-step retroviral MIR2 
transduction on the cell surface expression of MHCI and 
ICAM-1 molecules and assessed their ability to evade CTLs 
and NK cells, without MIR2-transduced cell expansion or 
selection. Flow cytometry analysis of the heterogeneously 
transduced cells showed that MHCI and ICAM-1 molecules 
were significantly downregulated in approximately 80% of 
the cells. Our results demonstrate that heterogeneous MIR2 
expression in a heterologous culture confers a significant 
(30%) immunoprotective effect to allogeneic human U937 
cells against CTLs, without altering their susceptibility to 
NK-mediated specific cell death in vitro. These results sug-
gest that our single-step method of employing viral immune 
evasion strategies can potentially be applied in the clinical 
transplantation of donor organs, tissues and cell-based tissue 
engineered constructs, which are currently limited by their 
short shelf-life. It is expected that the observed suppression 
of the acute cellular alloimmune response mediated by MIR2 
expression may significantly delay or even prevent immune 
rejection upon implantation into an allogeneic host.
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SUMMARY
Hemicorporectomy, or translumbar amputation, is a 
radical surgery involving the dissection of the body at 
the waist and is usually reserved for complex medical 
conditions including locally invasive malignancy and 
terminal pelvic osteomyelitis. Only 71 cases have 
previously been reported. We present a rare case of 
hemicorporectomy in a 53-year-old patient with terminal 
pelvic osteomyelitis which occurred after he suffered 
a gunshot wound at T6 causing paraplegia at the age 
of 31. Unfortunately, this patient continued to suffer 
recurrent hospitalisations and sepsis events secondary 
to chronic, non-healing advanced pressure ulcers and 
complicated urinary tract infections despite repeated 
courses of broad-spectrum intravenous antibiotics and 
surgical debridements. In light of his diminished quality 
of life and poor prognosis, the patient’s family chose to 
manage his condition conservatively with home hospice. 
This case illustrates the significant challenges in the 
medical and surgical management of hemicorporectomy 
patients.
BACKGROUND
Hemicorporectomy, or translumbar amputation, is 
a radical surgery involving dissection of the body at 
the waist (commonly between L4 and L5). It entails 
removal of the legs, genitalia, bladder, pelvic bones, 
anus and rectum, and is commonly performed in 
two stages, with a colostomy and ileal conduit being 
created during the first operation and the actual 
hemicorporectomy being done during the second 
operation. The first ever hemicorporectomy was 
performed in 1950, and as of 2017 a total of only 
71 cases have been reported.1 2 
The original indication for hemicorporectomy 
was locally invasive malignancy of the pelvis for 
which chemotherapy, radiotherapy or conventional 
surgeries were not beneficial or possible. In recent 
years, it has been performed for other indications, 
including terminal pelvic osteomyelitis, squamous 
cell carcinoma (SCC) in a pressure ulcer, pelvic 
chondrosarcoma, severe pelvic trauma, vascular 
malformations, and in one case gangrene secondary 
to acute aortic occlusion.3 Of the 71 reported cases 
of hemicorporectomy performed, 21 (30%) cases 
have been reported for terminal pelvic osteomy-
elitis, 43 (60%) cases for malignancy (13 cases 
were SCC arising from pressure ulcers), 4 cases for 
benign disease and 3 cases for trauma. Outcomes 
are generally more favourable for non-malignant 
versus malignant indications.4 For terminal pelvic 
osteomyelitis, more than 50% of patients survived 
at least 9 years, with an average survival of 11 years 
posthemicorporectomy.5 The average survival post-
procedure decreases to 2.9 years when malignancy 
is the indication for hemicorporectomy.5 Overall, 
one-third of patients survived at least 9 years after 
hemicorporectomy.5
Although published reports suggest prolonged 
survival (>50% survival for terminal pelvic osteo-
myelitis at 9 years) posthemicorporectomy, this 
does not take into account the quality of life and 
morbidity of patients.5 In the postoperative period, 
complications of hemicorporectomy include volume 
overload, wound dehiscence and delayed healing.5 
Some of the first patients to undergo this procedure 
died of pulmonary hypertension.6 For patients with 
long-term survival, other factors to consider include 
decreased body mass and circulating blood volume, 
as well as loss of muscle mass, which is thought to 
affect fluid, acid-base, electrolyte balance and drug 
dosing.7 Moreover, the radical nature of a hemi-
corporectomy severely distorts the body anatomy 
and may introduce new problems such as faecal 
and urine drainage from ostomy sites into depen-
dent areas, with chronic non-healing pressure ulcers 
causing infections and complicated urinary tract 
infections (UTIs) resulting in repeated sepsis events 
requiring multiple hospitalisations. Furthermore, it 
has also been reported that the loss of body surface 
area also affects heat dissipation and tempera-
ture regulation.8 Taken together, these factors can 
potentially diminish the quality of life and increase 
the morbidity of hemicorporectomy patients, which 
calls into question the best way to manage the 
complications of hemicorporectomy patients and 
provide comprehensive care in the inpatient and 
outpatient settings.
CASE PRESENTATION
Here, we present a 53-year-old African–American 
man who underwent a hemicorporectomy at the 
level of L2 (at age 49) after a series of surgical proce-
dures for terminal pelvic osteomyelitis, chronic 
advanced pressure ulcers and chronic complicated 
UTIs, which occurred after a gunshot wound at T6 
causing paraplegia at the age of 31 (box 1, figure 1). 
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Figure 1 Hemicorporectomy patient showing (A) urostomy with ileal 
conduit and (B) ileostomy.
Rare disease
His medical and surgical history was significant for hemicorpo-
rectomy with colectomy, splenectomy and creation of ileostomy 
and urostomy with ileal loop, multiple infected posterior and 
inferior thoracic pressure ulcers of all stages status post multiple 
debridements, terminal pelvic osteomyelitis, recurrent multi-
drug-resistant complicated UTIs with sepsis, methicillin-resis-
tant Staphylococcus aureus (MRSA) and vancomycin-resistant 
Enterococcus (VRE) bacteraemia with sepsis, hypertension, 
anaemia of chronic disease, chronic kidney disease (CKD), 
gastritis, oesophagitis, and pulmonary embolism. He presented 
to the Sinai-Grace Hospital Emergency Department with fever 
(reported by caregiver to be >39°C at home) and altered mental 
status. On admission, he was found to be hypotensive (systolic 
blood pressure ~82 mm Hg), with leukocytosis (white blood 
count (WBC) 14.1 x10^9/L with neutrophilic predominance 
and bands of 1.6 x10^9/L) and acute kidney injury on CKD 
(creatinine 1.36), and was diagnosed with severe sepsis likely 
secondary to an infected advanced chronic non-healing posterior 
thoracic pressure ulcer and a possible complicated UTI. He was 
intubated and mechanically ventilated in the medical intensive 
care unit (MICU) for airway protection due to his altered mental 
status (alert and oriented ×0). He was initiated on empiric anti-
biotics including intravenous cefepime and clindamycin, along 
with fluid resuscitation. Infectious disease was consulted for 
antibiotics management due to the patient’s history of multi-
drug-resistant organisms (MDROs). However, blood cultures 
remained negative during this admission. Urinalysis was posi-
tive for nitrite and leukocyte esterase, with >100/high power 
field (HPF)urine WBCs. Lactic acid was 1.7 on admission. Urine 
culture grew >100 000 colony-forming units/mL with multiple 
organisms present.
The patient’s mentation improved (alert and oriented ×3), 
and he was subsequently extubated on admission day 1. General 
surgery was consulted for surgical debridement of his extensive, 
advanced posterior thoracic pressure ulcer spanning 50 cm × 
50 cm at various stages (1–4) of healing (figure 2). All necrotic 
tissue was excised to obtain viable bleeding tissue and haemo-
stasis was achieved. Appropriate postoperative wound care was 
initiated with daily dressing changes with wet-to-dry dressings, 
soft care mattress, every 2-hour turns and adequate pain control. 
His ileostomy bag was replaced to ensure a proper seal to 
prevent faecal drainage into his posterior thoracic pressure ulcer. 
In addition, nutrition was consulted to optimise his nutritional 
intake to support wound healing. Antibiotics were continued for 
7 days as per infectious disease recommendations. Our patient 
was discharged home on admission day 7. He lived with his 
sister, who was his caregiver and power of attorney. Appropriate 
postdischarge wound care was initiated with home healthcare 
services for daily dressing changes, nursing care for ileostomy 
and urostomy changes, and home physical therapy. In addition, 
follow-up with the wound care clinic was arranged.
INVESTIGATIONS
See the Case presentation section.
TREATMENT
See the Case presentation section.
OUTCOME AND FOLLOW-UP
Our patient was readmitted 3 weeks later for another episode of 
sepsis with altered mental status. He was appropriately treated 
and recovered to his baseline. Psychiatry was consulted, and it 
was determined that he was not competent to make decisions 
Box 1 Timeline of significant medical and surgical events
  1994: initially became paraplegic secondary to a gunshot 
wound at T6.
  July 2006: elective transverse loop colostomy with 
subsequent excision and creation of ileostomy.
  November 2007: right hip disarticulation and amputation due 
to right femoral head osteomyelitis.
  December 2007: stage 4 sacral pressure ulcer, left second toe 
osteomyelitis.
  January 2008: recurrent urinary tract infections (UTIs) 
secondary to indwelling Foley catheter.
  February 2008: suprapubic catheter placed secondary to 
paraphimosis and erosion of the urethral meatus secondary 
to the indwelling Foley catheter.
  April 2008: sepsis secondary to penile shaft necrosis 
and penile ulcers; suprapubic catheter malfunction, with 
subsequent sepsis secondary to UTI from urocutaneous 
fistula.
  December 2009: ileovesicostomy using ileum as a loop and 
primary bowel anastomosis.
  2011/2012: urosepsis, stage 4 chronic sacral pressure ulcer 
debridement, septic left hip and sacral bone biopsy consistent 
with osteomyelitis.
  April 2012: multiple left lower extremity pressure ulcers with 
necrotic left toes; subsequent left hip disarticulation and 
translumbar amputation at L2 leading to his current state: 
hemicorporectomy.
  September 2012: enlargement of bilateral back and hip 
pressure ulcers; excisional debridement.
  November 2013: revision of colostomy due to prolapse; 
cystectomy and excision of ileovesicostomy; ileal conduit 
urinary diversion and bilateral ureteral stent placement.
  January 2016: prolapsed ileal loop, requiring revised ostomy.
  September 2016: sepsis due to large chronic back pressure 
ulcer—50×50 cm, grades 1–4.
  October 2016: patient dies in hospice care: sepsis secondary 
to advanced pressure ulcers.
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Figure 2 Evolution of pressure ulcers. (A) September 2011: stage 4 sacral pressure ulcer 7×9.5×2.8 cm, (B) January 2013: stage 3 left thorax 
pressure ulcer 31.5×11×0.1 cm, and (C) September 2016: stages 1–4 posterior thorax pressure ulcer 50×50 cm.
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regarding his medical care. In light of the fact that this patient 
had been admitted to the hospital on average 10 times/year in 
recent years, with 11 admissions over the last year alone, palli-
ative care was consulted to assess patient and family wishes and 
determine goals of care. After an extensive discussion with the 
patient and his family regarding his diminished quality of life 
and poor prognosis, his sister, the durable power of attorney, 
decided that it was best for him to enrol in home hospice, with a 
focus on comfort care. The patient was subsequently admitted to 
inpatient palliative care 2 weeks later with altered mental status. 
He subsequently died during this admission in palliative care.
This case highlights the significant medical, surgical, financial 
and social challenges faced by the families, their caregivers and 
medical professionals involved in the care of hemicorporectomy 
patients.
DISCUSSION
Here we present a case report of a 53-year-old African–American 
man who suffered a gunshot wound at T6 causing paraplegia at 
the age of 31 and subsequently underwent a hemicorporectomy 
at the level of L2 at the age of 49 for terminal pelvic osteomyelitis 
in a series of body-preserving surgical procedures over a period 
of 5 years (box 1). This radical surgical procedure prolonged his 
life, but arguably did not reduce his morbidity and significantly 
distorted his body anatomy, which presented unique challenges 
in his medical care. The close proximity of his anterior thoracic 
urostomy and ileostomy to each other and to his pressure ulcer 
frequently lead to stool and urine draining into his chronic pres-
sure ulcer located on his posterior and inferior thorax during 
ileostomy and urostomy bag changes (figure 1). As a result, 
he required recurrent hospitalisations for sepsis secondary to 
complicated UTIs and chronic, non-healing advanced pressure 
ulcers, which gradually progressed and evolved to encom-
pass larger areas of his posterior and inferior thorax, further 
altering his body morphology (figure 2). Surgeons performing 
repeated pressure ulcer debridement frequently had difficulty 
describing the exact location of the ulcer due to his distorted 
body anatomy. Furthermore, our patient had repeated ostomy 
prolapses requiring multiple surgical revisions likely due to the 
high intraperitoneal pressures generated by his body weight on 
peritoneum without a supporting bony frame (figure 2, box 1).
During each of his numerous hospital admissions, health-
care professionals struggled with his presenting diagnosis and 
the management of his multidrug-resistant infections, elec-
trolyte abnormalities, monitoring kidney function and blood 
pressure control. Infectious disease was frequently consulted 
to manage this patient due to his history of MDROs, and he 
was invariably placed on multiple broad-spectrum antibiotics. A 
biopsy of his chronic advanced non-healing pressure ulcer grew 
Acinetobacter baumannii resistant to all major classes of anti-
biotics (including carbapenems), MRSA and Zosyn-resistant 
Pseudomonas aeruginosa. He also had numerous bouts of VRE 
and MRSA bacteraemia, which required alternate broad-spec-
trum antibiotics such as daptomycin for treatment. In addition to 
increasing the cost of his medical care, repeated hospitalisations 
and treatments with broad-spectrum antibiotics also increased 
the chances of MDRO dissemination to other patients in the 
hospital.
This patient also required unconventional drug dosing due to 
his altered body composition and decreased body weight. For 
example, our patient had a total body weight of 30 kg with a 
reduced proportion of muscle mass since he was lacking his 
pelvis, sacrum and bilateral lower extremities. Therefore, his 
antibiotics, antihypertensive regimen and venous thromboem-
bolism prophylaxis regimen had to be altered to adjust for his 
body mass and composition. His altered anatomy (urostomy 
located beside ileostomy) and body composition also presented 
diagnostic challenges, including persistent pyuria with positive 
nitrite and leucocyte esterase, which made it difficult to deter-
mine if his recurrent sepsis events were attributed to a chronic 
complicated UTI or his chronic, non-healing advanced pres-
sure ulcers. In addition, he had a baseline systolic blood pres-
sure between 90 and 100 mm Hg, which is not uncommon in 
patients with hemicorporectomy and paraplegia. In the setting of 
sepsis, a small reduction in blood pressure when combined with 
errors in measurement can result in a false diagnosis of septic 
shock, which in this case frequently prompted placement of a 
central line and MICU admission as a precautionary measure. 
These factors undoubtedly increased patient discomfort, length 
of hospital stay and significantly increased cost burden to the 
healthcare system.
This case also presented unique challenges for allied health 
professionals, including nurses and social workers. This patient 
required long-term specialised urostomy and ileostomy care, as 
well as wound care and daily dressing changes for his chronic 
non-healing pressure ulcers. Appropriate outpatient follow-up, 
education and training for caregivers on aseptic technique and 
patient hygiene are crucial to decreasing mortality and morbidity 
and improving the quality of life for hemicorporectomy patients.
The management of chronic non-healing advanced pressure 
ulcers is generally very costly to the healthcare system and 
significantly reduces the quality of life of the patient. Alterna-
tive treatment options such as maggot debridement therapy and 
hyperbaric oxygen therapy are currently in development and 
have shown promising results in institutions that have access to 
such treatments.9 10 More research examining the efficacy and 
cost-effectiveness of various prevention and treatment strategies 
is needed, ideally with the goal of establishing specific guidelines.
This case also highlights the need to educate the patient and 
family and establish goals of care in hemicorporectomy patients, 
with quality of life and patient wishes as the guiding princi-
ples. A patient’s mental well-being including decision-making 
capacity, self-image, ability to perform activities of daily 
living, the potential desire to return to work or school, finan-
cial concerns, potential social isolation, pain management and 
radical changes in ability to perform specific sexual activities 
must also be addressed. The patient involved in this case had 
clearly expressed his wish to live and share his life with his son 
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Patient’s perspective
The patient died in September 2016 after a recurrent bout of 
sepsis while he was in home hospice.
Learning points
  Hemicorporectomy patients require a multidisciplinary 
approach to care.
  Hemicorporectomy secondary to terminal pelvic osteomyelitis 
has the potential of prolonging life, but may also lead 
to a significantly diminished quality of life if adequate 
multidisciplinary care is not provided to the patient.
  Hemicorporectomy patients present unique challenges for 
inpatient and outpatient management.
  Early patient and family education regarding the quality of 
life and prognosis is required to establish goals of care for 
decision-making and provide options for comprehensive 
outpatient care including home healthcare services, physical 
and occupational therapy, psychiatric care, wound care, and 
even palliative/hospice care in select patients.
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and family until late 2016, when his disease burden overtook his 
ability to make rational decisions, requiring a durable power of 
attorney for decision-making.
Although the patient in this case provides a unique account 
of the significant healthcare challenges in managing the poten-
tial complications of some hemicorporectomy patients, it is 
important to highlight that many patients do enjoy a productive 
life and experience a less complicated posthemicorporectomy 
course. For example, Peterson and Sardi11 describe a case of 
hemicorporectomy for SCC (Marjolin’s ulcer), where the patient 
remained disease-free for at least 7 years (as of November 2003) 
after hemicorporectomy and was employed as a computer 
programmer, independent in activities of daily living and 
retained the ability to drive. Other case reports suggest that some 
hemicorporectomy patients can live multiple decades despite a 
grave preoperative diagnosis.12 A case series of one woman and 
eight men (all paraplegic) who underwent hemicorporectomy 
for terminal pelvic osteomyelitis between 1981 and 2005 found 
that for the four surviving patients at follow-up, none suffered 
recurrent decubitus ulcers (with a range of survival after surgery 
of 1.7–22 years).5 For the patients who died, the cause of death 
was urosepsis for one patient, a fall for one patient, portal vein 
thrombosis for one patient and unknown cause for two patients. 
This makes our patient unique as the majority of posthemicor-
porectomy patients do not suffer recurrent osteomyelitis and 
advanced pressure ulcers leading to recurrent sepsis events. 
However, similar to our patient in this case, these patients had 
also undergone multiple surgical procedures including wound 
debridements and local flaps in an attempt to treat chronic pres-
sure ulcers prior to hemicorporectomy. At the time that hemi-
corporectomy was considered, one patient had an ileostomy, 
four patients had colostomies and three patients had undergone 
procedures for urinary diversion.5
These notable examples illustrate that a significant number 
of hemicorporectomy patients can prolong their life as well as 
enjoy a relatively good quality of life with a multidisciplinary 
approach to care. After hemicorporectomy, all patients should 
undertake a rehabilitation process that involves the integra-
tion of different services such as occupational and physical 
therapy for increasing upper body strength and acquiring new 
mobility skills, nutrition, enterostomal therapy and wound 
care nursing, and psychological counselling.5 A previous study 
showed that patients who survived the procedure for terminal 
pelvic osteomyelitis and had long-term follow-up were likely 
to be happy with their decision to have had the procedure as 
it prolonged their lives and also relieved them from the pain 
of living with chronic pressure ulcers.5 Overall the procedure 
has both benefits and risks, and patients and their families 
should properly understand both implications and make the 
best decision while consulting with healthcare providers.13 
Furthermore, Jankowski and Campo-Engelstein13 suggest that 
beyond assessing the risks and benefits of hemicorporectomy, 
the concept of informed consent, justice and resource alloca-
tion, and the loss and lived body are important considerations 
and remain topics of debate.
Unfortunately, there are currently no guidelines or standards 
of care for the management of hemicorporectomy patients, 
either on an inpatient or outpatient basis. This is primarily due 
to the rarity of the procedure and the paucity of subsequent 
data regarding outcomes, complications and treatments. We 
hope that this case may help healthcare providers anticipate and 
manage some of the potential complications in similar patients 
who have undergone hemicorporectomy or other radical surgical 
procedures.
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